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Abstract 
 
 
 
Type 2 diabetes is associated with increased hepatic lipogenesis and glucose 
production. Enzymes of lipogenesis are co-ordinately induced by insulin and glucose. 
However, the enzyme glucose 6-phosphatase (G6Pc), which catalyses the final 
reaction in hepatic glucose production is repressed by insulin but induced by glucose 
and is markedly elevated in type 2 diabetes.  Another gene that is repressed by insulin 
and induced by glucose in muscle is thioredoxin interacting protein (TXNIP), which 
is abnormally elevated in muscle in type 2 diabetes. TXNIP gene regulation in liver 
has not been reported.  The induction of hepatic lipogenic enzymes by glucose is 
attributed to the transcription factor ChREBP-Mlx, whereas the glucose-induction of 
G6Pc is attributed to covalent modification of FOXO transcription factors by O-
GlcNAc formed by the hexosamine biosynthesis pathway (HBP).   The aim of this 
thesis was to investigate the role of the HBP in regulation by glucose of G6Pc and 
TXNIP gene expression in hepatocytes.    
This thesis investigated three commonly used methods to modulate HBP flux and 
covalent modification by O-GlcNAc. (1) An inhibitor of glutamine:fructose 6-
phosphate amidotransferase (6-diazo-5-oxo-l-norleucine, DON), the rate limiting 
enzyme of the HBP, was established to be a valid tool to study glucose-regulated gene 
expression.  (2) Substrates that enter the HBP after GFAT, such as glucosamine which 
is widely used to demonstrate links between HBP or O-GlcNAc modification and 
insulin resistance were shown to be invalid tools. (3) Inhibitors of O-GlcNAc 
modification or expression of O-GlcNAc transferase were of limited use to alter 
protein modification by O-GlcNAc.   
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Glucose caused a larger induction of G6Pc and TXNIP mRNA in the absence of 
insulin than in its presence, and this induction could be largely accounted for by Mlx-
dependent mechanisms (supporting involvement of ChREBP or MondoA) and by 
FOXO transcription factors.  G6Pc and TXNIP expression were confirmed to be 
regulated by distinct mechanisms based on the induction of TXNIP but not G6Pc by 
the glucose analogue, 2-deoxyglucose, through an Mlx-independent mechanism.  
Insulin caused rapid translocation of both FOXO1 and FOXO3A from the nucleus to 
the cytoplasm. Both glucose and 2-deoxyglucose opposed the translocation of 
FOXO1 and FOXO3A by insulin, and they stimulated translocation of FOXO3A to 
the nucleus in the absence of insulin.    
Inhibition of HBP flux with the GFAT inhibitor had the following effects:  (i) 
counteraction of the glucose-induction of both G6Pc and TXNIP mRNA; (ii) 
counteraction of glucose-induced translocation of ChREBP to the nucleus without 
affecting the signalling metabolite, fructose 2,6-bisphosphate; (iii) counteraction of 
glucose-induced translocation of FOXO1 and FOXO3A to the nucleus.  A role for O-
GlcNAc modification of both ChREBP and FOXO3A was supported by wheat-germ 
agglutinin precipitation. The results of this thesis support involvement of both HBP 
flux and O-GlcNAc modification of ChREBP and FOXO3A in glucose-regulated 
expression of G6Pc and FOXO3A but they do not support a role for glucosamine as 
an experimental tool to study glucose-induced insulin resistance. 
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Abstract 
 
 
 
Type 2 diabetes is associated with increased hepatic lipogenesis and glucose 
production.   Whereas enzymes of lipogenesis are co-ordinately induced by insulin 
and glucose, the enzyme glucose 6-phosphatase (G6Pc), which catalyses the final 
reaction in hepatic glucose production is repressed by insulin but induced by glucose 
and is markedly elevated in type 2 diabetes.  Another gene that is repressed by insulin 
and induced by glucose in muscle is thioredoxin interacting protein (TXNIP), which 
is abnormally elevated in muscle in type 2 diabetes. TXNIP gene regulation in liver 
has not been reported.  The induction of hepatic lipogenic enzymes by glucose is 
attributed to the transcription factor ChREBP-Mlx, whereas the glucose-induction of 
G6pc is attributed to covalent modification of FOXO transcription factors by O-
GlcNAc formed by the hexosamine biosynthesis pathway (HBP).   The aim of this 
thesis was to investigate the role of the HBP in regulation by glucose of G6Pc and 
TXNIP gene expression in hepatocytes.    
This thesis investigated three commonly used methods to modulate HBP flux and 
covalent modification by O-GlcNAc. (1) An inhibitor of glutamine:fructose 6-
phosphate amidotransferase (6-diazo-5-oxo-l-norleucine, DON), the rate limiting 
enzyme of the HBP, was established to be a valid tool to study glucose-regulated gene 
expression.  (2) Substrates that enter the HBP after GFAT, such as glucosamine which 
is widely used to demonstrate links between HBP or O-GlcNAc modification and 
insulin resistance were shown to be invalid tools. (3) Inhibitors of O-GlcNAc 
modification or expression of O-GlcNAc transferase were of limited use to alter 
protein modification by O-GlcNAc.   
Glucose caused a larger induction of G6Pc and TXNIP mRNA in the absence of 
insulin than in its presence, and this induction could be largely accounted for by Mlx-
dependent mechanisms (supporting involvement of ChREBP or MondoA) and by 
FOXO transcription factors.  G6Pc and TXNIP expression were confirmed to be 
regulated by distinct mechanisms based on the induction of TXNIP but not G6Pc by 
the glucose analogue, 2-deoxyglucose, through an Mlx-independent mechanism.  A 
rapid effect of insulin in causing translocation of both FOXO1 and FOXO3A from the 
nucleus to the cytoplasm was confirmed.  This study shows that both glucose and 2-
deoxyglucose opposed the translocation of FOXO1 and FOXO3A by insulin, and they 
stimulated translocation of FOXO3A to the nucleus in the absence of insulin.    
Inhibition of HBP flux with the GFAT inhibitor had the following effects:  (i) 
counteraction of the glucose-induction of both G6Pc and TXNIP mRNA; (ii) 
counteraction of glucose-induced translocation of ChREBP to the nucleus without 
affecting the signalling metabolite, fructose 2,6-bisphosphate; (iii) counteraction of 
glucose-induced translocation of FOXO1 and FOXO3A to the nucleus.  A role for O-
GlcNAc modification of both ChREBP and FOXO3A was supported by wheat-germ 
agglutinin precipitation. The results of this thesis support involvement of both HBP 
flux and O-GlcNAc modification of ChREBP and FOXO3A in glucose-regulated 
expression of G6Pc and FOXO3A but they do not support a role for glucosamine as 
an experimental tool to study glucose-induced insulin resistance. 
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bisphosphatase 1 (liver isoform) 
PGC1α Peroxisome proliferator-activated receptor gamma coactivator 
1-alpha 
PhK   Phosphorylase kinase 
PKA   Protein kinase A 
PKB/Akt  Protein kinase B 
PP1   Protein phosphatase-1 
PPi-PFK  Pyrophosphate: fructose 6-phosphate phosphotransferase 
Ptdlns(3, 4, 5)P3 Phosphatidylinositol 3,4,5-trisphosphate 
PTG   Protein targeting to glycogen 
RNA   Ribonucleic acid 
RNase   Ribonuclease 
ROS   Reactive oxygen species 
RT-PCR  Reverse transcription polymerase chain reaction 
S4048 (1-[2-(4-Chloro-phenyl)-cyclopropylmethoxy]-3, 4-
dihydroxy5-(3-imidazo[4, 5-b]pyridin-1-yl-3-phenyl-
acryloyloxy)cyclohexanecarboxylic acid) 
SDS   Sodium dodecyl sulphate 
sh-RNA  Short hairpin ribonucleic acid 
SREBP-1c  Sterol regulatory element-binding protein-1c 
TBP2   thioredoxin binding protein 2 
TCA   Trichloroacetic acid 
Temed   Tetramethylethylenediamine 
TGF-β   The transforming growth factor beta 
TM   Tunicamycin 
TPI   triosephosphate isomerase 
Tris   Tris(hydroxymethyl)amino-methane 
TSA   Trichostatin A 
TRX   Thioredoxin 
TXNIP  Thioredoxin interacting protein 
UDP-GlcNAc  Uridine diphosphate N-acetylglucosamine 
UDP-glucose  Uridine diphosphoglucose 
WB   Western Blotting 
WGA   Wheat germ agglutinin 
Xylulose 5-P  Xylulose 5-phosphate 
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 Introduction 
 
1.1 General introduction on diabetes 
 
Diabetes mellitus is a heterogeneous group of disorders characterized by high 
blood glucose concentrations and associated abnormalities of lipid and protein 
metabolism. Insulin function is abnormal in diabetes, because of reduced secretion 
and tissue insensitivity to its effects. There are two main types, type 1 (insulin-
dependent) and type 2 (non-insulin-dependent), although an individual can be 
assigned to only one class, that designation may change with time (Holt, 2004). 
The current classification is hybrid, based largely on clinical features at diagnosis 
(e.g. type 1 and 2) but also on aetiological mechanisms or associations [e.g. 
malnutrition-related (MRDM) or gestational (GDM) classes]. While there are 
broad relationships between pathogenic mechanisms and certain types of diabetes, 
the connections are far from absolute. For example, autoimmune damage inflicted 
on the pancreatic (beta-cells) is usually responsible for type 1, but may be 
associated with type 2, impaired glucose tolerance (IGT) or indeed with normal 
glucose tolerance (Harris, 1988). 
The outcome of patients suffering from diabetes mellitus dramatically changed 
with the introduction of insulin therapy. However, with time it became clear that 
diabetic patients treated with insulin developed a series of complications that 
significantly reduced the quality and extent of life. The tissues and organ systems 
that were found to be affected are diverse including the retina, kidney, macro- and 
micro-vascular, and peripheral nerves (Ahmed, 2005). There are many theories 
explaining the development of these complications and take into account the 
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potential role of hyperglycemia, the lack of insulin and an imbalance of other 
hormones (Brownlee, 2001).  
One theory proposes a link between the hexosamine biosynthesis pathway (HBP) 
and insulin resistance (Buse, 2006). The aim of this thesis was test the hypothesis 
that the HBP in the liver has a role in glucose sensing and the regulation of key 
enzymes of glucose metabolism, glucose 6-phosphatase and TXNIP through 
regulation of expression of these genes. 
 
1.2 The role of the liver in the control of glucose metabolism 
 
The liver plays an important role in controlling the blood glucose concentration 
and this process is regulated by the pancreatic hormones insulin and glucagon. 
After a meal, increasing concentrations of glucose in plasma stimulate the beta-
cells in the pancreas to produce insulin and this stimulates glucose metabolism by 
liver, muscle and adipose tissue. High glucose uptake favours the pathways of 
glucose storage as glycogen synthesis, and also glycolysis to produce pyruvate 
which in liver and adipose tissue is then converted to fatty acid and triglyceride, 
glucose is also metabolised by the pentose mono-phosphate shunt to generate 
NADPH for lipid synthesis (Hers, 1976; Ferrer et al., 2003; Postic et al., 2004).  
Insulin stimulates conversion of glucose to glycogen and also to triglyceride both 
by rapid mechanisms involving covalent modification of proteins and by 
regulation of gene expression.  On the other hand, alpha cells in the pancreas 
produce glucagon when glucose concentrations decrease during fasting and this 
stimulates glucose production by glycogenolysis and gluconeogenesis through 
changes in covalent modification of proteins and control of gene expression (Hers, 
1976). 
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1.2.1 Regulation of glucose production and glycogen synthesis 
 
During fasting when glucose is not being absorbed from the gut / intestine, the 
liver maintains the blood glucose concentration by release of glucose by two 
pathways, glycogenolysis and gluconeogenesis pathways. The liver produces 
glucose from glycogen by glycogenolysis which involves phosphorolysis to form 
glucose 1-phosphate and also from gluconeogenesis pathway from non-
carbohydrate substrates such as lactate, amino acids and glycerol to glucose.  This 
pathway is very important when the liver glycogen stores have been depleted. The 
activities of unidirectional enzymes of gluconeogenesis, for example, 
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase and 
glucose 6-phosphatase (G6Pc) are regulated at the transcriptional level by insulin 
and glucagon (Postic et al., 2004). 
Several enzymes and proteins play an important role in the regulation of hepatic 
glycogen synthesis from glucose. Transport of glucose into the liver cells is by a 
glucose transport protein (GLUT2) which has a high activity and maintains 
equilibrium of glucose between intracellular and extracellular sinusoidal 
compartment. The first reaction of glucose metabolism is phosphorylation to 
glucose 6-phosphate (glucose 6-P), which is catalysed by glucokinase (GK) 
(Agius et al., 2008). Glucose 6-P is a substrate for  glycolysis, glycogen synthesis 
and pentose phosphate pathway (Ferrer et al., 2003; Postic et al., 2004). Fructose 
6-phosphate which is produced from glucose 6-phosphate by phosphoglucose 
isomerase (PGI) is a substrate for glycolysis and also for the hexosamine 
biosynthesis pathway.   
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Glycogen metabolism is controlled by key regulatory enzymes. Glycogen 
degradation is dependent on active glycogen phosphorylase (GP). Glycogen 
phosphorylase occurs in two forms: an active phosphorylated form 
(phosphorylase-a) and an inactive dephosphorylated form (phosphorylase-b). 
Phosphorylase kinase converts glycogen phosphorylase-b to phosphorylase-a, by 
phosphorylation of a serine residue (Ser-14) at the N-terminus.  Phosphorylase 
kinase is a hexadecamer composed of four sub-units.  The alpha and beta-subunits 
have an inihibitory effect on the catalytic unit.  They are regulated by 
phosphorylation by cAMP-dependent protein kinase, which releases the inhibition 
causing activation of the catalytic unit (Bollen et al., 1998).  cAMP-dependent 
protein kinase is a downstream target of glucagon signalling in liver cells. In 
contrast, insulin signalling stimulates the activity of phosphorylase phosphatase 
which is composed of protein phosphatse-1 (PP-1) in association with glycogen 
targeting subunits (including protein targeting to glycogen (PTG)).  Activation of 
phosphorylase phosphatase causes inactivation of glycogen phosphorylase-a by 
dephosphorlyation to phosphorylase-b. Glycogen synthesis is regulated by 
changes in covalent modification of both glycogen phosphorylase and glycogen 
synthase.  Glycogen synthesis is controlled by reversible phosphorylation on 
multiple sites.  Phosphorylation by multiple kinases including cAMP-dependent 
protein kinase, phosphorylase kinase, glycogen synthase kinase-3 and AMP-
activated protein kinase causes inactivation by phosphorylation to form glycogen 
synthase-b (GSb).  Glycogen synthase is activated by  dephosphorylation by 
glycogen synthase phosphatase (GSP) which comprises protein phosphatase-1 in 
association with glycogen targeting proteins (including GL).  Dephosphorylation 
causes activation to glycogen-synthase-a (Bollen et al., 1998; Ferrer et al., 2003; 
Hers, 1976; Agius, 2008). Glycogen phosphorylase-a is an allosteric inhibitor of 
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glycogen synthase phosphotase by binding to an allosteric site on GL (Pautsch et 
al., 2008). 
 
1.3 Insulin action in liver 
 
Insulin is a key hormone regulating glucose metabolism in many tissues, such as 
liver, the skeletal muscle and adipose tissue. The actions of insulin are uptake of 
glucose, amino acids transport, glycogen synthesis, protein synthesis and control 
of transcription of specific genes. However, some tissues have insulin-
independent glucose transport, such as liver and cells of the nervous system 
(Baron and Van Obberghen, 1995). In liver, large members of genes are regulated 
at the transcriptional level by insulin (O’Brien et al., 2001).  
 
1.3.1 Mechanisms of insulin signalling 
 
The insulin receptor (IR) is a member of the tyrosine kinase receptor family 
(Goalstone and Draznin, 1997). The receptor is a tetrameric glycoprotein 
(190kDa). It contains two α-subunits (insulin binding domain) and two β-subunits 
(transmembrane; tyrosine kinase) held together by disuphide bonds (Baron and 
Van Obberghen, 1995). Insulin binding to α-subunits induces autophosphorylation 
of the tyrosine kinase activity in the β-subunits and phosphorylation of insulin 
receptor substrate (IRS) proteins (Saltiel and Kahn, 2001).  After they are 
phosphorylated, IRS proteins interact with specific well-conserved domains, such 
as src-homology 2 domains (Goalstone et al., 1997). In addition, IRS proteins 
contact the plasma membrane by their pleckstrin homology domains. 
Phosphatidylinositol 3-kinase is a heterodimeric enzyme composed of a p110 
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catalytic subunit and a p85 regulatory subunit, which catalyzes the conversion of 
the lipid phoshatidylinositol Ptdlns(4, 5)P2 to Ptdlns(3, 4, 5)P3. Ptdlns(3, 4, 5)P3 
functions as the key second messenger in insulin signalling (Fritsche et. al., 2008). 
Ptdlns(3,4,5)P3 regulates the localization of 3-phosphoinositide-dependent protein 
kinase 1 (PDK1), protein kinase B (PKB) or also called Akt and protein kinase C 
(PKC) through interaction with the PH (pleckstrin homology) domain (Saltiel and 
Kahn, 2001). The activation of PKB/Akt occurs rapidly upon insulin stimulation 
of the cell. There are many proteins in cytosol and nucleus that are regulated by 
PKB/Akt, and are involved in glycogen synthesis, proteins synthesis and control 
of gene transcription.  
 
1.3.2 Insulin action on gene transcription 
 
Insulin is involved in regulation of expression of mRNA and protein levels of 
several genes. However, the mechanisms are incompletely understood. The action 
of insulin could be positive or negative on the transcription and mRNA translation 
of gene expression. One of the main genes regulated by insulin in the liver is 
glucokinase (Iynedjian, 2009). Transcription factors that have been implicated in 
the control by insulin include SREBP-1c, HNF4-α, FOXO1 and HIF-1a.  The role 
of SREBP-1c is controversial because although SREBP-1c is transcriptionally 
induced by insulin and also constitutive overexpression of SREBP-1c was shown 
to be associated with increased glucokinase expression (Foretz et al., 1999). Other 
studies showed that SREBP1c does not bind to the glucokinase promoter 
(Stoeckman and Towle, 2002) and also that activation of protein kinase B induces 
glucokinase expression in cells lacking SREBP-1c (Ono et al., 2003; Hansmannel 
et al., 2006).  Although several studies have provided evidence for binding of 
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FOXO1 to the glucokinase promoter (Ganjam et al., 2009), normal insulin 
induction of glucokinase in FOXO1 deficient cells has also been reported 
(Matsumoto et al., 2007), suggesting involvement of other mechanisms. The 
induction by insulin of glucokinase is inhibited by glucagon through a mechanism 
involving cyclic adenosine monophosphate (cAMP) (Nouspikel and Iynedjian, 
1992).   Insulin also induces several enzymes of lipogenesis (including FAS) and 
the pentose phosphate pathway and it is accepted that the induction of these genes 
by insulin unlike the induction of glucokinase is mediated by SREBP-1c 
(Hansmannel et al., 2006; Towle, 2001), 
Insulin represses several genes for example, phosphenolpyruvate carboxykinase 
(PEPCK), glucose 6-phosphatase (G6Pc), insulin-like-growth-factor-binding 
protein 1 (IGFBP-1) and tyrosine aminotransferase (TAT). These genes are 
induced by glucagon through an increase in cAMP via CREB/CRTC2 (O’Brien et 
al., 2001). Transcription factors that are implicated in the regulation of 
gluconeogenic gene expression by insulin include FOXO1, FOXO3, HNF4α, 
C/EBP and SREBP-1c  (O’Brien and Granner, 1996; Hutton and O’Brien, 2009). 
 
1.3.3 The role of FOXO in insulin regulation of transcription  
 
The FOXO’s family of transcription factors was first identified by Weigel et al., 
1989. There are more than 100 members of the FOX super family that are 
classified from A to R on the basis of sequence similarity (Myatt and Lam, 2007). 
The members of class O transcription factors include FOXO1 also known as 
Forkhead box 1 (FKHR), FOXO3A (FKHRL1), FOXO4 (AFX) and FOXO6 
(Jacobs et al., 2003).  These members of the FOXO family contain a conserved 
100 amino acid domain, which is called winged helix DNA-binding domain. The 
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FOXO transcription factors are regulated by insulin and other growth factors 
(Barthel et al., 2005) and they control expression of target genes involved in 
metabolism, apoptosis and cells stress (van der Horst and Burgering, 2007; Wang 
et al., 2009). The FOXO family transcription factors are expressed in several 
tissues such as liver, skeletal muscle, adipose and others. The action of insulin 
signaling in hepatocytes, which is regulated through protein kinase B (PKB/Akt) 
causes phosphorylation of FOXO1 an multiple sites including Thr24 which causes 
translocation from nucleus to cytoplasm (Desvergne et al., 2006; Matsumoto et 
al., 2007; Qu et al., 2006; Naimi et al., 2007) (Fig. 1.1).  FOXO1 plays an 
important role in glucose metabolism; its target genes included G6Pc, PEPCK, 
PGC-1α and IGFBP-1 in the liver (Bastie et al., 2005; Matsumoto et al., 2007; 
Barthel et al., 2005). In addition, the stimulation of expression of glucose 6-
phosphatase (G6Pc) and phosphoenolpyruvate carboxykinase (PEPCK) are 
induced by FOXO1 and PGC1α in the fasting state. However, in the fed state, 
insulin activates Akt to phosphorylate FOXO1 and PGC1α resulting in 
translocation to the cytoplasm. On another hand, some studies have reported that 
there is regulation of FOXO1 by inducing oxidative stress which is activated 
through various post-translational modifications including phosphrylation, 
acetylation and ubiquitination (Zhao Y, et al. 2010; Ponugoti B, et al. 2012). It 
seems that FOXO1 plays an important role in protection of cells from oxidative 
stress which is caused by glucose. Previous studies have reported that the FOXO1 
and FOXO3A transcription factors have been shown to bind the Thioredoxin 
interacting protein (TXNIP) promoter and regulate the expression of TXNIP in 
hepatocytes (Yu and Luo, 2009; Zhuo et al., 2010).  
 
 
Chapter 1                                                                                             Introduction  
 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1                                                                                             Introduction  
 11 
1.4 Glucose action on gene transcription 
Several studies have shown that high glucose concentration regulates gene 
transcription (Girard et al., 1997; Massillon, 2001; Dentin et al., 2012). This effect 
can be mediated either by an effect of glucose metabolism on insulin signalling or 
by an effect on transcription factors that are either regulated by insulin signalling 
or by other signals. Two general areas of research have emerged on glucose 
regulation of gene transcription:  the study of the covalent modification of 
proteins involved in insulin signalling (e.g. IRS1, Akt) or gene regulation 
(FOXO1) by covalent modification by O-GlcNAc and the study of transcription 
factors that are targets of glucose metabolism (e.g. ChREBP, MondoA, LXR). 
Studies on animal models fed a high carbohydrate diet identified enzymes of 
glycolysis and lipogenesis as target genes for both insulin and glucose through 
independent regulatory elements on the promoter. The regulatory element that 
binds SREBP-1c is termed the sterol regulatory element and it mediates regulation 
by insulin whereas the DNA element that is regulated by glucose is termed the 
carbohydrate response element (ChoRE) (Towle, 2001). Studies on the 
mechanism by which glucose regulates gene expression in both liver and adipose 
tissue showed that metabolic conditions that lead to an increase in glucose 6-P 
cause the induction of several genes and this led to the suggestion that glucose 6-P 
is the active metabolite for gene expression (Girard et al., 1997).  However, other 
studies on liver derived cell lines suggested a metabolite of the pentose phosphate 
pathway is most likely involved (Kahn, 1997) and based on experiments with 
xylitol which causes a similar or larger induction of gene expression than glucose 
a role for xylulose 5-P was suggested (Kabashima et al., 2003; Dentin et al., 2012; 
Uyeda and Repa, 2006). G6Pc catalyses the final reaction in hepatic glucose 
production and was also shown to be regulated by xylitol by a mechanism most 
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likely involving xylulose 5-P (Massillon, 2001). In non-hepatic cells, and in 
skeletal muscle of subjects with type 2 diabetes, TXNIP was identified as a major 
glucose inducible gene (Parikh et al., 2007). TXNIP is also induced by high 
glucose in hepatocytes (Ma et al., 2006). 
 
1.4.1 The role of ChREBP in glucose regulation of transcription  
 
The transcription factor Carbohydrate response element binding protein 
(ChREBP) has a key role linking glucose metabolism and control of gene 
expression of enzymes of glycolyis and lipogenesis. ChREBP is a large 
transcription factor, approximately 850 amino acid residues with a molecular 
weight of 100 kDa. ChREBP was discovered independently by two research 
groups.  Cairo group’s showed that the ChREBP gene (WBSCR14) is located in a 
DNA region that is mutated in patients with the developmental disorder Williams-
beuren Syndrome (Cairo et al., 2001). They showed expression of ChREBP at 
mRNA level by in situ hybridization or Northern Blot in various tissues including 
liver,  gut and brain and that it forms heterodimers with the protein Mlx. They 
also showed that ChREBP protein has a short half-life when transfected in Cos 
cells.  Mlx is a member of the Myc/Max/Mad family of transcription factors with 
a basic helix-loop-helix leucine zipper (bHLHZip) domain required for DNA 
binding by the resulting heterocomplex (Peterson and Ayer, 2011).  Mlx can serve 
as partner of various transcriptional regulators including Mad1, Mad4 and Mnt 
which function as repressors.   
 Uyeda group’s purified ChREBP by using the proximal promoter region of the 
pyruvate kinase gene to search for the transcription factor that regulates gene 
expression of enzymes of glycolysis and lipogenesis in animals fed a high 
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carbohydrate diet (Kawaguchi et al., 2001). They showed that ChREBP is 
expressed at high levels in liver and adipose tissue and that expression of 
ChREBP in liver is increased in animals fed a high carbohydrate diet (Uyeda et 
al., 2002). They proposed a major role for ChREBP in mediating the effect of 
high glucose on gene expression of enzymes of glycolysis and lipogenesis 
because ChREBP knock-out mice have a decreased induction of enzymes of 
lipogenesis in response to high-carbohydrate diets in vivo and also a decreased 
response of isolated hepatocytes from these animal models to glucose induction of 
gene expression (Iizuka et al., 2004).  Uyeda also showed that knock-down of 
ChREBP in the ob/ob mouse also down regulates the expression of lipogenesis in 
this model, suggesting that the induction of lipogenesis in an animal model of 
insulin resistance is also due to ChREBP (Iizuka et al., 2006). Similar results were 
obtained by other research groups who showed that down regulation of ChREBP 
in liver with sh-adenoviral vectors also decreases the expression of enzymes of 
lipogenesis and development of fatty liver in this model (Dentin et al., 2006). The 
suggested function of ChREBP from these studies is that it regulates the 
conversion of carbohydrate to fat on a high carbohydrate diet and also in models 
of hyperphagia and insulin resistance (Uyeda and Repa, 2006, Towle et al., 1997). 
Studies by Stoeckman and colleagues showed that ChREBP binds to the promoter 
of glucose responsive genes in the liver as a heterodimer with Mlx when 
hepatocytes are incubated at high glucose concentration.  In earlier studies they 
identified the glucose response element of carbohydrate responsive genes 
(Stoeckman et al., 2004) as consisting of two imperfect E-boxes separated by 5 
bases. Ma and colleagues then used a dominant negative variant of Mlx to identify 
new genes that are regulated by glucose through an Mlx-dependent mechanism. 
By using gene microarray studies they identified large numbers of genes that are 
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either induced or repressed by high glucose through an Mlx-dependent 
mechanism either directly or indirectly (Ma et al., 2006). The genes induced by 
glucose included not only enzymes of glycolysis and lipogenesis but also G6Pc 
and fructose 1,6-bisphosphatase. However, whether these genes are direct or 
indirect targets of ChREBP-Mlx was not determined. 
 
1.4.2 Mechanism of activation of ChREBP by glucose metabolism 
 
The mechanism by which glucose signalling activates ChREBP is incompletely 
understood. Uyeda and colleagues proposed that phosphorlyation of ChREBP on 
residues Ser(196) and Thr(666) by glucagon through activation of cAMP 
dependent protein causes accumulation of ChREBP in the cytoplasm, and high 
glucose cause dephosphorylation of these residues and translocation of ChREBP 
to  the nucleus and binding to DNA and for activation of gene transcription (Fig. 
1.2). Uyeda proposed that metabolism of glucose by the pentose phosphate 
pathway causes an increase in xylulose 5-P, which causes activation of the protein 
phosphatase 2A (PP2A) to dephosphorylate ChREBP and promote its nuclear 
localization and DNA binding (Kabashima et al., 2003; Dentin et al., 2012; Uyeda 
and Repa, 2006). However, other studies found that mutation of these residues did 
not affect the stimulation by glucose of translocation of ChREBP to the nucleus 
(Tsatsos and Towle, 2006).  Studies by Li and colleagues proposed activation of 
ChREBP by binding of glucose or glucose 6-P to the N-terminus of ChREBP (Li 
et al., 2010). These studies used islet beta cells and expression of a GAL4-
ChREBP fusion protein that is targeted constitutively to the nucleus and also a 
luciferase reporter containing ChoRE elements to study the metabolites of glucose 
that activate transcription by GAL4-ChREBP. These studies showed that the  
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stimulation by high glucose was inhibited with a glucokinase inhibitor and also by 
overexpression of PFK1 and PFK2 and suggested that the stimulation was by 
glucose 6-P.  They also showed a small activation by 2-deoxyglucose and 
concluded that activation of ChREBP after DNA binding is explained by glucose 
6-P. Dentin and colleagues studied the metabolite mechanism for ChREBP 
translocation, DNA binding and activation of transcription and proposed that the 
mechanism is not mediated by xylulose 5-P but by glucose 6-P (Dentin et al., 
2012), because changes in gene transcription correlated with changes in glucose 
6-P. 
 
1.4.3 Enzymes regulated conversely by glucose and insulin  
 
1.4.3.1 The role of glucose 6-phosphatase (G6Pc) 
 
Glucose 6-phosphatase (G6Pc or G6Pc1) is an important enzyme in glucose 
production.  It catalyzes the conversion of glucose 6-P to glucose the last step of 
glucose production by glycogenolysis and gluconeogenesis in the liver (Hutton 
and O’Brien, 2009). G6Pc protein consists of 357 amino acid with a molecular 
weight of approximately 36 kDa in liver (van de Werve et al., 2000). G6Pc is 
located inside the lumen of the endoplasmic reticulum with the catalytic site 
facing the lumen.   Function of G6Pc is coupled to a transporter protein encoded 
by SLC37A4 which transports glucose 6-P from the cytoplasm to the lumen.  The 
activity of G6Pc was higher on glucose 6-P rather than other substrates phosphate 
such as mannose 6-P, glucosamine 6-phosphate (GlcN 6-P) and 2-deoxyglucose 
6-phosphate (2-DOG 6-P) which catalyses specifically the hydrolysis of glucose 
6-P (Hutton and O’Brien, 2009).  
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There are three isoforms of the G6Pc gene family called G6Pc 1, 2 and 3.  The 
liver isoform known as G6Pc or G6Pc1 is expressed in hepatocytes, nephrocytes, 
enterocytes and in β-cells (Ven Schaftingen and Gerin, 2002). G6Pc2 is expressed 
in islet beta cells and G6Pc3 is expressed in all tissues. In the kidney G6Pc1 also 
has a role in glucose production and during fasting and diabetes it is thought to 
contribute to glucose production by up to 25%. During liver transplantation 
glucose production by the kidney is increased to compensate for the lack of 
contribution by the liver (Joseph et al., 2000). In the small intestine the suggested 
functions of G6Pc1 are in glucose transport and conversion of fructose to glucose 
(Bismut et al., 1993; Cui et al., 2004; Suzuki et al., 2011).  Whereas in the islet 
beta cells the suggested function of G6Pc1 and also G6Pc2 are as negative 
regulators of insulin secretion (Dos Santos et al., 2009). Although the major 
function of G6Pc1 is the production of glucose, another function in the liver is to 
maintain intracellular homeostasis of glucose 6-P by preventing excessive 
elevation in glucose 6-P (Aiston et al., 1999). The main evidence for this function 
comes from studies involving inhibitors of the G6PT, such as the chlorogenic 
derivative S4048. This inhibitor has little effect on the hepatocyte glucose 6-P 
concentration at 5mM glucose but it causes a very large increase in glucose 6-P 
accumulation at concentrations above 10mM (Harndahl et al., 2006). This 
supports an important function of G6Pc in the liver cell in homeostasis of 
intracellular glucose 6-P (Agius, 2013). 
In the liver the expression of G6Pc at both the mRNA levels and the activity is 
increased by glucose, glucagon, glucocorticoids and fatty acids and is decreased 
by insulin. The proximal G6Pc promoter region in the liver binds several 
transcription factors including FOXO1, HNF1, the glucocorticoid receptor, Foxa2, 
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HNF6, HNF4α, CREB and Sp1/Sp3. (Ayala et al., 1999; Barthel et al., 2001; 
Schmoll et al., 2000).  
 
1.4.3.2 The role of Thioredoxin interaction protein (TXNIP) 
  
TXNIP was first identified in 1993 and is also known as vitamin D3 up-regulated 
protein 1 (VDUP-1) and thioredoxin binding protein 2 (TBP2) and is a binding 
protein of thioredoxin (Chutkow et al., 2008). TXNIP is a 46kDa protein and 
member to a family of six structurally similar arrestin domain-containing proteins 
(ARRDC) also called α-arrestins. Thioredoxin (TRX) is a small (12kDa) 
multifunctional protein consisting of 105 amino acids and exists as many 
isoforms, such as TRX 1, the cytosolic (classical member) and TRX 2, the 
mitochondria-specific type, with a conserved catalytic site acting as a potent 
antioxidant protein reducing oxidized protein and preventing accumulation of 
excess reactive oxygen species (ROS) which protect cells from damage (Kaimul 
et al,. 2007). The function of thioredoxin is to transfer electrons from NADPH to 
the disulphide groups of proteins causing their reduction. TXNIP functions as an 
inhibitor of thioredoxin and the ratio of thioredoxin-to-TXNIP is thought to 
determine the redox state of –SH groups in proteins and reduce sulfhydryl groups 
(Fig. 1.3). There are two ways that the function and action of TRX can be 
inhibited by TXNIP: (i) TXNIP binds TRX and acts as a competitive inhibitor to 
remove TRX from proteins whose function is inhibited by the steric effect of TRX 
binding such as apoptosis signal regulating kinase 1. (ii) Increases in TXNIP 
expression by factors such as high glucose (Stoltzman et al., 2008; Cha-Molstad et 
al., 2009; Yu and Luo, 2009), various stress stimuli including H2O2, TGF-β, UV 
and heat shock (Junn et al., 2000; Han et al., 2003; Kim et al., 2004), the histone  
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deacetylase (HDAC) inhibitors (Butler et al., 2002) and NAD+ (Yu and Luo, 
2009) result in reduced TRX reductase activity.  
The increase in TXNIP-TRX complexes will result in more oxidized proteins on 
exposure to oxidative stress. There are several functions of TXNIP including 
regulation of glucose uptake and cell growth and apoptosis (Kaadige et al., 2009, 
Peterson et al., 2010, Kaadige et al., 2010, Chutkow et al., 2008).  TXNIP has 
therefore been proposed to have a role in causing apoptosis in islet β-cells 
(Kaadige et al., 2009, Peterson et al., 2010, Kaadige et al., 2010, Chutkow et al., 
2008). Through the inhibition of TRX, TXNIP overexpression enhances β-cell 
death and impairs insulin secretion (Minn et al., 2005; Chen et al., 2006).  
TXNIP is a key regulator of glucose metabolism and insulin signaling and 
therefore controls cellular energy status. Examples of enzymes which are very 
sensitive to the redox state of their thiol groups include phosphatases with 
sequence homology to tensin (PTEN) which is a negative regulator of insulin 
action (Akt downstream signaling) (Hui et al., 2008). Increasing Thiol redox 
status regulates enzyme involved in gluconeogenesis such as hepatic fructose-1,6-
bisphosphatase which is negatively regulated by fructose 2,6-bisphosphate (Hui et 
al., 2004). TXNIP overexpression inhibits Akt/PKB signalling (Shaw and Cantley, 
2006; Peterson and Ayer, 2011) and causes accumulation of transcription factors 
such as FOXO1 and FOXO3A in the nucleus. Furthermore, bioinformatics studies 
showed that TXNIP has a FOXO binding site which suggested regulation between 
FOXO and TXNIP (Fa-Xing and Luo, 2009). In pancreatic β-cells the induction 
of TXNIP mRNA gene expression by high glucose involves ChREBP, and has a 
role in promoting apoptosis (Minn, et al. 2005).  In several non-hepatic cell lines, 
high glucose induces TXNIP by MondoA (Peterson and Ayer, 2011). A recent 
study has shown that MondoA was more active than ChREBP in regulating 
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TXNIP by comparing the activity of MondoA and ChREBP at the TXNIP 
promoter using a luciferase-based reporter system in a Hela cell line (Yu et al., 
2009).  
Some research studies showed that high glucose causes an increase in ROS and 
this increases TXNIP mRNA expression (Qi et al., 2007) or  ROS activates 
TXNIP by activation of MAPK signalling (Fang et al., 2011). Reactive oxygen 
species (ROS) or oxidative stress is a pathogenic factor of hyperglycemia and 
diabetes complication. The major sources of ROS production on biological 
systems were found in the mitochondria and NAD (PH) oxidase (Valko et al., 
2007). The increase of ROS in biological system causes damage of DNA, lipids, 
membranes and proteins.  
 
1.5 The Hexosamine Biosynthesis Pathway (HBP)  
 
Several studies have proposed that high glucose concentration causes insulin 
resistance through increased flux through the hexosamine biosynthesis pathway 
(HBP) and that this pathway contributes to the glucose toxicity of diabetes 
(Whelan et al., 2008; Yang et al., 2008; Vosseller et al., 2002; Arias, 2004).  
The first reaction of this pathway is the synthesis of glucosamine 6-P from 
fructose 6-P and glutamine catalysed by the enzyme glutamine:fructose 6-
phosphate amidotransferase (GFAT) the rate-limiting step of the HBP from 
glucose (Copeland et al., 2008; Love and Hanover, 2005). The concentration of 
glucose 6-P in the liver is related to the extracellular glucose concentration and 
also to the activities of glucokinase and glucose 6-phosphatase (Agius et al., 
2008).  Glucose 6-P is in equilibrium with fructose 6-P, the first intermediate of 
the glycolytic pathway.  Fructose 6-phosphate in addition to being an intermediate 
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of glycolysis is also a substrate for the hexosamine biosynthesis pathway (HBP).   
An alternative route for synthesis of glucosamine 6-P is from glucosamine which 
can be phosphorylated by glucokinase or other hexokinases.  Glucosamine is often 
used in experimental studies to increase flux through the HBP.  The glucosamine 
6-phosphate is converted through a sequence of reactions into uridine 
diphosphate-N-acetylglucosamine (UDP-GlcNAc) and this is a substrate for 
various pathways of glycosylation of proteins which include N-GlcNAcylation 
and O-GlcNAcylation modification of protein (Copeland et al., 2008; McClain 
and Crook, 1996; Love and Hanover, 2005) (Fig. 1.4).   
The O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) catalyses 
the transfer of O-GlcNAc to serine and threonine residues (Copeland et al., 2008; 
Wang et al., 2009). This reaction is reversed by the enzyme Beta-N-
acetylglucosaminidase (OGA or also known as O-GlcNAcase) which catalyses 
the removal of the O-GlcNAc group. The role of O-linked glycosylation of 
proteins has been studied using inhibitors of OGT and OGA and various studies 
have suggested a role for this covalent modification in the regulation of insulin 
action.  Several studies have suggested that O-linked glycosylation plays a key 
role in insulin resistance by regulating gene expression, insulin signalling and 
glucose uptake (Buse, 2006; Copeland et al., 2008; Love and Hanover, 2005).  
Three different experimental approaches have been used to study the function of 
the hexosamine biosynthesis pathway (HBP). One method involves use of the 
GFAT inhibitors azaserine (AZN) and 6-diazo-5-oxonorleucine (DON), to block 
the metabolism of glucose by the HBP (Zachara and Hart, 2006; McClain and 
Crook, 1996).  Another involves incubation with glucosamine which is converted 
to glucosamine 6-phosphate. Glucosamine enters the HBP after GFAT and leads 
to increased production of glucosamine 6-phosphate because it by passes the rate  
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limiting step. A third approach involves overexpression of GFAT. There are two 
isoforms of GFAT; GFAT1 is expressed ubiquitously, whereas GFAT2 is 
expressed in liver.  The first purification of GFAT from rat liver was described by 
Pogell and Gryder in 1957 (Huynh et al., 2000).  GFAT1 and GFAT2 differ in 
their kinetic and regulatory properties (Ye et al., 2004; Zhou et al., 1998; Oki, et 
al., 1999; Hu et al., 2004).   
 
1.5.1 The enzymes of O-GlcNAc metabolism (OGT and OGA) 
 
There are three isoforms of OGT, the 110 kDa and 78kDa forms are found in the 
nucleus as heterotrimers (nOGT) and the 103 kDa is found in the mitochondria 
(mOGT) (Hurtado-Guerrero et al., 2008). The domain structures of OGT are an 
N-terminal tetratricopeptide repeat (TPR) domain and a C-terminal catalytic 
domain (Zachara and Hart, 2006). There are two isoforms of OGA, a 130 kDa and 
a 75 kDa.  OGA comprises an N-terminal hexosaminidase domain and a putative 
C-terminal histone acetyltransferase (HAT) domain (Rexach et al., 2008; Zachara 
and Hart, 2006). O-(2-acetamido-2-deoxy-d-glucopyranosylidene) amino N-
phenylcarbamate (PUGNAc) is inhibitor of OGA, which causes an increase in O-
linked glycosylation levels and resulted in the establishment of insulin resistance 
(Copeland et al., 2008).  Inhibitors of OGA (PUGNAc) as of OGT (BADGP) have 
been ued to study the role of O-GlcNAc modification of proteins in insulin action, 
and insulin resistance. These studies have also used glucosamine at concentrations 
up to 10 mM to increase covalent modification of protein by O-GlcNAc, which 
was shown by western blotting using an antibody against O-GlcNAc 
(D'Alessandris et al., 2004; Copeland et al., 2008). In addition, streptozotocin 
(STZ) is another inhibitor of OGA (Li et al., 2012). However, some studies have  
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reported that STZ is a poor inhibitor of OGA and there are many side effects 
(toxic to cells) (Copeland et al., 2008).  
 
1.5.2 Covalent modification by O-GlcNAc in insulin signaling  
 
Increased O-GlcNAc modification by overexpression of OGT or inhibition of O-
GlcNAcase (OGA) with PUGNAc in 3T3-L1 adipocytes and skeletal muscle 
caused insulin signalling pathway dysfunction (Vosseller et al., 2002; Matthew, 
2008). In addition, treatment of 3T3-L1 adipocytes with PUGNAc which 
increased O-linked glycosylation decreased insulin stimulation of 2-deoxyglucose 
uptake but did not affect IRS protein tyrosine phosphorylation by insulin 
suggesting that glycosylation affects downstream sites in insulin signalling 
(Vosseller et al., 2002).  However, another study has reported that PUGNAc did 
not affect insulin-stimulated phosphorylation of Akt or glycogen synthase kinase-
3 (GSK-3) in the skeletal muscle (Arias et al., 2004). Furthermore, some studies 
showed that OGT has an Ptdlns(3, 4, 5)P3 binding domain and that insulin 
signalling causes translocation of OGT from cytoplasm to nucleus which causes 
covalent modification of Akt. They also showed that increased O-GlcNAc 
modification by overexpression of OGT caused a decrease the phosphorylation of 
Akt at Thr 308 and increase phosphorylation of IRS1 at Ser 307 and Ser 632/635 
(Yang et al., 2008). 
 
1.5.3 Covalent modification of transcription factors by O-GlcNAc 
 
Covalent modification of transcription factors by O-GlcNAc affects the location 
and activity by different mechanisms including:: (i) by controlling the length of 
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time transcription factors spend in the nucleus; (ii) by targeting transcription 
factors for proteolytic degradation; (iii) by regulating transcription factors DNA 
binding; (iv) by complex formation between transcription factors (modulating 
protein-protein interactions) and (v) by modifying chromatin structure 
(Whitmarsh and Davis, 2000).  
Two groups suggested an effect of O-GlcNAc modification on ChREBP protein 
by high glucose.  Sakiyama H, et al. 2010 showed that inhibitors of OGA caused 
an increased effect of glucose and inhibition of GFAT caused a decreased effect 
of glucose on ChREBP activation of gene expression measured with a luciferase 
reporter assay (Sakiyama et al., 2010). Guinez and colleagues reported that OGT 
binds to ChREBP and that animal models of hyperglycaemia show increased O-
GlcNAc modification of ChREBP which results in its stabilisation resulting in 
increased protein level of ChREBP in liver (Guinez et al., 2011).  
Other studies have reported that O-GlcNAc glycosylation of FOXO1 caused by 
glucose, GlcN and PUGNAc resulted in the induction of G6Pc and PGC1α 
mRNA levels (Kuo M, et al. 2008). Studies by Housley and colleagues show that 
high glucose causes O-GlcNAc modification of FOXO1 in the absence of insulin 
which induces G6Pc and PEPCK mRNA levels (Housley et al., 2008). Therefore, 
O-GlcNAc modification of FOXO1 increased expression of G6Pc gene in 
glucotoxicity in diabetes and obesity (Kuo et al., 2008; Housley et al., 2008; 
Housley et al., 2009; Ido-Kitamura et al., 2012). 
 
1.5.4 Endoplasmic reticulum (ER) stress and the HBP 
 
The endoplasmic reticulum (ER) is a central organelle which synthesizes various 
proteins secretory products. Several pathways are integrated to regulate lipid, 
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glucose, cholesterol and protein metabolism (Sundar Rajan, S. et al. 2007; 
Yoshida H. 2007; Gregor, MF. et al. 2007). ER is a major site of protein synthesis 
and folding.  Ribosomes attached to the ER translate peptides into the luminal 
space of the ER. In the ER luminal protein chaperones such as BiP/GRP78, 
calnexin and calreticulin help folding and prevent aggregation of unfolded or 
misfolded proteins. Folded proteins released into the Golgi apparatus for transport 
to cellular destination or secretion (Gregor, MF. et al. 2007). In addition, other 
functions of the ER are site of triglyceride synthesis and assembly of lipid droplet, 
cholesterol sensing and sequestration of the sterol-regulatory element binding 
protein (SREBP-1c), which is released in response to low cholesterol or insulin 
signalling and accumulation of calcium which plays a role in cellular calcium 
homeostasis (Gregor, MF. et al. 2007).   
Various studies have shown that compounds that alter either the flux through the 
HBP or protein glycosylation (glucosamine, tunicamycin and other glycosylation 
inhibitors) cause ER stress. Tunicamycin and 2-deoxy-D-glucose are inhibitors of 
N-glycosylation but 2-deoxy-D-glucose is less efficient than tunicamycin 
(Yoshida H. 2007; Werstuck, GH. et. al. 2006; Kim, AJ. et. al. 2004).  
Changes in glycosylation of proteins can lead to abnormal accumulation of 
proteins in the ER which stimulates the unfolded protein response (UPR) (Kim, 
AJ. et. al. 2004). For example, Chaperone protein such as BiP normally binding to 
three transmembrane proteins such as eukaryotic initiation factor 2α kinase 
(PERK), inositol-requiring enzyme-1 (IRE-1) and activating transcription factor-6 
(ATF-6) which causes stress sensing proteins inactive. The larger excess of 
unfolded proteins or accumulation (also bound by BiP) made less BiP available 
for binding to the unfolded protein response (UPR) sensors. BiP (chaperone) 
dissociates from PERK, IRE-1 and ATF-6, which leads to the activation of many 
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signalling pathways (Gregor, MF. et al. 2007; Sundar Rajan, S. et al. 2007; 
Robertson, LA. et. al. 2006). The activation of PERK, IRE-1 and ATF-6 causes 
phosphorylation of eukaryotic translational initiation factor 2α (elf2α) which 
inhibits protein synthesis, phosphorylation of IRE-1 activates JNK and NFkB and 
ATF-6 is released to the Golgi where it becomes an active transcription factor and 
translocates to the nucleus and induces protein chaperone expression (Gregor, 
MF. et al. 2007; Sundar Rajan, S. et al. 2007). 
 
1.6 Hypothesis and aims of project 
 
Type 2 diabetes is associated with increased hepatic and peripheral insulin 
resistance.  The hepatic insulin resistance is associated with increased lipogenesis 
and glucose production.  The increased hepatic lipogenesis is generally explained 
by the induction of enzymes of glycolysis and lipogenesis by high glucose 
concentration through activation of ChREBP (Towle, 2005). The increased 
gluconeogenesis, which is associated with increased expression of the enzyme 
glucose 6-phosphatase (G6Pc), is explained covalent modification of transcription 
factors by O-GlcNAc as a result of increased flux through the hexosamine 
biosynthesis pathway (HBP). G6Pc is induced by glucagon and repressed by 
insulin and transcription factors that are regulated by these hormones are 
implicated in the covalent modification by O-GlcNAc (Housley et al., 2008, Kuo 
et al., 2008, Dentin et al., 2008). Insulin resistance in extrahepatic tissues is 
associated with increased expression of TXNIP which is also induced by high 
glucose (Parikh et al., 2007) and is a target gene for FOXO transcription factors.  
There is little information on flux through the HBP in liver or whether glucose 
regulation of gene expression correlates with changes in HBP flux.   
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This thesis tested the hypothesis that gene expression of G6Pc and TXNIP in 
hepatocytes is regulated by the glucose-activated transcription factor ChREBP-
Mlx and by flux through the HBP through covalent modification of transcription 
factors. 
The aims of the thesis were: first, to develop methods for measurement of flux 
through the HBP in primary hepatocytes and to validate experimental tools to 
change flux through the HBP, to establish the role of the pathway in glucose 
regulation of gene expression;  second, to determine whether glucose regulation of 
G6Pc occurs through the glucose-regulated transcription factor ChREBP or 
through covalent modification by O-GlcNAc;  third to compare the regulation by 
glucose of G6Pc with TXNIP which represent major glucose-inducible genes in 
insulin resistance in liver and peripheral tissues, respectively. 
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2.1 Materials  
 
2.1.1 Animals 
 
Male albino Wister rats, of the Hanover strain (body weight 180-380 g), were 
obtained from either B&K Universal Ltd (Hull, UK) or from Harlan Bicester, UK. 
They were subjected to light-dark cycles every 12 h with free access to water and 
fed ad libitum on standard laboratory chow. 
 
2.1.2 Chemicals and Reagents 
 
Buffer and common salts were obtained from BDH Laboratory Supplies (Poole, 
Dorset, UK). Commercial chemicals and reagents were purchased from 
manufacturers indicated in table 2-1. 
Chemicals/Reagents Supplier Cat. No. 
Eagles’ Minimum Essential Medium (X1) Gibco, Invitrogen  32360 
Non-essential amino acids (100x) Gibco, Invitrogen 11140-035 
Neonatal bovine serum Gibco, Invitrogen 26010-074 
Streptomycin sulphate Sigma S0130 
Tunicamycin Sigma T7765 
Benzamidine Sigma B-6506  
Phenyl methanesulfonyl fluoride Sigma P7626 
Penicillin G sodium salt Sigma P3032  
4-Dimethylaminobenzaldehyde Sigma 15,647-7  
Glucose 6-phosphate Sigma P7879  
2-Deoxy-D-glucose Sigma D8375  
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Xylitol  Sigma X3375  
3-O-Methyl-D-glucopyranose Sigma M4879 
N-acetyl-D-glucosamine Sigma A8625  
Allose Sigma 285005  
D-Glucosamine Sigma G-4875  
5-Thioglucose Sigma 88635 
O-(2-Acetamido-2-deoxy-D-
glucopyranosylidenamino) N-
phenylcarbamate (PUGNAc) 
Tocris Bioscience A7229  
6-Diazo-5-oxo-L-norleucine (DON) Sigma D2141 
Benzyl2-acetamido-2-deoxy-a-D-
galactopyranoside (BADGP) 
Sigma B4894 
Azaserine Sigma A4142 
[U-14C]glucose PerkinElmer  NEC042V250UC 
[2-3H]glucose PerkinElmer  NEC238C001MC 
3H-leucine PerkinElmer  NET1166001MC 
D-glucosamine-1-14C Sigma G2770 
N-acetylglucosamine-1-14C Sigma 311537 
Actinomycin D Sigma A1410 
Bromopyruvic acid Sigma 16490 
Verapamil Sigma PHR1131 
PD 169319 Sigma P9248 
Paraformaldehyde Sigma P6148 
Trizol Sigma 15596-018 
Primer random p(dN)6 Roche 11034731001 
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(ECL) detection kit   Thermo Scientific 32106 
(ECL) detection kit  Plus GE heathecare Ltd  32106 
2-Bromo-2-chloro-1,1,1-trifluoroethane Sigma B4388 
Gelatine Sigma G7041 
BSA Sigma A7906 
dNTP mix Promega U1240 
LightCycler Faststart DNA Master SYBR Roche 3003230 
PMSF Sigma P7626 
Protease inhibitor cocktail Sigma P8340 
ChIP assay kit protocol Millipore 17-295 
Lectin from Triticum vulgaris-Agarose Sigma L1882 
Phenol/chloroform/isoamyl alcohol mix Sigma 77617 
S4048 Gift from Dr. D. Schmoll, Aventis, 
Pharma GnbH, Frankfurt, Germany 
 
2.1.3 Enzymes 
 
Commercial enzymes were purchased from manufacturers indicated in table 2-2 
Enzymes Source Cat. No. 
Collagenase Sigma C5138 
Glucose 6-phosphate dehydrogenase (G6PDH) Sigma G8404 
Phosphoglucomutase (PGM) Sigma P3397 
Insulin Sigma I5523 
Diaphorase Sigma D5540 
Aldolase Sigma A8811 
Glycerophosphate dehydrogenase Sigma G6880 
Triosephosphate isomerase (TPI) Sigma T6258 
Superscript II reverse transcriptase Invitrogen 18064-071 
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RNase free DNase I  Roche 10776785001 
RNasin Plus RNase inhibitor Promega N2615 
Proteinase K Sigma P4850 
M-MLV reverse transcriptase Invitrogen 28025-021 
 
2.1.4 Antibodies 
Commercial antibodies were purchased from manufacturers indicated in table 2-3 
Antibodies Host 
(Applications) 
Supplier Cat. No. 
FOXO1 (C29H4) Rabbit (WB, IF) Cell signaling 2880 
FOXO3A (75D8) Rabbit (WB, IF) Cell signaling 2497 
Phospho-FOXO1 (Ser256) Rabbit (WB) Cell signaling 9461 
Phospho-FOXO1 (Thr24) 
/FOXO3A (Thr32)  
Rabbit (WB) Cell signaling 9464 
Phospho-Akt (Ser473) Rabbit (WB) Cell signaling 9271 
O-GlcNAc (CTD 110.6) Mouse (WB) Covance MMS-248R 
O-GlcNAc (RL2) Mouse (WB) Thermo Scientific MA1-072 
TXNIP Mouse (WB, IF) MBL K0205-3 
OGT (DM-17) Rabbit (WB) Sigma O6014 
Mlx Goat (ChIP) Santa cruz Sc-14705 
FKHR/FOXO1 (H-128) Rabbit (ChIP) Santa cruz Sc-11350 
FKHR/FOXO3A (H-144) Rabbit (ChIP) Santa cruz Sc-11351 
ChREBP Rabbit (WB, 
ChIP) 
Novus NB-400-135 
MondoA Rabbit (ChIP) Sigma SAB2104303 
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Anti-acetyl-Histone H4 Rabbit (ChIP) Merck Millipore 06-866 
NF-Y Rabbit (ChIP) AbD serotec AHP298 
IgG Rabbit (ChIP) Santa cruz Sc-2027 
GAPDH Mouse (WB) Hytest 5G4 
SREBP1c (2A4) Mouse (WB, IF) Abcam Ab3259 
Mouse immunoglobulins 
HRP 
Mouse (WB) Dako P0260 
Polyclonal goat anti-rabbit 
immunoglobulins HRP 
Rabbit (WB) Dako Po448 
Anti-mouse IgM H&L 
(goat) POD 
Mouse (WB) Calbiochem 401225 
Alexa fluor 488 goat anti-
rabbit IgG  
Rabbit (IF) Invitrogen A11008 
Alexa fluor 488 donkey 
anti-mouse IgG  
Mouse (IF) Invitrogen A12102 
 
2.1.5 Adenoviral vectors 
Commercial adenoviral vectors were purchased from manufacturers indicated in 
table 2-4 
Adenoviral vectors Source 
Glucokinase adenovirus (Becker et al., 1996) 
ChREBP/WT, Mlx/WT, MondoA/WT 
and Mlx dominant negative (Mlx-DN) 
Gifts from H.Towle (Stoeckman et al., 
2004) 
PFK/WT and PFK-KD Gifts from A. Lange (Arden et al., 
2008) 
FOXO3A/WT (Cat.No. 1576) Vector biolabs the gene 
delivery company 
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CREB1/WT (Cat.No. 1363) Vector biolabs the gene 
delivery company 
Pre-Made Adenovirus-OGT (Cat.No. 000619A) abm Applied 
biological materials inc. 
 
Each batch was tested for overexpression in hepatocytes and lysates were 
aliquoted and stored at -80°C.  
 
2.1.6 Primers for Real time RT-PCR 
 
Primers were designed using the online Roche Universal ProbeLibrary Assay 
Design tool. Primers were synthesised by MWG Operon Biotech Ltd (Milton 
Keynes, UK) (table 2-5). 
 Primers 
ChREBP (Mlxipl) 
 
FWD: GGGACATGTTTGATGACTATGTC 
REV: AATAAAGGTCGGATGAGGATGCT 
DEC1 (Dec1) 
 
FWD: CGTGAAAGCATTGACAAACC 
REV: TTCTTTCCCGACAGATCACC 
FAS (Fasn) 
 
FWD: ACCTGTCCCAGGTGTGTGAT 
REV: GCTGTGGATGATGTTGATGA 
G6pc (G6pc) 
 
FWD: CTACCTTGCGGCTCACTTTC 
REV: ATCCAAGTGCGAAACCAAAC 
Glucokinase (Gck) 
 
FWD: GATACCTGGGGAACAGCAAA 
REV: TAGGTGGAGACCCTGCTGAT 
FOXO1 (FOXO1) 
 
FWD:TCAGGCTAGGAGTTAGTGAGCA 
REV: GGGGTGAAGGGCATCTTT 
FOXO3A (FOXO3A) 
 
FWD:TTCAAGGATAAGGGCGACAG 
REV: GGCTGTGCAGTGACAGGTT 
Mlx (Mlx) 
 
FWD: TCTGTCCCCAACACAGATGA 
REV: ACGATGGCTTTGCTGAGTTT 
MondoA (Mlxip) 
 
FWD: ATCCACAGCGGCCACTTCATG 
REV: TCATGCACTCGAAGAGCTTGG 
GFAT1 (GFAT1) 
 
FWD: GCAGCCAGAATCTGTTGTGA 
REV: GCCATACCAGCGTGGTAACT 
GFAT2 (GFAT2) 
 
FWD: CCAGGCTGAAGAGACTGGAC 
REV: TCAGCCACTGCAGCAATATC 
Pck1 (Pck1) 
 
FWD: TGGCTACGTCCCTAAGGAA 
REV: GGTCCTCCAGATACTTGTCGA 
PFKFB3 (Pfkfb3) 
 
FWD: CACGGCGAGAATGAGTACAA 
REV: TTCAGCTGACTGGTCCACAC 
L-PK (Pklr) FWD: CTGGAACACCTCTGCCTTCTG 
Chapter 2                                                                            Materials and Method 
 37 
 
REV: CACAATTTCCACCTCCGACTC 
PTG (Ppp1r3c) 
 
FWD: GAGGATTTGCTTGGCACATT 
REV: CTTGGAGTCAGCAAACACGA 
GAPDH (GAPDH) 
 
FWD: AGGGCTGCCTTCTCTTGTGAC 
REV: TGGGTAGAATCATACTGGAACATGTAG 
CREB (CREB) 
 
FWD: TTCTACAATATGCACAGACCACTG 
REV: CATCACCAGAGGCAGCTTG 
TXNIP (Txnip) 
 
FWD: ACCAGTGTCTGCCAAAAAGG 
REV: GCCATTGGCAAGGTAAGTGT 
OGT (OGT) FWD: ACCCTTCTACCCTGCAGATG 
REV: GCATATTGTTGAATATTGGGCTCT 
 
2.1.7 Primers for ChIP assays 
 
Primers were designed using gene sequence information from NCBI databases 
and the NCBI primer designing tool. Primers were synthesised by MWG Operon 
Biotech Ltd (Milton Keynes, UK) (table 2-6). 
 Primers 
G6pc (ChoRE region) 
 
FWD: GCATCAGCCCTGTGTGAATA 
REV: GAGTTGAGGGCAAACAGAGC 
G6pc coding region FWD: CTACCTTGCGGCTCACTTTC 
REV: ATCCAAGTGCGAAACCAAAC 
TXNIP (ChoRE region) 
 
FWD: CGCACCCGAACAACAACCAT 
REV: AAGCGGGAGCCGGAAACGG 
TXNIP coding region FWD: ACCAGTGTCTGCCAAAAAGG 
REV: GCCATTGGCAAGGTAAGTGT 
 
2.2 Hepatocyte isolation and culture 
 
Rat hepatocytes were isolated by a two-step collagenase perfusion technique 
based upon the method of Seglen (Seglen, PO. 1976). The rat was killed by 
placing in a chamber saturated with Halothane vapour for 5 minutes.  Briefly, 
after lapaotomy, the portal vein and superior vena cava were cannulated and the 
liver was perfused with Ca2+-free EGTA-containing buffer (148 mM NaCl, 6.7 
mM KCl, 10 mM HEPES, 0.2 mM EGTA, 10 µg/ml phenol red, pH 7.4)  at 20-30 
ml/min for 15 min, followed by Ca2+ containing collagenase buffer (100 ml) (20 
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mg/100 ml collagenase, 124 mM NaCl, 6.7 mM KCl, 2 mM CaCl2, 1 mM 
MgSO4, 20 mM HEPES, 10 µg/ml phenol red, pH 7.4) until digestion (15-20 
min).  The liver was then dissociated in MEM supplemented with 75 mg/l 
penicillin and 50 mg/l streptomycin, 2 mM glutamine and 0.1 mM non-essential 
amino acids. The cell suspension was filtered through 80 µm nylon mesh and 
centrifuged at 50 g to pellet viable cells. The cell pellet was washed 3 times and 
suspended in MEM supplemented with 5% (v/v) neonatal calf serum, non-
essential amino acids, 2 mM L-glutamine, 75 mg/l penicillin and 50 mg/l 
streptomycin. Cells were seeded into gelatine coated (0.1% gelatine) multiwell 
plates and cultured at 37 °C equilibrated at 5% CO2 and 95% air. After cell 
attachment (4 h) MEM was removed and replaced with fresh MEM containing 5 
mM glucose with 10 nM dexamethasone and 10 nM insulin depending on the 
study, for overnight culture. For enzyme overexpression using recombinant 
adenoviruses, MEM was removed after attachment (2 h) and replaced by serum-
free MEM containing various titres of adenovirus (2 h-4 h). The medium was 
removed and replaced with fresh MEM containing 10 nM dexamethasone and 10 
nM insulin for overnight culture. Short-term experiments were carried out the 
following day (day1). 
 
2.3 Preparation of Radioactive substrates for metabolic studies 
 
For radiochemical assays, required amounts of [U-14C] glucose (1 µCi/ml), D-
glucosamine-1-14C (4-5 µCi/ml), N-acetylglucosamine-14C (2-3 µCi/ml), [2-
3H]glucose (1 µCi/ml), 3H-leucine (0.4-0.5 µCi/ml) were dried down under 
nitrogen gas to remove the 90% ethanol, solvent. The dried isotope was then 
transferred to the MEM. A 50 µl aliquot of the radioactive MEM was mixed with 
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1ml scintillation cocktail and counted using a liquid scintillation analyser for 
determination of specific activity (TRI-CARB 2700). 
 
2.3.1 Determination of glycogen synthesis 
 
Glycogen synthesis was determined from the incorporation of [U-14C] glucose 
into cellular glycogen which was isolated by ethanol (66%) precipitation. After 
overnight culture or short incubation with treatment, the cells were incubated with 
MEM containing [U-14C] glucose and other additions as indicated for 3 hours. At 
the end of the incubation the medium was removed and cells were washed once 
with 0.15 M NaCl and then extracted with 0.1 M NaOH (0.4 ml / well) and frozen 
until later analysis.  To precipitate protein, 250 µl of cell extract was added to 300 
µl of 20% trichloroacetic acid (TCA) containing 0.75 mg/ml glycogen and the 
mixtures vortexed and finally centrifuged at 13,000 g, 4 °C for 15 minutes.  500 µl 
of supernatant was added to 1ml of 95% ethanol and centrifuged for 20 minutes at 
13,000 g, 4 °C.  The supernatant was then aspirated and the pellet washed twice 
with 1ml of 66% ethanol and centrifuged for 15 minutes at 13,000 g, 4 °C. After 
the second wash, the pellet was left to dry overnight.  
The following day, 150 µl of deionised water was added to the pellet and heated at 
55 °C for 15 minutes to dissolve the pellet. 1ml of scintillation cocktail was added 
to the samples and vortexed until clear.  Radioactivity was then measured and 
results expressed as nmol of glucose incorporated into glycogen per 3 h per mg of 
protein. 
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Calculation 
 
 
 
  dpm  × Total vol of cell ext. in well × Total vol. of cell ext. + glycogen /TCA ×      1 
   SA      vol. added to glycogen/TCA        vol. added to ethanol                               Protein 
(dpm/nmol)                                                                                                                                   
(mg/well) 
 
= nmol of glucose incorporated into glycogen per mg of protein. 
 
 
2.3.2 Determination of incorporation of radiolabelled substrate into protein 
 
Inorporation of 14C-labelled glucose, 14C- or 3H -labelled glucosamine and 3H-
labelled leucine into protein was measured as described by (Simkin, JL. and 
Jamieson, JC. 1967). 
Following overnight culture or short incubation with treatment, cells were 
incubated with MEM containing glucosamine-1-14C (4-5 µCi/ml) or [U-14C] 
glucose (1-2 µCi/ml) or 3H-leucine (0.4-0.5 µCi/ml) or N-actylglucosamine-14C 
(2-3 µCi/ml) in MEM for the time interval indicated.  At the end of the incubation 
the medium was removed and cells were washed twice with 0.15 M NaCl.  Cells 
were then extracted with 200 µl of extraction medium (containing 5 mg/ml of 
BSA, 20mM GlcN in 0.1 M NaOH) and sonicated.  Protein was then precipitated 
by addition of 200 µl of 10% trichloroacetic acid (TCA) to 200 µl of cell extract 
followed by vortexing and centrifuged at 13,000 g, 4 °C for 15 minutes. The 
supernatant was aspirated and the pellet re-suspended in 500 µl of 5% 
trichloroacetic acid (TCA) containing 10mM GlcN followed by centrifugation for 
10 minutes at 13,000 g, 4 °C.   The following washes were then performed:  (i) 
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5% TCA; (ii) 0.1 M NaCl/acetone (2:8); (iii) Ethanol/ether/chloroform (2:2:1); 
(iv) Ether (x2) 
Following the final wash, pellets were left to air dry overnight.  The following 
day, pellets were re-suspended in 150 µl of 0.1M NaOH and heated at 55 °C for 
30 minutes.  Radioactivity was then measured   and results expressed as nmol of 
glucose incorporated into glycogen per 3 h per mg of protein. 
 
Calculation 
 
 
  
 
 =   dpm      ×    Total vol of cell ext. in well   ×        1 
      SA              vol. added to glycogen/TCA       Protein 
(dpm/nmol)                                                                                                                                   
(mg/well) 
 
= nmol of glucose incorporated into protein per 3h per mg of protein. 
 
2.3.3 Determination of glucose phosphorylation  
 
Glucose phosphorylation was measured from detritiation of [2-3H] glucose (1-2 
µCi/ml). After incubation, the medium was collected. Duplicate wells were pooled 
and 1 M HCl was added in the ratio of 10 % acid to the total sample volume. 50 µl 
of acidified sample was transferred to a 500 µl microcentrifuge tube which is 
placed inside a 5 ml scintillation vial containing 750 µl H2O and stoppered. For 
blank correction, the tubes were incubated at 37 °C for at least 2 days to allow the 
3H2O to equilibrate between the two solutions. To determine the level of tritiated 
water the small ependorf was removed and scintillation cocktail was added to the 
scintillation vial and counted. Results expressed as nmol of glucose detritiated per 
3 h per mg of protein. 
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Calculation 
 
 
 
 
 
 
= nmol of glucose detritiated per 3h per mg cell protein. 
 
 
 
2.4 Metabolite determination 
 
2.4.1 Glucose 6-phosphate (glucose 6-P) 
 
Glucose 6-P was determined using an endpoint fluorimeter coupled enzyme assay 
(Zhu et al. 2009). This method is based on the oxidation of glucose 6-P by glucose 
6-P dehydrogenase (G6PDH) to yield NADPH, which is then used to reduce 
resazurin in the presence of diaphorase to produce resorufin (see principle of 
reaction below). Resorufin is highly fluorescent and can be detected by excitation 
at 530 nm and emission at 590 nm using a fluorimeter.  
 
Principle of the reaction: 
                                                 
                                           G6PDH 
Glucose 6-P + NADP                                     6-phosphogluconate + NADPH 
 
                                         Diaphorase 
NADPH + Resazurin                                     NADP + Resorufin (Ex 530, Em 590) 
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After incubation, cells were snap frozen in liquid nitrogen and plates stored at -80 
°C, until extraction. Cells were extracted in 150 µl of 3% perchlorinc acid, 
sonicated, transferred to microcentrifuge tube and centrifuged for 10 minutes, 
13000g at 4°C.  
The supernatants (100 µl) were neutralised with 5 M KOH.   The perchloric acid 
solution was first titrated against 5 M KOH using universal indicator to determine 
the exact volume for neutralisation. The acid extracts were then neutralised with 
the estimated volume of 3 M KOH without indicator which inteferes with the 
assay. Samples were cooled for a few minutes on ice to precipitate KClO4 and 
centrifuged for 5 minutes, 13000g at 4°C.  
Glucose 6-P was then assayed using glucose 6-phosphate dehydrogenase from the 
rate of formation of NADPH.  The assay cocktail contained 50 mM Tris-base 
neutralised with acetic acid to pH 7.8, 1 mM NADP, 2 mM EDTA and 0.03 Units 
/ ml (5 µl of 1:5 dilution 700 U/ml) glucose 6-phosphate dehydrogenase.  
 Glucose 6-phosphate standards (5, 10 and 20 µM) were prepared in perchloric 
acid and neutralised similarly to the samples.   
 
2.4.2 Fructose 2,6-bisphosphate (F2,6-P2) 
 
F2,6-P2 was determined by measurement of NADH absorbance using kinetic 
analysis at 340 nm, 37°C. Decreased NADH is indicative of activation of PPi-
PFK by F2,6-P2 and is a measure of F2,6-P2 concentration,: 
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Principle of the reaction: 
       Fructose 2,6-P2 
 
                                                         PPi-PFK 
      Fructose 6-P + PPi                                                         fructose 1,6-P2 + Pi 
 
          aldolase 
      Fructose 1,6-P2                                                          Glyceraldehyde 3-P 
 
                                        Triosephosphate isomerase (TPI) 
     Glyceraldehyde 3-P                                                         DHAP 
 
                                                   G3PDH 
DHAP + NADH + H+                                               Glycerol 3-phosphate + NAD+ 
 
 
On termination of incubations, the MEM was aspirated and 0.15 M NaOH was 
added (400 µl/well, 12-well plate), before the plate was heated at 80°C for 5 min. 
Plates were then cooled and stored at -20°C. On the day of the assay, standards of 
5, 10, 20, 40, 60, 100, 150 and 300 nM F2,6-P2 were prepared. Plates were thawed 
and samples were sonicated in the plate before 10 µl of samples and standards 
were added to a 96-well plate. 120 µl of main reagent (described below) was then 
added to each well and NADH absorbance was measured by kinetic analysis at 
340 nm, 37°C. Levels of F2,6-P2 were determined using a F2,6-P2 standard curve 
and results are expressed as pmol/mg cell protein.  
Main reagent: 0.1 M Tris-acetate, 2 mM Mg-acetate, 1 mM fructose 6-P* 
(described below), 0.15 mM NADH, Aldolase A2714 (0.5 U/ml), 
Glycerophosphate dehydrogenase / triosephosphate isomerase (1 U/ml), PPi-PFK 
(0.01 U/ml) and 0.45 mM pyrophosphate.  
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*Fructose 6-P was acidified to destroy contaminating F2,6-P2: 304 mg 
disodium salt was dissolved in 5 ml water. 2 ml of 1 mol/l HCl was then added 
and incubated at 37°C for 10 min, before the solution was neutralised with 0.95 
ml of 2 M NaOH and aliquoted.  
 
2.4.3 Determination of Glucosamine 6-phosphate(GlcN 6-P) and N-
Acetylglucosamine (NAG) 
Principle: 
 
A modified colorimetric method for the estimation of GlcN 6-P and NAG was 
used (Morgan and Elson, 1934; Ghosh et. al., 1960). 
 
Stock Reagents: 
Ehrlich’s reagent (0.5 g of 4-dimethylaminobenzaldehyde added to 625 µl of 10 
M HCl and then diluted to 50 ml with glacial acetic acid) . 
NaHCO3, saturated solution 
5% acetic anhydride solution (prepared fresh and kept cold) 
0.8 M Sodium borate solution (pH 9) 
5% (v/v) Perchloric acid (PCA) (4 ml 60% stock made up to 48 ml with water). 
3 M K2CO3 
Hepatocyte extraction and neutralisation:  
After incubation, cells were snap frozen in liquid nitrogen and plates stored at -80 
°C, until extraction. Cells were extracted in 5% perchloric acid (PCA) (150-200 µl 
for 6 well plates), transferred to ependorfs and centrifuged for 15 minutes, 13000g 
at 4°C.  
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The supernatants (100-150 µl) were neutralised with (16-24 µl) 3 M K2CO3 using 
universal indicator. Samples were cooled a few minutes on ice to precipitate 
KClO4 and centrifuged for 5 minutes, 13000g at 4°C.  
Standard preparation: 
GlcN and NAG standards (5, 20, 50, 100, 150 and 200µM) were prepared in 
perchloric acid and neutralised similarly to the samples.   
The Procedure: 
 
80 µl of hepatocyte neutralised extracts and standards were treated with 10 µl of 
saturated NaHCO3 solution and with or without 10 µl of ice-cold 5% acetic 
anhydride solution for determination of GlcN 6-P or NAG respectively. After 
vigorous shaking, the tubes were left at room temperature for 3 minutes and then 
heated in a heater block at 100 °C for 3 minutes to destroy excess acetic anhydride 
and the tubes cooled at room temperature. The tubes were treated with 20 µl of 0.8 
M sodium borate solution (pH 9), mixed and then heated in a heater block at 100 
°C for 3 minutes. After cooling, the tubes were treated with 600 µl of Ehrlich’s 
reagent. The tubes were incubated for 20 minutes at 37 °C. The optical densities 
were measured in a spectrophotometer at 585 nm.  
 
2.5 Enzyme activity determination  
 
 
2.5.1 Determination of Glycogen phosphorylase-a (GPa) 
 
Glycogen phosphorylase-a  (GPa) activity was measured in the glycogenolytic 
direction spectrometrically by coupling to phosphoglucomutase (PGM) and 
glucose 6-phosphate dehydrogenase (G6PDH) and measuring NADPH production 
from the increase in absorbance at 340 nm.  
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       PGM 
Glycogen              G-1-P                               G-6-P                   6-phosphogluconate 
     Pi                G16P2            NADP                NADPH     
 
After overnight culture or short incubation with treatment, cells were immediately 
snap frozen in liquid nitrogen and stored at -80 °C until use. 200 µl equivalent of 
extraction buffer (25 mM Hepes pH 7.5, 150 mM KF, 0.5 mM EDTA, 1 mM 
PMSF and 1 mM benzamidine) was added to 1 well of a 24 well plate, cells 
sonicated and centrifuged at 13,000 g, 4 °C for 6 minutes.  Assays were 
performed in 96-well plates containing 50 µl of the sample supernatant and 200 µl 
of main reagent (50 mM Imidazole pH 7.5, 50 mM NaF, 0.5 mM EDTA, 2 mM 
MgCl2, 0.5 mM Caffeine, 2 mg/ml glycogen, 0.5% of 100 mM NADP, 0.5% of 1 
mM G16P2, 0.33 U/ml PGM and 0.44 U/ml G6PDH, 2.5 mM phosphates.  
Enzyme activity was monitored for 18 minutes and determined from the linear 
rate of increase in absorbance at 340 nm.  Enzyme activities are expressed as 
milliunits per mg cell protein, where 1 munit is the amount of enzyme needed to 
convert 1 nmol of substrate per min. 
 
 
2.5.2 Determination of GFAT activity 
 
Glutamine:fructose 6-phosphate amidotransferase (GFAT)  activity was 
determined from an end point assay with glutamine and fructose 6-P to form GlcN 
6-P, which was then measured after acetylation by a modified colorimetric 
method for the estimation of GlcN 6-P and NAG (Ghosh, S. et. al., 1960).  
Hepatocytes were extracted in 200 µl of buffer containing 25 mM HEPES, 150 
mM KF, 0.5 mM EDTA, 1 mM PMSF, 1 mM benzamidine (pH 7.5), 2mM 
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glutamine, 2mM fructose 6-phosphate and protease inhibitor cocktail (1/1000). 
Cells were transferred to microcentrifuge tube and incubated for 1 hour at 37 °C 
and then heated in a heater block at 100 °C for 3 minutes to destroy the enzyme. 
Levels of GlcN 6-P and NAG were determined as described in section 2.4.3.  
 
2.6 Determination of mRNA and protein expression  
2.6.1 Semi-quantitative real-time (RT)-PCR 
 
This study utilised semi-quantitative real-time (RT)-PCR for determination of 
steady state mRNA levels.  RNA was extracted from rat hepatocyte monolayers 
using Trizol reagent. Culture medium was removed and cells washed once with 1 
x saline (150 mM NaCl) followed by the addition of 250 µl trizol (24-well plates) 
and vigorous scraping.  Trizol was then transferred to individual eppendorfs and 
incubated at room temperature.  After 5 minutes 200 µl of chloroform was added 
and samples shaken vigorously for 15 seconds followed by incubation at room 
temperature for 2 minutes.  Samples were then spun at 12,000g, 4˚C for 15 
minutes and the aqueous upper phase transferred to fresh eppendorf tubes and 
isopropanol (0.5 ml per 1ml TRIZOL extracted) added and mixed thoroughly.  
Following incubation at room temperature for 10 minutes, samples were spun at 
12,000g, (4˚C, 10 minutes) and supernatant removed.  Pellets were washed with 
250 µl 75% ethanol (diluted in pure H2O, Sigma-Aldrich, UK), and re-pelleted by 
a final centrifugation at 7,500g, 4˚C for 5 minutes.  Ethanol was aspirated and 
samples air dried at room temperature for 10 minutes.  Finally, pellets were 
resuspended in 10 µl H2O and incubated at 55˚C for 10 minutes. 
 
Chapter 2                                                                            Materials and Method 
 49 
Reverse Transcription 
Genomic DNA was removed by treatment with RNase free DNase I for 15 
minutes at 37°C, followed by denaturation of the enzyme at 70°C for 10 minutes.  
The RNA was quantified on Spectromax (260:280 nm).  Primer random (1 µg/ml) 
was added to 1 µg RNA and samples incubated for 10 minutes at 70˚C.  Samples 
were incubated for 1 hour containing 1 x RT buffer, 10mM DTT, 250 µM dNTP 
mix, 5 U/µl Superscript II reverse transcriptase at 42˚C or M-MLV reverse 
transcriptase at 37˚C. The total volume of cDNA was 40 µl and the final 
concentration was 25ng/µl.  RT-PCR was performed with 50ng of reverse 
transcribed RNA, in a final volume of 10µl PCR reaction mixture containing 
0.5µM of forward and reverse primer, 3mM MgCl2 and 1 x lightCycler FastStart 
DNA Master SYBR. There are four programmes designed for PCR; pre-
incubation and denaturation, amplification, melting curve and cooling.  Samples 
were denatured at 95˚C for 10 minutes, followed by 40 cycles consisting of 95˚C 
for 15 seconds, 58˚C for 7 seconds and 72˚C for 15 seconds.   
 
2.6.2 Western blotting 
 
Hepatocytes were extracted in a buffer containing 25 mM HEPES, 150 mM KF, 
0.5 mM EDTA, 1 mM PMSF, 1 mM benzamidine (pH 7.5), followed by 
sonication. The samples were diluted with 0.25 volumes of 4 x SDS loading 
buffer containing 0.5 M Tris, 10 % SDS (w/v), 10 % glycerol, 4 % 
mercaptoethanol and 0.1 % bromophenol blue in ethanol and denatured at 100 °C 
for 5 min. The samples were loaded into SDS polyacrylamide gel for 
electrophoresis (180 V for 60 min). After electrophoresis, the gels were 
electrophoretically transferred (semi-dry) onto nitrocellulose membranes (ECL 
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Hybond N, Amersham Biosciences Buckinghamshire, UK) using a Trans-Blott 
SD semi-dry transfer cell from Biorad Laboratories Ltd. (Hertfordshire, UK) at 15 
V for 50 min. 50 ml transfer buffer (30 g Tris base, 144 g glycine, 150 ml 
methanol and 800 ml water) was used. Membranes were stained with Ponceau 
Red (0.1 %) to verify equal amounts of protein between lanes prior to Western 
blot analysis. After Ponceau Red staining the membranes were blocked 1h in 
TBST (3.035 g Tris base, 8.4 g NaCl, 2 ml concentrated HCl, 5 ml Tween-20 and 
1 liter water) containing 5 % BSA. Membranes were incubated with the primary 
antibody overnight. Membranes were washed vigorously four times in TBST. 
They were then incubated with the peroxidase conjugated anti-rabbit/mouse IgG 
secondary antibody for 1h. They were washed four times in TBST as before. 
Membranes were developed using ECL chemiluminescence reagent according to 
the manufacturer’s instructions followed by brief exposure to ECL X-ray film.  
 
2.6.3 Determination of cellular protein  
 
Cellular protein on the NaOH (0.1M) extracts was measured spectrometrically by 
a modified Lowry method. The basic principle of this reaction is that an active 
constituent of Folin-phenol reagent, phosphomolybdic-tungstic acid, is reduced by 
protein to form a coloured complex which can be measured at 750 nm.  
A combination of start and main reagents are used in the assay.  The main reagent 
(10% (w/v) Na2CO3 in 0.5 M NaOH, H2O, CuSO4.5H2O and Na+/K+ tartate in a 
10:40:1:1 ratio) is activated with Folin and Ciocalteu’s phenol diluted with 
distilled water in a 1:1 (v/v) ratio.  BSA standards at 0.25, 0.5 and 1 mg/ml were 
diluted in 0.1M NaOH and used for the standard curve.  
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2.7  Immunoprecipitation assays 
 
2.7.1 Wheat germ agglutinin (WGA) precipitation 
 
Hepatocytes were extracted in a buffer (pH 7.5) containing 25 mM HEPES, 150 
mM KF, 0.5 mM EDTA, 1 mM PMSF, 1 mM benzamidine and 1:1000 with 
protease inhibitor cocktail,  followed by addition of 30ul WGA agarose beads 
with or without 5mM N-acetylglucoseamine (NAG) for 2h at 4 °C. After three 
washes with extraction buffer with or without 5mM NAG, the samples were 
diluted 1:1 with 4 x SDS loading buffer containing 0.5 M Tris, 10 % SDS (w/v), 
10 % glycerol, 4 % mercaptoethanol and 0.1 % bromophenol blue in ethanol and 
denatured at 100 °C for 5 min. The samples were then processed by western 
blotting as detailed in section 2.6.2. 
 
2.7.2 Chromatin Immunoprecipitation (ChIP) 
 
2.7.2.1 Chromatin Immunoprecipitation 
 
ChIP assays were performed using the ChIP Assay Kit protocol (Millipore) with 
slight modifications. Cross-linking of hepatocytes was performed by addition of 
formaldehyde to incubation medium to a final concentration of 1% for 10 min at 
37 ºC, before addition of glycine to a final concentration of 0.125M for 5 min at 
room temperature to quench the cross-linking reaction. Samples were washed 
twice and harvested with ice cold PBS containing 1mM PMSF and 1:300 protease 
inhibitor cocktail. Cells were pelleted by centrifugation for 4 min at 2,000 g and 
resuspended in 3ml SDS lysis buffer (1% SDS, 10mM EDTA, 50 mM Tris, pH 
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8.1). Cell lysates were then sonicated using Bioruptor UCD-300 on high setting 
with 10 cycles of 30 seconds on and 20 seconds off, to give sheared DNA 
fragments between 100 and 1000bp in length, then centrifuged at 13,000g for 10 
min at 4 ºC and 500µl cell supernatants were diluted 10-fold in ChIP dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH 
8.1, 167mM NaCl). Diluted cell supernatants were pre-cleared with 75µl protein 
A agarose / salmon sperm DNA (50% slurry) containing 600µg sonicated salmon 
sperm DNA (Sigma-Aldrich cat no. 31149), 1.5mg BSA and 4.5mg recombinant 
protein A agarose (Upstate Biotechnology cat no. 16-125) suspended in TE 
buffer, pH 8.0. Following centrifugation at 1,000g for 2 min to pellet agarose, cell 
supernatants were incubated with 6µg of antibodies against either IgG, Acetyl-H4, 
ChREBP, MondoA, FOXO1, FOXO3A or NF-Y, overnight with rotation at 4 ºC. 
IgG, Acetyl-H4, ChREBP, MondoA, FOXO1, FOXO3A and NF-Y 
immunocomplexes were collected by incubation with 120µl protein A 
agarose/salmon sperm DNA (50% slurry), whilst Mlx immunocomplexes were 
collected by incubation with 120µl protein G agarose (Upstate Biotechnology cat 
no. 16-266) / salmon sperm DNA (50% slurry) for 3 h with rotation at 4 ºC. Beads 
were washed with low salt (catalog no. 20-154), high salt (cat. no. 20-155), LiCl 
(cat. no. 20-156) and TE (cat. no. 20-157) wash buffers for 5 min each with 
rotation at 4 ºC. Immune complexes were eluted by addition of 250µl elution 
buffer (1% SDS, 0.1M NaHCO3) for 30 min with rotation at room temperature. 
Elution was performed twice and the eluates combined to give a total volume of 
500µl, and cross-links were reversed with addition of 20µl 5M NaCl and heating 
at 65 ºC for 4 hr. Samples were then incubated with 0.5M EDTA, 1M Tris-HCl, 
pH 6.5 and Proteinase K for 1 h at 45ºC. DNA was recovered by 
phenol/chloroform extraction. 
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2.7.2.2 Phenol/chloroform extraction 
 
Phenol/chloroform extraction was performed on eluted immune complexes 
(approximately 500µl total volume). 500µl phenol/chloroform/isoamyl alcohol 
mixture was added to eluted immune complexes and samples vigorously shaken 
before being centrifuged at 13,000g for 5 min. 450µl of supernatant was 
transferred to fresh eppendorf tubes and combined with 950µl 95% ethanol and 
25µl 10M NH4OAc before centrifugation at 13,000g for 5 min. Supernatants were 
removed using a needle and syringe and pellets were washed with 250µl 70% 
ethanol, before samples were vortexed and centrifuged at 13,000g for 2 min. 
Ethanol was removed using a needle and syringe and pellets were left to air dry 
for approximately 15 min. Pellets were then resuspended in 10µl molecular 
biology grade H2O and heated at 55ºC for 10 min.  
 
2.7.2.3 Touchdown real-time PCR 
 
Touchdown real-time PCR was performed on DNA recovered by 
phenol/chloroform extraction using 1µl DNA, 0.5µmol/l of each primer (listed in 
Table 2.6) and 1x LightCycler FastStart DNA Master SYBR Green I in a final 
reaction volume of 10µl in LightCycler capillaries run on a Roche LightCycler. 
Samples were denatured at 95°C for 10 min followed by 2 cycles of 95°C for 15 
sec, 68°C for 7 sec (annealing) and 72°C for 15 sec (elongation). The annealing 
temperature was then lowered by 1°C every 2 cycles until the final annealing 
temperature of 58°C was reached, whereby 30 cycles of 95°C for 15 sec, 58°C for 
7 sec and 72°C for 15 sec were performed. This method of real-time PCR gives a 
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selective advantage to the specific PCR product over the spurious non-specific 
products that can appear at lower annealing temperatures, and thereby improves 
the sensitivity and specificity of the PCR reaction. Melt curve analysis was also 
performed to confirm amplification of specific transcripts only, and all the primer 
sets listed in Table 2.6 produced only a single peak on their respective melt 
curves, therefore confirming specificity of all primer sets used.  
 
2.8 Immunostaining 
 
Immunostaining was performed to determine the changes in subcellular 
localisation of ChREBP, FOXO1, FOXO3A and SREBP1c in response to 
different substrates in hepatocytes. Hepatocytes were cultured on glass coverslips 
that had been sterilised with ethanol, flame dried and placed in 24-well plates.  
 
2.8.1 Fixation 
Upon termination of short-term incubations, MEM was aspirated and coverslips 
were washed twice with PBS. Cells were fixed by addition of 4% 
paraformaldehyde (described below) and incubation for 30 min at room 
temperature. Paraformaldehyde was then aspirated and coverslips were washed 
twice with 1xPBS.  
 
4% paraformaldehyde: 1g paraformaldehyde was dissolved in 50ml nanopure 
H2O (heated to 70-80°C) with 200µl 2M NaOH and 5ml 10xPBS. 
Paraformaldehyde was then cooled on ice before being used for fixation.  
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2.8.2 Immunofluorescence 
500µl 1mg/ml sodium borohydride (made up in 1xPBS) was added to each 
coverslip and incubated for 10 min at room temperature to quench 
autofluorescence of hepatocytes. Coverslips were then washed twice with 1xPBS 
and 500µl 0.2% Triton-X100 (made up in PBS) was added and incubated for 10 
min at room temperature to permeabilise the cells and improve antibody 
penetration. Coverslips were then washed twice with 1xPBS and transferred to a 
12-well plate lined with parafilm. 25µl 1% BSA / 0.2% Triton-X100 was added to 
each coverslip and incubated for 10 min at room temperature to act as a blocking 
solution to reduce background and unspecific staining. Cells were then washed 
twice with 1xPBS and 25µl primary ChREBP, FOXO1, FOXO3A or SREBP1c 
antibodies (described below) were added to each coverslip and incubated for 2 – 3 
h at room temperature or overnight at 4°C. Primary antibody was removed and 
cells washed with 1xPBS three times for 10 min each on a shaker, before 25µl 
Alexa Fluor 488-conjugated anti-rabbit or mouse secondary antibody (described 
below) was added to each coverslip and incubated for 1 h at room temperature. 
Secondary antibody was then removed and cells were washed with 1xPBS three 
times for 10 min each on a shaker. 0.2µg/ml DAPI was then added to cells and 
incubated for 5 min at room temperature to stain nuclei before cells were washed 
twice with 1xPBS, then placed on a paper towel and allowed to air dry for 20 – 30 
min.  
Primary antibody (1:150 dilution) (volume per coverslip) 
0.17µl ChREBP, FOXO1, FOXO3A or SREBP1c antibodies 
2.5µl 10% BSA in PBS 
12.5µl 0.2% Triton-X100 in PBS 
9.83µl 1xPBS  
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Secondary Alexa Fluor 488-conjugated antibody (1:50 dilution) (volume per 
coverslip) 
0.5µl Alexa Fluor 488-conjugated antibody 
2.5µl 10% BSA in PBS 
12.5µl 0.2% Triton-X100 in PBS 
9.5µl 1x PBS 
 
2.8.3 Mounting and imaging of coverslips 
 
Once coverslips had air dried, they were mounted face down onto glass slides 
using Mowiol R-4088 containing 2.5% DABCO to help prevent fading of the 
immunofluorescent dyes (Valnes and Brandtzaeg 1985). Coverslips were left to 
dry and then examined using a Nikon E400 fluorescent microscope. Images were 
taken at 40x magnification and captured using a Nikon DXM1200 digital camera. 
For quantification, >100 cells were imaged for each substrate condition and 
ChREBP, FOXO1, FOXO3A or SREBP1c localisation was scored as to whether: 
i) cytoplasm > nuclear; ii) nuclear ≥ cytoplasm. The percentage of cells displaying 
either greater cytoplasmic or nuclear ChREBP, FOXO1, FOXO3A or SREBP1c 
was then calculated.  
 
2.9 Statistical analysis 
Results are expressed either as means ± SEM or are representative of the number 
of experiments indicated. Statistical analysis was performed with the Student’s 
paired t-test experiments. A P value of < 0.05 was considered to be statistically 
significant.  
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The Hexosamine pathway: flux measurements and concentrations 
of pathway intermediates 
 
3.1 Aims and rationale 
After glucose enters the liver cell it is metabolised to glucose 6-phosphate by 
glucokinase which is a key regulatory step in glucose metabolism. Glucose 6-
phosphate is either metabolised by glycogenesis or the pentose phosphate pathway 
or it is converted to fructose 6-P which can either enter into glycolysis or the 
HBP. According to Marshall and colleagues from studies on adipocytes and other 
cell types, about 2-5 % of total intracellular glucose enters the HBP (Marshall et 
al., 1991). The HBP involves the conversion of fructose 6-P and glutamine to 
GlcN 6-P, a reaction catalysed by the rate-limiting step enzyme 
glutamine:fructose 6-phosphate amidotransferase (GFAT). GlcN can also enter 
the HBP by phosphorylation to GlcN 6-P which bypasses the rate-limiting GFAT 
step. Conversion of GlcN to GlcN 6-P is catalysed by glucokinase (Van 
Schaftingen, 1995). GlcN 6-P is ultimately converted into uridine diphosphate-N-
acetylglucosamine (UDP-GlcNAc) which is the substrate for various 
glycosylation modifications which include N-GlcNAcylation and  O-
GlcNAcylation of proteins in the ER and Golgi compartments or O-
GlcNAcylation of protein in the cytoplasm or nucleus (Copeland et al., 2008; Hart 
et al., 2011) (Fig. 3.1).    
One of the enzymes that uses UDP-N-acetylglucosamine as substrate is O-linked 
beta-N-acetylglucosamine transferase (OGT) which catalyses the transfer of O-
GlcNAc to serine and threonine residues (Copeland et al., 2008; Wang et al., 
2009). This reaction is reversed by the enzyme beta-N-acetylglucosaminidase 
(OGA or also known as O-GlcNAcase) which catalyses the removal of the O-
GlcNAc group. The role of O-linked glycosylation of proteins has been studied  
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using inhibitors of OGT and OGA or by overexpression of these proteins. Various 
studies have suggested a role for this covalent modification in the regulation of 
insulin action by regulating Akt on Ser473 and Thr303 in hepatoma cells (HepG2) 
(Soesanto et al., 2008) and in adipose tissue (Yang et al., 2008). Studies on 
adipose tissue have reported that the HBP plays an important role in regulating 
gene expression of the lipogenic enzyme FAS and ACC (Rumberger et al., 2003). 
A recent study in hepatocytes reported that the HBP plays a key role in insulin 
resistance by inducing gene expression of G6Pc (Dentin et al., 2008). Other 
studies have reported that overexpression of GFAT which increases flux through 
the HBP results in ER stress and accumulation of lipid by induction gene 
expression of fatty acid synthase (FAS) in hepatoma cells (HepG2) (Sage et al., 
2010).  
 
The aims of this study were: first, to test the validity of GFAT inhibitors and 
substrates that enter the HBP after the GFAT catalysed reaction as potential tools 
to study the role of the HBP in control of gene expression; second, to determine 
whether the hepatocellular concentrations of down-stream intermediates of the 
HBP are altered by various substrates that enter the HBP either before or after 
GFAT; third, to estimate flux through the HBP in hepatocytes at glucose 
concentrations that are commonly used to study glucose-regulated gene 
expression; fourth, to test whether inhibitors of OGT and OGA can be used as 
potential tools to study the role of covalent modification of proteins in cell 
regulation. 
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3.2 Results 
 
3.2.1 Glutamine: fructose-6-phosphate amidotransferase (GFAT) activity in 
hepatocytes and effects of inhibitors 
Previous studies have used azaserine (AZN) and 6-diazo-5-oxo-l-norleucine 
(DON) at concentrations of 20-40 µM to inhibit GFAT activity and flux through 
the HBP in adipocytes (Marshall et al., 1991).  These studies showed that these 
inhibitors block the insulin resistance caused by high glucose in various non-
hepatic cells (Zachara and Hart, 2006; McClain and Crook, 1996). However, the 
effects of these inhibitors on GFAT activity in hepatocytes have not been 
reported. The first aim was to determine the concentrations of AZN and DON and 
incubation time required to inhibit GFAT activity in primary hepatocytes. 
Hepatocytes were incubated with AZN or DON at 20 µM for either 4 h or 18 h 
and the enzyme activity of GFAT was determined in supernatants of hepatocyte 
lysates by incubation with fructose 6-P and glutamine in an end-point assay 1h 
(Ye et al., 2003). On termination of the assay the product (GlcN 6-P) was 
acetylated and determined by the method of Morgan and Elson (Morgan and 
Elson, 1934; Ghosh et al., 1960).  The assay was validated from sample blanks 
from which glutamine was omitted.  In contrast with previous studies on 
adipocytes where AZN was shown to be a potent inhibitor of GFAT at 
concentrations of 2-10 µM in 18 h incubation (Marshall et al., 1991), in this study 
there was only 17% inhibition of GFAT activity after 18 h incubation with 20 µM 
AZN (Fig 3.2, A). However, there was 70% inhibition with 20 µM DON after 18 
h.  Figure 3.2 B, shows concentration-dependent inhibition of GFAT activity by 
DON (5, 10, 20 and 40 µM) on GFAT activity after 18 h (39, 68, 73 and 96 %). 
The results show maximum inhibition at 40 µM DON.   
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3.2.2 GFAT mRNA expression in hepatocytes and absence of effect of DON 
The activity of GFAT in rat liver has different kinetic properties from that in other 
tissues (Huynh, QK. et al. 2000). There are two isoforms of GFAT encoded by 
separate genes: GFAT1, which is expressed in all tissues and GFAT2 which 
differs in its kinetic and regulatory properties and is expressed in liver (Ye et al., 
2004; Huynh et al., 2000; Zhou et al., 1998; Oki et al., 1999; Hu et al., 2004). The 
next aim was to determine gene expression of GFAT (GFAT1 and GFAT2) with 
or without 40 µM DON. Hepatocytes were incubated with the GFAT inhibitor 
DON at 10, 20 and 40 µM for 18 h and mRNA levels were determined. The 
results showed that there was no effect of DON on GFAT 1 and GFAT2 mRNA 
expression (Fig. 3.3).   
 
3.2.3 Absence of effect of DON on glucose phosphorylation  
 
After finding that GFAT activity in hepatocytes can be inhibited by more than 
90% by 40 µM DON during culture for 18 h we next tested whether this treatment 
affects glucose phosphorylation, the first reaction in glucose metabolism.  This 
was measured using [2-3H] glucose which measures the glucokinase catalysed 
reaction.  There was no significant effect of 20 µM and 40 µM DON on glucose 
phosphorylation (Fig 3.4).  This suggests that DON (40 µM for 18 h) can be used 
to inhibit GFAT without inhibiting glucose phosphorylation. 
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3.2.4 Measurement of intermediates of the hexosamine biosynthesis pathway: 
effects of substrates 
 
3.2.4.1 Effects of glucose and GFAT inhibitors on accumulation of NAG-
metabolites in hepatocytes 
 
Having established the concentration of DON and incubation time required to 
inhibit GFAT activity in hepatocytes, the next aim was to determine the effects of 
glucose and other substrates on the concentrations of metabolic intermediates of 
the HBP and also to determine whether DON affects the concentrations of these 
intermediates.  In the HBP, GlcN 6-P the first intermediate is converted by 
acetylation to N-acetylglucosamine (NAG 6-P) which is metabolised to N-
acetylglucosamine 1-P (NAG-1-P) and then to UDP-N-acetylglucosamine. NAG-
metabolites were measured by the method of Morgan and Elson which measures 
all N-acetylglucosamine metabolites.  Incubation of hepatocytes with 25 mM or 
50 mM glucose for 4 h caused a 2-3 fold increase in concentration of NAG-
metabolites relative to 5 mM glucose (Fig 3.5). Pre-treatment of the hepatocytes 
with 20 µM DON for 18 h partially counteracted the increase in NAG-metabolites 
caused by high glucose. While pre-treatment with 40 µM DON totally 
counteracted the increase in NAG-metabolites caused by 25 mM and 50 mM 
glucose (Fig 3.5).    
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3.2.4.2 Effect of glutamine and octanoate on NAG-metabolites in hepatocytes 
 
We tested the effects of glutamine which is a substrate for GFAT (Fig 3.1) and 
octanoate which is a source of acetyl units for acetylation of GlcN 6-P to N-
acetylglucosamine 6-P (Fig 3.6, A,B) on the total concentration of NAG-
metabolites in hepatocytes incubated with 5 mM or 25 mM glucose for 4 h. These 
experiments showed that 10mM glutamine caused a small but significant increase 
in concentration of NAG-metabolites at high glucose  (Fig. 3.6A) and octanoate 
also caused a significant increase NAG-metabolites at high glucose (Fig. 3.6B).  
 
3.2.4.3 Effects of glucosamine (GlcN) and N-acetylglucosamine (NAG) on N-
Acetylglucosamine metabolites 
 
The above studies show that accumulation of NAG metabolites of the HBP is 
increased between 2 and 3 fold by 25 mM and 50 mM glucose (Fig. 3.5).  The 
next aim was to compare the effects on the accumulation of NAG metabolites of: 
(i) GlcN, which enters the HBP after GFAT and is generally used at 
concentrations as high as 10 mM in studies of the HBP in hepatocytes and 
hepatoma cells (Dentin et al., 2008; Taylor et al., 2009) and (ii) NAG which 
enters the HBP after the acetylaton of GlcN 6-P.   The effects of a range of 
concentrations of GlcN and NAG on the accumulation of HBP intermediates 
(NAG-metabolites) were tested. These experiments showed that GlcN (0.5 to 10 
mM) caused a concentration dependent accumulation of HBP-metabolites with a 
similar effect of 0.5mM GlcN as high glucose concentration. However, higher 
concentrations of GlcN (1, 5 and 10mM) caused a much larger stimulation (9-50-
fold) than glucose (Fig. 3.7, A). NAG (10 mM and 20 mM) also caused a  
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significant increase in NAG-metabolites but this was much smaller than the 
increase caused by GlcN (Fig 3.7, B). This could be because NAG is transported 
into hepatocytes less efficiently than GlcN (Van Schaftigen, 1995) or because it is 
phosphorylated by a different kinase from GlcN. 
 
3.2.4.4 Accumulation of GlcN 6-P with GlcN 
 
Because glucosamine caused a large accumulation of NAG-metabolites (Fig. 3.7, 
A) in further experiments the effect of GlcN on both GlcN 6-P and NAG 
metabolites was determined by using a modification of the method of Morgan and 
Elson (Morgan and Elson, 1934; Ghosh et al., 1960), involving acetylation of the 
samples with acetic anhydride to convert GlcN 6-P to NAG 6-P. The acetylated 
sample measures the sum total of GlcN 6-P and NAG-metabolites and the 
difference between acetylated and non acetylated samples (NAG-metabolites) 
measures GlcN 6-P. From this data we can see that at 1 mM and 5 mM GlcN there 
is accumulation of both GlcN 6-P and NAG-metabolites, but at 10 mM GlcN 
there is a much greater accumulation of GlcN 6-P than of NAG-metabolites (Fig 
3.8). This means that above 5 mM GlcN, the enzyme glucosamine 6-phosphate N-
acetyltransferase (GlcN 6-P NATase) becomes the rate limiting enzyme resulting 
in accumulation of its substrate.   
 
3.2.4.5 Effects of GlcN and NAG on glucose phosphorylation, glucose 6-
phosphate and phosphorylase-a in hepatocytes. 
 
The above experiments demonstrate that both GlcN and NAG cause a large 
increase in NAG metabolites accumulation. The next step was to determine the  
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effects of GlcN on glucose phosphorylation and glucose metabolism, to test 
whether GlcN concentrations can be found that raise NAG-metabolites without 
interfering with other metabolic pathways of glucose metabolism. The initial 
experiments tested the effects of a range of concentrations of GlcN (0.1 to 5.0 
mM) on glucose phosphorylation, glucose 6-P, glycogen synthesis and the activity 
of glycogen phosphorylase. These experiments showed that GlcN caused a 
concentration dependent inhibition of glucose phosphorylation (Fig. 3.9A), 
lowering of glucose 6-P (Fig. 3.9B), activation of glycogen phosphorylase-a (Fig. 
3.9C) and inhibition of glycogen synthesis (Fig. 3.9D), with significant effect at 
0.5 mM GlcN for glucose phosphorylation, glucose 6-P and glycogen synthesis (P 
< 0.05) and 2.0 mM GlcN for glycogen phosphorylase-a (P < 0.05).   
Because GlcN is a competitive inhibitor of glucokinase, the inhibition of glucose 
phosphorylation by GlcN is probably explained by a direct effect of GlcN on 
glucokinase. This was tested in hepatocytes overexpressing glucokinase (Fig. 
3.9E).  In these experiments which have a higher glucokinase activity, as shown 
by the 2-fold increase in glucose phosphorylation (Fig. 3.9E), significant 
inhibition occurred at higher GlcN concentration (2 mM rather than 0.5 mM).  In 
cells expressing endogenous glucokinase (Fig. 3.9A-D) GlcN inhibited glucose 
phosphorylation at the same concentrations (0.5 mM) that causes an increase in 
NAG metabolites (Fig. 3.7).  This means that GlcN cannot be used to selectively 
increase HBP flux without inhibiting glucose phosphorylation and other pathways 
of glucose metabolism. We therefore tested the effects of NAG, which causes a 
smaller increase in NAG-metabolites than GlcN (Fig.3.7B).   However, 10 mM 
NAG also caused a significant inhibition of glucose phosphorylation similar or 
greater than the inhibition by 0.5 mM GlcN (Fig. 3.9F).  
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3.2.4.6 Mechanism of activation of phosphorylase-a by GlcN  
 
The inhibition by both GlcN and NAG of glucose phosphorylation could be 
caused by inhibition of glucokinase because both compounds are strong 
glucokinase inhibitors (Vandercammen and Van Schaftingen, 1991) or by an 
independent mechanism.  We therefore compared the effect of GlcN with a 
glucokinase inhibitor that is not an amine (5-thioglucose (5TG)) and with two 
amines that are not glucokinase inhibitors such as galactosamine (GalN) and 
methylamine (MethN). Surprisingly all compounds tested lowered glucose 6-P 
and raised phosphorylase a, but the increase in phosphorylase-a was greatest with 
GlcN (Fig. 3.10). When glucokinase was overexpressed it prevented the increase 
in phosphorylase-a caused by the glucokinase inhibitor, 5TG, but it did not 
prevent the activation of phosphorylase-a by GlcN (Fig. 3.11).  Because 
glucokinase overexpression increased glucose 6-P to basal with 2 mM GlcN but it 
did not prevent the activation of phosphorylase, these results suggest that the 
effect of GlcN on phosphorylase is at least in part independent of the lowering of 
glucose 6-P. Possible mechanisms that could explain the activation of 
phosphorylase by GlcN that is not prevented by glucokinase overexpression are 
calcium release from the ER which would be expected to cause activation of 
phosphorylase kinase through calmodulin (Bollen et al., 1987). 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 78 
3.2.5 Flux through the hexosamine pathway (HBP) measured with GFAT 
inhibitors 
 
3.2.5.1 Validation of GFAT inhibitors for studying flux through the pathway at 
varying glucose concentration: effects on glucose phosphorylation and protein 
synthesis  
 
The next aim was to determine the rate of the HBP in hepatocytes from the 
incorporation of [U-14C] glucose into protein in comparison with the rate of 
glucose phosphorylation. The rate of glucose phosphorylation incubated with 25 
mM glucose was 226 nmol / 4 h per mg protein and this was not significantly 
affected by DON (20-40 µM) as shown previously (Fig 3.4). Time course 
incubations (up to 4 h) of the incorporation of glucose into protein determined 
using [U-14C]glucose showed that this was linear with time and also that addition 
of GlcN decreased the incorporation of 14C-glucose into protein (Fig. 3.12A). The 
incorporation of 14C-glucose into protein was then determined in 3h incubations in 
cells treated without or with cycloheximide (CX) to inhibit protein synthesis or 40 
µM DON to inhibit GFAT (Fig. 3.12B.  Protein synthesis was also determined 
from leucine incorporation into protein in parallel incubations (Fig. 3.12C). CX 
inhibited protein synthesis (leucine incorporation) by 90% and it inhibited glucose 
incorporation into protein by 70%. This shows that incorporation of glucose into 
protein (24 nmol / 4 h per mg protein) is in part due to labelling of amino acids 
and in part (~ 20%) to other mechanisms that are not due to protein synthesis. 
In the presence of 40 µM DON the incorporation of glucose into protein was 
inhibited by 20% (from 24 to 18 h). If DON fully inhibits the HBP and has 
negligible effect on protein synthesis then the contribution of the HBP to 14C- 
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glucose incorporation into protein is around 20%. The DON-sensitive rate of 14C-
glucose incorporation corresponded to 6 nmol/4 h per mg protein. This is 
approximately 3% of the rate of glucose phosphorylation (226 nmol/4 h per mg) 
measured in similar incubation conditions (Fig 3.4). These calculations assume 
that DON does not affect protein synthesis. In the leucine experiments there was a 
small though not significant effect of DON on protein synthesis. This suggests 
that DON may slightly overestimate the contribution of the HBP. 
To further confirm that the incorporation of 14C-glucose into protein represents 
the hexosamine pathway additional incubations were performed without or with 
NAG which is expected to dilute the incorporation of label from glucose into 
protein. At concentrations of 5 mM and 10 mM, NAG caused a greater inhibition 
of incorporation of 14C-glucose into protein than for inhibition of glucose 
phosphorylation (Fig. 3.13). This is consistent with 14C-glucose incorporation into 
protein by covalent modification through the HBP.   
 
3.2.5.2 Validation of OGT and OGA inhibitors from protein labelling with 14C-
glucose, 14C-glucosamine and 14C-N-acetylglucosamine  
 
Studies on covalent modification of proteins by OGT often use inhibitors of OGT 
or inhibitors of OGA to alter the covalent modification of proteins. We next used 
radioactive labelling of proteins with radioactive [U-14C]glucose, glucosamine-1-
14C and N-acetylglucosamine-1-14C to test whether inhibitors of OGT (benzyl-
2acetamido-2-deoxy-alpha-D-galactopyranoside (BADGP), alloxan) and OGA 
(PUGNAc) alter total protein labelling in hepatocytes. Tunicamycin (TM), an 
inhibitor of N-linked glycosylation was used as a control. Hepatocytes were 
incubated with radioactive glucose, glucosamine and N-acetylglucosamine for 4 h  
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and protein was precipitated (after lipid extraction to eliminate incorporation of 
glucose, GlcN and NAG into lipid).   These studies showed no effect of 5 mM 
alloxan but significant inhibition by BADGP (10 mM) of glucose, GlcN and NAG 
labelling and inhibition by tunicamycin of GlcN and NAG labelling (Fig. 3.14).    
Although BADGP caused significant inhibition it also caused some cell death.  
An effect of BADGP on cell stress was evident from the increase in 
phosphorylase (Fig. 3.15). When the effects of alloxan, BADGP and tunicamycin 
were tested in 4 h incubation with the radioactive labels (Fig. 3.16), both 
tunicamycin and BADGP inhibited GlcN incorporation into protein (similar to the 
inhibition of NAG incorporation) and they also inhibited protein synthesis (Fig. 
3.16A, B).  Unexpectedly PUGNAc an inhibitor of OGA which is expected to 
have opposite effects as BADGP on GlcN labelling had no effect (Fig. 3.16A). To 
test whether the inhibitory effects of BADGP on GlcN labelling may be due to 
non-specific effects we determined the incorporation of 14C-glucose into 
glycogen, which is very sensitive to cell stress involving an increase in cytosolic 
calcium (Fig. 3.16C).  In these experiments, BADGP but not tunicamycin 
inhibited label incorporation into glycogen. This is consistent with the activation 
of glycogen phosphorylase by BADGP (Fig. 3.15) and also with the changes in 
cell morphology.   Together, these results do not provide support for use of either 
BADGP or PUGNAc as inhibitors of OGT and OGA that affect covalent 
modification of proteins without non-specific effects. 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results 1 
 86 
3.2.5.3 O-GlcNAc covalent modification of protein in hepatocytes 
 
We used an antibody to O-GlcNAc to covalent modification of proteins 
glycosylation by high glucose, overexpression of OGT, GlcN and inhibitor of 
OGA (PUGNAc) in hepatocytes incubated with 5 mM or 25 mM glucose by 
immunoblotting. These experiments showed that 25 mM glucose increased O-
GlcNAc modification to protein compared with 5mM glucose and both 0.5 mM 
GlcN and 100 uM PUGNAc also increased O-GlcNAc immunoactivity at 25 mM 
glucose (Fig. 3.17).  
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3.3 Discussion  
 
Glucose metabolism by the HBP and modification of proteins via O-GlcNAc are 
both suggested to be involved in the development of insulin resistance. The role of 
the HBP has been studied from experiments with GFAT inhibitors and 
incubations with GlcN. The role of covalent modification of proteins with O-
GlcNAc has been studied from experiments with GlcN which causes covalent 
modification of protein and from overexpression of OGT and OGA (Yang et al., 
2008; Soesanto et al., 2008) and from experiments with inhibitors of these 
enzymes (Sakiyama et al., 2010; D’Alessandris et al., 2004). The majority of 
studies on the role of the HBP in insulin resistance were performed on adipocytes 
and muscle cells and other non-liver cell lines with relatively few studies on liver 
or hepatocytes (Dentin et al. 2008). Liver differs from other tissues in its activity 
and kinetic properties of GFAT which are at least partly due to expression of the 
GFAT2 isoform. To study the role of the HBP in control of gene expression in 
hepatocytes it was first necessary to establish valid concentrations of inhibitors 
and substrates that enter the HBP that are appropriate for liver cells. This study 
therefore tested the effects of commonly used GFAT inhibitors and substrates of 
the HBP in hepatocytes as well as inhibitors of OGT and OGA. 
 
3.3.1 GFAT inhibitors 
 
Azaserine (AZN) and 6-diazo-5-oxonorleucine (DON) are inhibitors of GFAT 
(Marshall et al., 1991). Previous studies on adipocytes reported that AZN was a 
potent inhibitor of GFAT at a concentration of 2-10 µM during 18 h incubation 
(Marshall et al. 1991). The present study found that the enzyme activity of GFAT 
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was only inhibited by 9% following incubation with 20 µM of AZN for 18 h, 
whilst with 20 µM of DON for 18 h the inhibition was 67%.  The optimal 
concentration of DON was found to be 40 µM for an 18 h incubation, which 
completely blocked the enzyme activity of GFAT (96%).  The weak inhibitory 
effect of azaserine in hepatocytes may be due to the different isoform of GFAT 
expressed in hepatocytes (Ye et al., 2004; Huynh et al., 2000; Zhou et al., 1998; 
Oki et al., 1999; Hu et al., 2004) or to other differences in amino acid metabolism 
in liver.  The long incubation time required for inhibition of GFAT by DON is 
explained by covalent modification of the enzyme in the presence of DON (Sage 
et al., 2009; Marshall et al., 1991). Treatment of hepatocytes with 40 µM DON for 
18 h had no significant effect on the rate of glucose phosphorylation as 
determined by the phosphorylation of [2-3H]glucose which is the general method 
for measurement of glucokinase flux in hepatocytes.  It also had little effect on the 
rate of protein synthesis in hepatocytes as determined from the incopororation of 
labelled leucine into protein. Further support for the validity of DON was 
obtained from the measurement of NAG metabolites which represent the 
intermediates of the HBP that are formed after the acetylation of GlcN 6-P. High 
glucose concentrations caused a moderate (2-3 fold) increase in the concentrations 
of NAG metabolites and this effect was prevented by treatment with 40 µM DON.   
These results together support the validity of DON as an experimental tool to 
determine the role of the HBP in hepatocytes incubated with high glucose 
concentration.    
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3.3.2 GlcN and NAG 
 
Incubation with high concentrations of GlcN is the most commonly used method 
to show the importance of HBP in the development of insulin resistance (Sage et 
al., 2009; Dentin et al., 2008; Taylor et al., 2009). In addition a recent study that 
reported regulation of G6Pc gene expression through the HBP in hepatocytes used 
GlcN at a concentration of 10 mM (Dentin et al., 2008). In this study we 
compared the effects of GlcN with the effects of high glucose concentration on the 
accumulation of NAG metabolites. High glucose (25 mM to 50 mM) caused an 
increase in NAG metabolites of between 2-fold and 3-fold in comparison with 
basal glucose concentration (5 mM). This increase in NAG-metabolites is similar 
to the increase in glucose 6-P or the concentrations of intermediates of glycolysis 
between the fed and fasted states in the liver in vivo (Casazza and Veech, 1986).   
However, with millimolar concentrations of GlcN as are often used in studies on 
the HBP (Dentin et al., 2008), the increase in NAG metabolites was about 10-20 
fold greater than with high glucose. In addition GlcN also caused accumulation in 
GlcN 6-P. This metabolite was not detectable in incubations without GlcN 
indicating that although it is an intermediate of the HBP it is normally present in 
the hepatocytes at very low concentrations. This could either be explained by a 
lower activity of GFAT compared with the activity of the glucosamine 6-
phosphate N-acetyltransferase (GlcN 6-P NATase) the second enzyme in the 
HBP, or by feed-back inhibition of GFAT activity by GlcN 6-P, which would 
prevent accumulation of this metabolite from glucose. The increase in GlcN 6-P 
concentration was very high at 5 mM or 10 mM GlcN. This indicates that in these 
conditions the GlcN 6-P NATase becomes rate limiting. The high accumulation of 
this phosphorylated intermediate can cause depletion of cell ATP and also 
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inorganic phosphate. NAG which unlike GlcN is not a substrate for glucokinase 
but is phosphorylated by another kinase, N-acetylglucosamine kinase (Berger et 
al., 2002), caused a much smaller increase in NAG metabolites than GlcN. This 
lower rate of accumulation of NAG-metabolites can also be in part due to a slower 
rate of transport of this sugar analogue into hepatocytes. Unlike DON, which had 
no effect on glucose phosphorylation, both GlcN and NAG were found to inhibit 
glucose phosphorylation. Both compounds are inhibitors of glucokinase and the 
inhibition of glucose phosphorylation is probably best explained by direct 
inhibition of glucokinase.  The lowering of glucose 6-P can be explained by the 
inhibition of glucose phosphorylation, and the inhibition of glycogen synthesis 
can be explained by the lowering of glucose 6-P, which is an allosteric activator 
of glycogen synthase. This conclusion is supported by the experiments with 
glucokinase overexpression. However, the activation of glycogen phosphorylase 
by GlcN can be caused by two mechanisms: the lowering of glucose 6-P and by 
calcium release from the ER which causes activation of phosphorylase kinase. 
The activation of phosphorylase was not prevented by overexpression of 
glucokinase. The lowest concentrations of GlcN and NAG (0.5 mM and 10 mM) 
that caused a significant increase in NAG metabolites also caused inhibition of 
glucose phosphorylation.  
 In summary, this study shows that GlcN and NAG are more effective than 
glucose at raising NAG-metabolites in hepatocytes. However, unlike DON they 
also cause inhibition of glucose phosphorylation. They therefore cannot be used to 
alter flux through the HBP without also affecting metabolism through other 
metabolic pathways.    
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3.3.3 Incorporation of labelled glucose, GlcN and NAG into protein   
 
As expected from the entry of GlcN and NAG into the HBP after the rate limiting 
step, experiments comparing the incorporation of radiolabelled glucose, GlcN and 
NAG into protein showed much higher labelling of protein with GlcN and NAG 
compared with glucose. In addition, experiments using cycloheximide (CX) to 
inhibit protein synthesis showed that 70% of the glucose label that was 
incorporated into protein was due to labelling of amino acids that are used for 
protein synthesis.  It was estimated from comparison of the effects of CX on label 
incorporation from with either glucose or leucine into protein that about 20% of 
the glucose labelling of protein was caused by covalent modification of protein.   
From the effects of DON on the incorporation of labelled glucose into protein it 
was also estimated that the contribution of the HBP to glucose labelling of 
proteins was about 20%. This calculation assumes a selective effect of DON on 
the HBP and no inhibition of protein synthesis. Although labelling of protein by 
leucine was not significantly decreased by DON, there was a trend towards lower 
incorporation.  However, this was less than for glucose labelling inhibition by 
DON.  
The experiments testing the effects of commonly used inhibitors of OGT and 
OGA did not identify inhibitors that are free of cytotoxic effects at concentrations 
that cause changes in covalent labelling of proteins. PUGNAc a commonly used 
inhibitor of OGA had no effect on label incorporation into protein.  Experiments 
testing the effects of two commonly used OGT inhibitors on the covalent 
modification of protein with GlcN, NAG or glucose showed that BADGP but not 
alloxan inhibited labelling of protein. However, BADGP also caused inhibition of 
protein synthesis as measured from leucine incorporation and it also caused 
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activation of phosphorylase and inhibition of glycogen synthesis suggesting the 
induction of cell stress. Therefore the most commonly used inhibitors of OGT and 
OGA are not useful experimental tools to alter the covalent labelling of proteins 
with O-GlcNAc in hepatocytes. 
 
3.4 Summary 
This study has shown that: 
 
 
• The GFAT inhibitor DON (40uM) inhibits GFAT activity in hepatocytes 
after 18 h culture by ~96% and has little or no effect on glucose 
phosphorylation, protein synthesis or GFAT mRNA expression.  It can 
therefore be used as an experimental tool to study the HBP in hepaotyctes. 
 
• The concentration of NAG-metabolites but not that of GlcN 6-P was 
significantly raised at 25mM glucose compared with 5mM glucose 
indicating that glucose is metabolised by the HBP at 25mM.  This effect of 
glucose was inhibited by DON confirming its validity as a tool to the study 
the HBP. 
 
• GlcN was a very effective substrate for the HBP and it caused a larger 
increase in NAG metabolites than glucose.  At high concentrations GlcN 
also caused a large increase in GlcN 6-P indicating that GlcN 6-P NATase 
becomes rate limiting.  However, GlcN is also a very strong inhibitor of 
glucose phosphorylation and therefore affects other pathways of glucose 
metabolism.  
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• NAG is a better substrate than glucose but a weaker substrate than GlcN at 
increasing NAG metabolites.  Unlike GlcN it dos not increase GlcN 6-P 
but it is also a glucokinase inhibitor. 
 
• Flux through the HBP was determined from the DON-sensitive 
incorporation of 14C-glucose into protein and was 3% of glucose 
phosphorylation.  
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Figure 3.1 The hexosamine biosynthesis pathway and modification of proteins via O-
GlcNAc (Hart et al., 2011).
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Figure 3.2  Effects of azaserine (AZN) and 6-diazo-5-oxonorleucine (DON) on 
glutamine:fructose-6-phosphate amidotransferase (GFAT) activity 
Hepatocyte monolayers were pre-cultured 18 h in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- AZN and DON.  They were then incubated for 
4 h or 22 h in MEM containing 5 mM glucose, with 20 µM AZN and DON (A) and the 
concentrations of DON (B) indicated for determination of GFAT activity. Results are 
expressed as means ± SEM for 3 experiments, duplicate treatments (n=6).  o P < 0.05 
effects of DON + P < 0.05 effects of AZN
o o
o
DON (µM)
22h
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Figure 3.3  Effects of 6-diazo-5-oxonorleucine (DON) on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 or 25 mM glucose, with 10, 20 and 40µM DON and indicated for 
determination of gene expression of (A,B)GFAT1, (C,D) GFAT2. Mean ± SEM 4-6 
experiments, duplicate treatments (n=8-12). , aP< 0.05 effect of glucose, oP< 0.05 
effect of DON. 
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Figure 3.4  Effects of 6-diazo-5-oxonorleucine (DON) on glucose 
phosphorylation
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON. They were then incubated for 4 h in 
MEM containing 25 mM glucose 2-3H-glucose (3 uCi /ml) with 20 and 40 µM DON 
indicated for determination of glucose phosphorylation. Results are expressed as 
means ± SEM for 3 experiments, duplicate treatments (n=6). . 
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Figure 3.5  Effects of 6-diazo-5-oxonorleucine (DON) on N-acetylglucosamine
(NAG) metabolites 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON. They were then incubated for 4 h in 
MEM containing 5, 25 and 50 mM glucose, with 20 and 40µM DON indicated for 
determination of N-acetylglucosamine metabolites. Results are expressed as means ±
SEM for 3 experiments, duplicate treatments (n=6).  a P < 0.05, effects of glucose, o
P < 0.05, effects of DON.
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Figure 3.6  Effects of glutamine and octanoate on N-acetylglucosamine (NAG) 
metabolites 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON. They were then incubated for 4 h in 
MEM containing 25 mM glucose with 0, 2 and 10 mM glutamine and 40 µM DON (A) 
indicated for determination of N-acetylglucosamine metabolites. They were then 
incubated for 4 h in MEM containing 5 and 25 mM glucose with 0.5 mM octanoate (B) 
for determination of N-acetylglucosamine metabolites. Results are expressed as means 
± SEM for 3 experiments, duplicate treatments (n=6). a P < 0.05, effects of glucose,  o
P < 0.05 effects of DON, uP < 0.05, effects of glutamine and +P < 0.05, effects of 
octanoate
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Figure 3.7  Effects of glucosamine (GlcN) and N-acetylglucosamine(NAG) on
N-acetylglucosamine metabolites 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5 and 25 mM glucose, with 0.5, 1, 5 and 10 mM glucosamine (GlcN) 
(A) and 1, 5, 10 and 20 mM N-acetylglucosamine (NAG) (B), indicated for 
determination of N-acetylglucosamine metabolites. Results are expressed as means 
± SEM for 3 experiments, duplicate treatments (n=6).  
GlcN (mM)
NAG (mM)
70
Figure 3.8  Effects of glucosamine concentration on GlcN 6-P and N-
acetylglucosamine metabolites 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 50 mM glucose (Glc) and glucosamine (GlcN) (1, 5 and 10 mM), 
indicated for determination of GlcN 6-P, N-acetylglucosamine metabolites and 
both. Results are expressed as means ± SEM for 3 experiments. s P < 0.05 effects 
of glucosamine.
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Figure 3.9 Effects of glucosamine (GlcN) and N-acetylglucosamine (NAG) on 
glucose phosphorylaion, glucose 6-phosphate, phosphorylase-a activity and 
glycogen synthesis 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone and 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 25 mM glucose and the concentrations of GlcN indicated for determination 
of glucose phosphorylation (A), glucose-6phosphate (B), phosphorylase-a activity (C) 
and glycogen synthesis (D). They were then incubated for 4 h in MEM containing 25 
mM glucose, untreated or treated with vectors for expression of glucokinase (GK) (E) 
and the concentrations of NAG (F) and  indicated for determination of glucose 
phosphorylation. Results are expressed as means ± SEM for 4 experiments.  s P < 0.05 
effects of glucosamine, m P < 0.05 effects of N-acetylglucosamine. 
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Figure 3.10  Comparison of glucosamine (GlcN) with other hexosamines and a 
glucokinase inhibitor 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 25 mM glucose and the concentrations of glucosamine (GlcN), 5-
thioglucose (5TG), galactosamine (GalN) and methylamine (MethN) indicated for 
determination of glucose 6-phosphate (A) and phosphrylase-a activity (B). Results 
are expressed as means ± SEM for 3 experiments, duplicate treatments (n=6).
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Figure 3.11  Comparison of glucosamine (GlcN) and 5-thioglucose (5TG) 
without or with glucokinase overexpression (GK) 
Hepatocyte monolayers were untreated or treated with vectors for expression of 
glucokinase (GK) and pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose. They were then incubated for 4 h in MEM 
containing 25mM glucose and the concentrations of 5-thioglucose (5TG) and 
glucosamine (GlcN), indicated for determination of glucose 6-phosphate (A) and 
phosphrylase-a activity (B). Results are expressed as means ± SEM for 3 
experiments, duplicate treatments (n=6).
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Figure 3.12 Effect of DON on 14C-glucose incorporation into protein  and 3H-
leucine incorporation into protein
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
25 mM glucose and glucosamine (GlcN), 14C-glucose (6 uCi/ml) for time course (A). 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- 6-diazo-5-oxonorleucine (DON).  They were 
then incubated for 4 h in MEM containing 25 mM glucose, 14C-glucose ( 6 uCi/ml) 
(B) and 3H-leucine (2 uCi/ml) (C) with 20 and 40 µM DON and 5 µM cycloheximide
(CX). Results are expressed as means ± SEM for 4 experiments.  o P < 0.05 effects of 
DON, xP < 0.05 effects of CX, sP < 0.05 effects of GlcN
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Figure 3.13 Effect of N-acetylglucosamine (NAG) on glucose incorporation into 
protein  and glucose phosphorylation
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 25 mM glucose, 14C-glucose (6 uCi/ml) (A) and 2-3H-glucose (3 uCi/ml) 
(B) with 5 and 10 mM N-acetylglucosamine (NAG). Results are expressed as means 
± SEM for 3 experiments, duplicate treatments (n=6). 
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Figure 3.14 Effect of inhibitors of N-linked and O-linked glycosylation on 
glucose, glucosamine and N-acetylglucosamine incorporation into protein
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
Insulin and 10 nM dexamethasone, 5 mM glucose. They were then incubated for 4 
h in MEM containing 25 mM glucose, 14C-glucose (6 uCi/ml) (A), 14C-
glucosamine (20uCi/ml) (B) and 14C-N-acetylglucosamine (20 uCi/ml) (C) with 
10 mM benzyl-2acetamido-2-deoxy-alpha-D-galactopyranoside (BADGP), 5 mM
Alloxan and Tunicamycin (TM). Results are expressed as means ± SEM for 4 
experiments. #P< 0.05 effect of BADGP, $P< 0.05 effect of TM.
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Figure 3.15  Effect of glucosamine (GlcN) and N-acetylglucosamine (NAG) 
without or with BADGP on glycogen phosphorylase-a activity 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose. They were then incubated for 4 h in MEM 
containing 5 mM glucose and the concentrations of glucosamine (A) and N-
acetylglucosamine (B), without or with 10 and 20 mM BADGP, indicated for 
determination of phosphrylase-a activity. Results are expressed as means ± SEM 
for 2 experiments, duplicate treatments (n=4).
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Figure 3.16 Effect of inhibitors of N-linked and O-linked glycosylation on 
glucose and leucine incorporation into protein or glycogen
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10nM 
Insulin and 10 nM dexamethasone, 5 mM glucose. They were then incubated for 
4 h in MEM containing 25 mM glucose, 14C-glucose (6 uCi/ml) (A,C) and 3H-
leucine (2 uCi/ml) (B) with 2, 5 and 10 mM benzyl-2acetamido-2-deoxy-alpha-
D-galactopyranoside (BADGP), 5 mM Alloxan, 2.5 µg/ml Tunicamycin (TM) 
and 100 µM O-(2-acetamidO-2deoxy-D-glucopyranosylidene) amino-N-
phenylcarbamate (PUGNAc).  Results are expressed as means ± SEM for 3 
experiments, duplicate treatments (n=6). #P< 0.05 effect of BADGP, $P< 0.05 
effect of TM.
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Figure 3.17  Effects of ovrexpression of OGT, PUGNAc and glucosamine 
(GlcN) on O-GlcNAc modification of protein 
Hepatocyte monolayers were were either untreated or treated with vectors for 
expression of O-linked beta-N-acetylglucosamine transferase(Ad-OGT). After 18h 
pre-cultured in MEM containing 10 nM dexamethasone, 5 mM glucose.  They were 
then incubated for 4 h in MEM containing 5 mM glucose,  25  mM glucose, 0.5mM 
GlcN, 100µM PUGNAc and determination of O-GlcNAc protein by immunoblotting
assay. Representative of 2 experiments. 
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The role of HBP in mediating glucose control of gene expression 
in hepatocytes 
 
4.1 Aims and rationale 
 
The liver plays a key role in glucose homeostasis by two mechanisms: (i) the 
uptake and storage of glucose via glycogenesis and glycolysis/lipogenesis, (ii) the 
release of glucose via glycogenolysis and gluconeogenesis. Gene expression of 
the enzymes in these metabolic pathways is regulated by the hormones insulin and 
glucagon and also by glucose. Two mechanisms have been the focus of glucose 
control of gene expression. First the regulation by the transcription factor 
ChREBP (Carbohydrate response element binding protein) of enzymes of 
glycolysis and lipogenesis including L-type pyruvate kinase (L-PK), fatty acid 
synthase (FAS) and acetyl-CoA carboxylase (ACC) (Towle et al., 1997; Girard et 
al., 1997; Rumberger et al., 2003). ChREBP interacts with Max-like protein X 
(Mlx) to form a heterotetramer that binds carbohydrate responsive elements 
(ChoRE) in the promoters of glucose-responsive genes to increase transcription 
(Shih et al., 1995; Yamashita et al., 2001; Stoeckman et al., 2004). Suggested 
mechanisms by which glucose metabolism causes activation of ChREBP include:  
(i) xylulose 5-P an intermediate of the pentose phosphate pathway which causes 
dephosphorylation of ChREBP (Uyeda et al., 2002); (ii) glucose 6-P the first 
intermediate of glucose metabolism (Dentin et al., 2012); (iii) fructose 2,6-
bisphosphate (F2,6P2), an allosteric regulator of the enzyme of glycolysis 
phosphofructokinase-1 (Arden et al., 2012; Petrie et al., 2013).  
The second mechanism for glucose regulation of gene expression focuses on the 
covalent modification of transcription factors by O-linked beta-N-
Chapter 4                                                                                                   Results 2 
 97 
acetylglucosamine (O-GlcNAc) transferase (OGT) which uses as substrate UDP-
GlcNAc generated by the HBP. The regulation of G6Pc by glucose has been 
shown in several studies (Massillon, 2001; Ma et al., 2006). This mechanism is 
often described as “glucotoxicity” because induction of G6Pc by high glucose 
further aggravates the hyperglycaemia (Gautier-Stein et al., 2012). A recent study 
proposed that this mechanism involves covalent modification by O-GlcNAc of 
CREB regulated transcription coactivator 2 (CRTC2), the binding protein of 
CREB; this was supported by the observation that GlcN is more effective than 
glucose at inducing G6Pc (Dentin et al., 2008).   
 
The objective of the work in this chapter was to determine the role of HBP in 
mediating control of G6Pc gene expression by glucose. 
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4.2 Results 
 
4.2.1 Glucose induces G6Pc irrespective of the presence of insulin or glucagon 
 
Several studies have reported induction of G6Pc by high glucose. In all these 
studies the glucose stimulation was shown in the either the absence of hormones 
(Massillon, 2001; Dentin et al., 2008) or in the presence insulin, (Ma et al., 2006) 
but there have been no comparisons in different hormone conditions. The first aim 
was to determine the induction of G6Pc by glucose (25 mM compared with 5 
mM) in the absence or presence of insulin or glucagon. Incubation of hepatocytes 
with 25 mM glucose, for 4 h caused a 6 fold  increase in G6Pc mRNA in the 
absence of insulin and 3 fold increase with insulin (Fig 4.1, A). Insulin inhibited 
G6Pc gene expression by 60% at 5 mM glucose and by 80% with 25 mM glucose. 
High glucose also increased G6Pc in the presence of glucagon (Fig. 4.1B).  
Because glucosamine was shown to cause greater induction of G6Pc than glucose 
(Dentin et al., 2008), we tested the effects of GlcN in cells treated without or with 
glucagon to activate CREB. However, there was no significant stimulation by 5 
mM GlcN on G6Pc mRNA in these experimental conditions (Fig 4.1, B).  
 
4.2.2 Glucosamine does not mimic the induction of G6Pc by high glucose 
 
We next tested the effects of GlcN on G6Pc mRNA levels at different 
concentrations (0.5, 1, 5 and 10 mM GlcN) in comparison with 25 mM glucose in 
either the absence or presence of insulin (Fig. 4.2). Glucose (25 mM) increased 
G6Pc mRNA by 10-fold in absence of insulin or 3-fold in the presence of insulin. 
However, there was no significant effect of GlcN in either absence or presence of  
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insulin at concentrations of 0.5 to 10 mM (Fig 4.2, A and B). We next compared 
the effects of GlcN and N-acetylglucosamine (NAG) concentration (5, 7 and 
10mM) on both NAG metabolites (Fig 4.3, A and B) and G6Pc mRNA levels (Fig 
4.3, C and D). NAG unlike GlcN enters the HBP after GFAT and does not cause 
changes in GlcN 6-P, whereas GlcN causes a larger increase in GlcN 6-P than in 
NAG metabolites (Chapter 3). These experiments showed that GlcN (0.5 to 10 
mM) caused a concentration-dependent accumulation of NAG-metabolites with a 
similar or higher effect of 0.5mM GlcN as 25mM glucose (Fig 4.3A). However, 
higher concentrations of GlcN (1, 5 and 10mM) caused a much larger stimulation 
(9-50 fold) than glucose. NAG caused a smaller increase in cellular accumulation 
of NAG-metabolites than GlcN and this was significant with concentrations of 
NAG at 10mM or higher (Fig. 4.3B). These concentrations of GlcN and NAG 
which significantly increase NAG metabolites to a similar or higher level than 
glucose did not increase G6Pc mRNA (Fig 4.3 C and D). 
 
4.2.3 Glucosamine partially counteracts the glucose elevation of glucose 6-
phosphate and Fructose 2,6-bisphosphate  
 
The next aim was to determine the effect of GlcN in metabolism of glucose and 
formation of other metabolites of glucose that may be involved in G6Pc induction 
such glucose 6-P and F2,6P2. In this study we used the lowest concentration of 
GlcN that increases NAG metabolites to test its effect on glucose 6-P and F2,6P2 
(Fig. 4.4). Incubation of hepatocytes with 25 mM glucose for 4 h caused an 
increase in concentration of both glucose 6-P and F2,6P2 relative to 5 mM 
glucose. Pre-treatment of the hepatocytes with 0.5 mM GlcN partially  
 
Chapter 4                                                                                                   Results 2 
 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                   Results 2 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                   Results 2 
 104 
decreased both glucose 6-P and F2,6P2 at 25mM glucose (Fig. 4.4). These results 
show that there is lowering by GlcN of glucose metabolites even at 0.5 mM. 
 
4.2.4 OGT does not enhance the glucose induction of G6Pc 
 
Various studies including that by (Dentin et al., 2008) and others (Yang et al., 
2008) have used overexpression of OGT and OGA to test the role of O-GlcNAc 
modification of proteins in regulation of G6Pc and other genes (Soesanto et al., 
2008). We therefore determined the effects of OGT overexpression in incubations 
both with 5 and 25 mM glucose. In these experiments overexpression of OGT was 
confirmed by immunoblotting (Fig. 4.5, A). There was no significant stimulation 
of G6Pc mRNA levels at either 5 or 25 mM glucose by OGT overexpression (Fig 
4.5, B). 
 
4.2.5 DON inhibits the glucose induction of G6Pc but not the induction of PTG 
 
We next tested the effects of inhibition of GFAT with DON on G6Pc gene 
expression.  In the previous Chapter we established the concentrations of DON 
and incubation times required to inhibit GFAT activity in hepatocytes, and also 
that DON inhibits the increase in NAG metabolites by 25 mM glucose. For these 
experiments it was necessary to pre-culture the hepatocytes with DON before 
incubation with 25 mM glucose. When the effects of 25 mM glucose were tested 
in cells without or with preculture with DON,  glucose (25 mM) caused 4-fold 
stimulation and this effect was partially but significantly inhibited by DON (Fig 
4.6, A). However, there was no significant effect of DON on GAPDH mRNA 
levels (Fig 4.6, B). To test whether the inhibitory effect of DON is due to  
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lowering of NAG metabolites (by inhibition of the HBP) or  non-specific effects 
independent of NAG metabolites, we used  a low concentration of GlcN (0.5 mM) 
which increases NAG metabolites by entry after GFAT, on mRNA expression of 
various genes (G6Pc, TXNIP, L-PK and PTG). The result of this study shows that 
high glucose (25 mM) significantly stimulated gene expression of all 4 genes and 
treatment with DON inhibited the glucose stimulation of G6Pc and TXNIP but not 
on L-PK and PTG. In the presence of 0.5 mM GlcN the inhibitory effect of DON 
on G6Pc was significantly attenuated (Fig. 4.7, A) and in the case of L-PK, GlcN 
stimulated in the presence of DON (Fig. 4.7, C). These results suggest that the 
effect of DON on gene expression is probably at least in part due to NAG 
metabolites. 
 
4.2.6 NAG and GlcN partially reverse the effects of DON on G6Pc 
 
The inhibitory effect of GlcN on L-PK and G6Pc gene expression at 25 mM 
glucose (Fig 4.7 A and C), suggests a counter-regulatory effect of GlcN on 
glucose activation. To test whether this effect of GlcN may be due to GlcN 6-P 
and not NAG metabolites, we compared the effect of 0.5 mM GlcN with NAG 
which does not increase GlcN 6-P. In this experiment there was a small inhibition 
of the stimulation by 25 mM glucose by GlcN (Fig 4.8, A) but not by NAG (Fig 
4.8, B). However, both GlcN and NAG partially reversed the inhibition of G6Pc 
gene expression by DON. This confirms: first, that the inhibitory effect of DON at 
25 mM glucose is  in part due to the lowering of NAG metabolites (because it is 
reversed by both GlcN and NAG); secondly that GlcN but not NAG has an 
inhibitory effect at 25 mM glucose suggesting that this effect is probably due to 
GlcN-6-P rather than NAG metabolites.   
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4.2.7 DON counteracts induction of G6Pc by ChREBP; DON inhibits ChREBP 
translocation 
 
We next tested the effect of overexpression of ChREBP with an adenoviral vector 
on the glucose-induction of G6Pc. The available antibodies for ChREBP did not 
detect any immunoactivity in cells not treated with the adenovirus. In cells treated 
with the adenoviral vector for overexpression of ChREBP there was increased 40-
fold in ChREBP mRNA (Fig. 4.9, A).   Overexpression of ChREBP increased 
G6Pc mRNA at both 5 mM and 25 mM glucose but the stimulatory effect of 
ChREBP overexpression was much greater at 25 mM glucose (Fig 4.9, B). 
Immunoblotting experiments showed weak immunoactivity in cells treated with 
the adenoviral vector (Fig. 4.9, C). The induction of G6Pc by ChREBP at 25 mM 
glucose was inhibited by DON. In addition, we tested whether GlcN (0.5 mM) 
reverses this effect of DON with overexpression of ChREBP. In these 
experiments GlcN partially reversed the inhibition of G6Pc by DON with 
ChREBP overexpression (Fig 4.10).  Immunoblotting for ChREBP in the 
overexpression experiments showed lower immunoactivity in DON-treated cells. 
We next tested whether DON affects the translocation of ChREBP between the 
nucleus and cytoplasm under low and high glucose from immunostaining for 
ChREBP with the Novus antibody (Fig. 4.11).  For these experiments it was 
necessary to overexpress ChREBP because the endogenous protein was not 
detectable with the antibody. The results showed greater nuclear staining for 
ChREBP after 1 h incubation with 25 mM glucose and this effect was 
significantly inhibited in cells pre-treated with DON (Fig 4.11). These results 
suggest that the effect of DON on gene expression may be in part on ChREBP 
activation.  
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4.2.8 Substrate stimulation of G6Pc: DON does not affect the increase in 
fructose 2,6-bisphosphate  
 
Previous studies suggested a role for substrates such as glucose 6-P or xylulose 5-
P in ChREBP activation through activation of a type 2A phosphatase that 
dephosphorylates ChREBP (Uyeda et al., 2002).  The role of xylulose 5-P 
metabolites was demonstrated from studies using xylitol, that is metabolised to 
xylulose 5-P,  Masillon study showed a higher induction of G6Pc by xylitol  
compared with 25 mM glucose (Massillon, 2001). Work from our laboratory 
identified a role for and F2,6P2 in regulation of ChREBP target genes by glucose 
and also in the glucose stimulation of ChREBP translocation from the cytoplasm 
to the nucleus (Arden et al., 2012). Our next aim was therefore to test whether the 
inhibition of G6Pc gene expression or ChREBP translocation by DON can be 
explained by an effect of DON on the metabolites involved in ChREBP 
activation. Therefore, we first tested the effect of DON on G6Pc gene expression 
with various substrates (Fig. 4.12A). The expression of G6Pc mRNA was 
stimulated (3-fold) by xylitol (5 mM) and (6-fold) by 25 mM glucose and these 
effects were additive resulting in a much larger induction of G6Pc (16-fold) in the 
combined presence of 5 mM xylitol and 25 mM glucose. The stimulation by 25 
mM glucose was also enhanced by overexpression of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFK-WT) which increases F2,6P2  (10-fold) 
and also by S4048 (19-fold), an inhibitor of transport of glucose 6-P to the 
endoplasmic reticulum (ER), which causes a large increase in both glucose 6-P 
and F2,6P2. Treatment with DON did not affect the stimulation of G6Pc mRNA 
by xylitol but it inhibited the stimulation by 25 mM glucose either alone or in 
combination with xylitol, S4048 and PFK-WT overexpression. We compared the  
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effects of DON on G6Pc with the expression of PTG, which shows similar but 
smaller fold induction of expression by substrates as G6Pc. PTG which was 
recently shown to be a target for Mlx-MondoA rather than ChREBP-Mlx (Petrie 
et al., 2013), unlike the inhibition of G6Pc mRNA, DON did not inhibit the 
substrate stimulation of PTG mRNA (Fig 4.12B).  
 
4.2.9 PFK-KD blocks the glucose induction but not the elevation in NAG 
metabolites 
 
The stimulation of G6Pc by glucose is suggested to be due to F2,6P2 because 
lowering of this metabolite with a kinase-deficient variant of PFK2/FBPase-2 
(PFK-KD) inhibits the stimulation by high glucose.   We therefore tested whether 
PFK-KD also affects NAG metabolites. Treatment of hepatocytes with 25mM 
glucose caused an increase in glucose 6-P, F2,6P2 ,  NAG metabolites and G6Pc 
mRNA (Figs 4.13, A-D).  Treatment with PFK-KD lowers G6Pc mRNA and 
F2,6P2 but not  glucose 6-P or NAG metabolites, suggesting that the effect of 
PFK-KD cannot be explained by changes in glucose 6-P or NAG- metabolites. 
 
4.2.10 DON does not affect fructose 2,6-bisphosphate  
 
We next tested whether the effect of DON can be explained by a lowering of 
F2,6P2 (Fig 4.14) Treatment with DON lowered G6Pc mRNA and NAG 
metabolites but not F2,6P2 , indicating that the effect of DON is not explained by 
lowering  in F2,6P2 . 
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4.2.11 ChREBP and FOXO1 mRNA gene expression 
 
We also tested whether the effect of DON can be explained by changes in gene 
expression of ChREBP and FOXO1 (Fig 4.15).  There was no significant effect of 
DON on either ChREBP or FOXO1 mRNA levels.   
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4.3 Discussion  
Hepatic enzymes involved of glycolysis and lipogenesis are induced by both 
insulin and elevated glucose (Uyeda et al., 2002, Towle, 2005), whereas the 
gluconeogenic enzyme G6Pc is repressed by insulin but induced by glucose.  The 
induction of enzymes of glycolysis and lipogenesis by high glucose is mediated 
by the transcription factors ChREBP and Mlx, which bind as a heterotetramer 
(Towle, 2005). This mechanism is sometimes described as an adaptive mechanism 
for energy storage in accordance with the “Thrifty Genotype Hypothesis” (Uyeda 
et al., 2002). The induction of G6Pc by high glucose is also at least in part 
mediated by ChREBP and Mlx (Arden et al., 2011). This mechanism is often 
described as “glucotoxicity” because induction of G6Pc by high glucose further 
aggravates the hyperglycaemia (Gautier-Stein et al., 2012). However, an 
alternative hypothesis to explain the induction of G6Pc by high glucose is that it 
represents a mechanism for intrahepatic homeostasis of inorganic phosphate to 
protect the liver from ATP depletion and steatosis (Arden et al., 2012).   
The results of the present study show increased G6Pc mRNA levels by glucose in 
both the absence and the presence of insulin confirming an insulin-independent 
mechanism for glucose-induction of G6Pc in hepatocytes. The aim of the present 
study was to determine whether the increase in G6Pc mRNA by glucose is 
mediated by the HBP. To test this we used two experimental approaches:  
incubation with concentrations of glucosamine and NAG to increase the 
concentration of NAG metabolites and inhibition of GFAT with DON. A recent 
study published before the start of this project had reported a very large induction 
of G6Pc by GlcN (10 mM), as evidence for the HBP. 
 The experiments with GlcN and NAG which were tested over a wide range of 
concentrations and incubation conditions did not provide evidence for induction 
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of G6Pc by an increase in NAG metabolites. GlcN was tested in both the absence 
and presence of insulin and without or with glucagon in the pre-culture or final 
incubation. The concentrations of GlcN and NAG used were confirmed to 
increase NAG metabolites by a similar or greater extent than high glucose 
concentration. The lack of increase in G6Pc is not consistent with the recent study 
(Dentin et al., 2008) which reported a greater induction of G6Pc by 10 mM GlcN 
than by 25 mM glucose (5-fold vs 2-fold). Possible explanations for the lack of 
stimulatory effect of GlcN on G6Pc gene expression are that it inhibits 
metabolism of glucose and formation of other metabolites of glucose that are 
involved in G6Pc induction such as glucose 6-P and F2,6P2  (Fig. 4.4). GlcN is a 
glucokinase inhibitor and inhibits glucose phosphorylation and elevation in 
glucose 6-P caused by high glucose (Chapter 3). This study therefore used a range 
of concentration of GlcN, but significant lowering of both glucose 6-P and F2,6P2 
was also observed at the lowest GlcN concentration (0.5 mM) that raises NAG 
metabolites.  
Using the second approach of inhibition of GFAT with a concentration of DON 
that counteracts the increase in NAG metabolites by high glucose, there was clear 
evidence for inhibition of the glucose stimulation by at least 50% and in some 
experiments up to 70%. To test whether the effect of DON may be due to non-
specific effects unrelated to lowering of NAG metabolites low concentrations of 
glucosamine or NAG were used to reverse the lowering of NAG metabolites by 
DON (Figs. 4.7, 4.8, 4.10). These experiments showed that the inhibition by DON 
was in part reversed by GlcN or NAG. This suggests that the glucose stimulation 
of G6Pc may be at least in part mediated by flux through the HBP, but the 
inhibition by DON may also in part involve additional mechanisms that are not 
reversed by NAG metabolites. For these experiments GlcN was used at a 
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concentration of 0.5 mM to minimise the inhibition of glucose phosphorylation 
(Fig. 3.7). However, even at this low concentration, GlcN tended to lower G6Pc 
mRNA at high glucose. Interestingly a study that determined G6Pc mRNA by 
Northern Blot showed that 2 mM GlcN inhibited the induction of G6Pc by 25 mM 
glucose (Massillon, 2001). This inhibition by GlcN of the glucose stimulation 
may be explained by the lowering by GlcN of metabolites formed from glucose 
that are involved in ChREBP activation and translocation. 
Previous studies have suggested that the glucose induction of ChREBP target 
genes is mediated by glucose 6-P (Dentin et al., 2012), xylulose 5-P (Kabashima 
et al., 2003) or F2,6P2 (Arden et al., 2012). In this study overexpression of 
ChREBP caused an increase in G6Pc at both 5mM glucose and 25mM glucose 
suggesting involvement of ChREBP in G6Pc induction. This was confirmed in 
other experiments by ChIP assays which showed glucose dependent recruitment 
of ChREBP to the G6Pc promoter (Petrie et al., 2013).  In this study we confirmed 
that DON does not lower F2,6P2  indicating that the inhibition of G6Pc by DON is 
not explained by this mechanism. This study also confirmed that lowering of 
F2,6P2 by expression of PFK-KD lowers G6Pc mRNA but does not lower either 
glucose 6-P or NAG metabolites. We can therefore conclude that the glucose 
induction of G6Pc involves at least two independent mechanisms the elevation in 
F2,6P2 and also increased flux through the HBP which is also necessary for 
induction of G6Pc.  
A comparison of the effects of DON on the mRNA levels of various genes 
showed no significant effect of DON on either PTG which is a MondoA target 
gene or on L-PK which is a ChREBP target gene (Figs. 4.6 and 4.11). One 
possible explanation is that the effect of DON is not mediated through ChREBP 
but through other transcription factors. Another possible explanation is that 
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because glucose causes a larger stimulation of G6Pc than L-PK, additional 
transcription factors may be involved in the G6Pc induction acting separately or 
synergistically with ChREBP and DON may affect the interaction between 
ChREBP and other transcription factors. The experiments on ChREBP 
translocation showed that DON at least in part inhibits ChREBP translocation to 
the nucleus, suggesting a possible mechanism for the inhibitory effect of G6Pc 
mRNA.   
 
 
4.4 Summary 
 
This study has shown that: 
 
• High glucose concentration (25 mM vs 5 mM) induces G6Pc both in the 
absence of hormones and also in the presence of insulin or glucagon. 
 
• Elevation of NAG metabolites with glucosamine or N-acetylglucosamine 
did not mimic the effect of high glucose on G6Pc mRNA and 
overexpression of OGT also did not induced G6Pc mRNA. 
 
• Inhibition of HBP flux with a GFAT inhibitor counteracted glucose-
induced and ChREBP-induced G6Pc gene expression and this effect was 
in part reversed by treatment with glucosamine. This suggests a role for 
the HBP flux in mediating glucose induction of G6Pc expression.   
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• Stimulation of G6Pc by glucose is inhibited by both lowering of F2,6P2 
with PFK-KD and also by DON and these treatments are each selective for 
F2,6P2 and NAG metabolites respectively.  This indicates that at least two 
independent metabolite signalling pathways are involved in the glucose 
induction of G6Pc: elevation in F2,6P2 and flux through the HBP  
 
• Although DON inhibits glucose induced G6Pc mRNA expression it does 
not inhibit the induction of either L-PK which is a ChREBP target gene or 
PTG which is a MondoA target gene.  This suggests that additional 
regulators may be involved in glucose induction of G6Pc.  This is 
supported by the much larger induction of G6Pc by glucose compared 
with L-PK or PTG.   
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Figure 4.1  Effects of insulin on G6Pc mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5 and 25 mM glucose, with or without 10 nM insulin (A) and 5 and 25 
mM glucose and 5 mM glucosamine, with 6 h and overnight (o/n) glucagon (B), 
indicated for determination of G6Pc mRNA levels. Mean ± SEM 8-12 experiments, 
duplicate treatments (n=16-24). aP< 0.05 effect of glucose, cP< 0.05 effect of insulin, 
sP< 0.05 effect of glucoseamine and  jP< 0.05 effect of glucagon. 
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Figure 4.2  Effects of glucosamine (GlcN) on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5 and 25 mM glucose and 0.5, 1, 5 and 10 mM glucosamine (GlcN) without insulin 
(A) and with insulin (B), indicated for determination of G6Pc mRNA levels. Results 
are expressed as means ± SEM 3 experiments, duplicate treatments (n=6). aP<0.05 
effect of glucose.
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Figure 4.3  Effects of glucosamine (GlcN) and N-acetylglucosamine (NAG) on 
gene expression and NAG-metabolites
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5 and 25 mM glucose and 0.5, 1, 5 and 10 mM glucosamine (GlcN) (A, 
C) and 1, 5, 7, 10 and 20 mM N-acetylglucosamine (NAG) (B, D), indicated for 
determination of NAG-metabolites (A, B) and G6Pc mRNA levels (C, D). Results 
are expressed as means ± SEM 3-6 experiments, duplicate treatments (n=6-12) . 
aP<0.05 effect of glucose.
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Figure 4.4  Effect of glucosamine on glucose 6-P and fructose 2,6-bisphosphate
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5 mM and 25 mM glucose and 0.5 mM glucosamine (GlcN) and indicated for 
determination of glucose 6-P (A) and F2,6P2 (B). Mean ± SEM 4-6 experiments, 
duplicate treatments (n=8-12) , aP< 0.05 effect of glucose, sP< 0.05 effect of GlcN. 
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Figure 4.5  Effects of OGT on G6Pc mRNA expression
Hepatocyte monolayers were untreated or treated with vectors for expression of 
OGT and pre-cultured overnight in MEM containing 10 nM dexamethasone, 5 
mM glucose.  They were then incubated for 4 h in MEM containing 5 mM 
glucose,  25  mM glucose and determination of OGT protein expression by 
immunoblotting assay (A) and G6Pc mRNA levels (B). Mean ± SEM 4 
experiments, duplicate treatments (n=8). 
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Figure 4.6  Effects of 6-diazo-5-oxonorleucine (DON) on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 mM and 25 mM glucose, with 40µM DON and indicated for 
determination of gene expression of (A)G6Pc, (B) GAPDH. Mean ± SEM 4-6 
experiments, duplicate treatments (n=8-12), aP< 0.05 effect of glucose, oP< 0.05 
effect of DON. 
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Figure 4.7  Effects of 6-diazo-5-oxonorleucine (DON) and glucosamine (GlcN) 
on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 mM and 25 mM glucose and 0.5 mM glucosamine (GlcN), with 
40 µM DON and indicated for determination of gene expression of (A) G6Pc, (B) 
TXNIP, (C) L-PK and (D) PTG. Mean ± SEM 4-6 experiments, duplicate 
treatments (n=8-12), aP< 0.05 effect of glucose, oP< 0.05 effect of DON sP< 0.05 
effect of GlcN. 
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Figure 4.8  Effects of 6-diazo-5-oxonorleucine (DON), glucosamine (GlcN) and N-
acetylglucosamine (NAG) on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 mM and 25 mM glucose and 0.5 mM glucosamine (GlcN) (A),  5 
mM N-acetylglucosamine (NAG), with 40 µM DON and indicated for determination of 
gene expression of G6Pc. Mean ± SEM 4-6 experiments, duplicate treatments (n=8-12), 
aP< 0.05 effect of glucose, oP< 0.05 effect of DON sP< 0.05 effect of GlcN mP< 0.05 
effect of NAG. 
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Figure 4.9  Effects of overexpression of ChREBP-WT on G6Pc mRNA 
expression
Hepatocyte monolayers were either untreated or treated with vectors for expression 
of ChREBP-WT at two viral titres (two fold dilution). After 18 h pre-culture, they 
were then incubated for 4 h in MEM containing 5 and 25 mM glucose, indicated for 
determination of ChREBP (A) and G6Pc (B) mRNA levels and protein expression by 
immunoblotting assay (C). Mean ± SEM 4 experiments, duplicate treatments (n=8), 
aP< 0.05 effect of glucose, hP< 0.05 effect of vectors for expression of ChREBP-
WT. 
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Figure 4.10  Effects of ChREBP on G6Pc mRNA expression
Hepatocyte monolayers were untreated or treated with vectors for expression of 
ChREBP-WT and pre-cultured overnight in MEM containing 10 nM dexamethasone, 5 
mM glucose and +/- DON.  They were then incubated for 4 h in MEM containing 5 
mM glucose,  25  mM glucose and 0.5 mM glucosamine, with 40 µM DON and 
determination of G6Pc mRNA levels (A) and ChREBP protein expression by 
immunoblotting assay (B). Mean ± SEM 4 experiments, duplicate treatments (n=8), 
aP< 0.05 effect of glucose, oP< 0.05 effect of DON, sP< 0.05 effect of GlcN and hP< 
0.05 effect of ChREBP
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Figure 4.11  Effects of DON on translocation of ChREBP
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and -/+ DON.  They were then incubated for 1 h in MEM 
containing 5 mM and 25 mM glucose. Cells were scored as having greater levels of 
ChREBP in the cytoplasm or nucleus as described in methods. Images representative of 2 
experiments, coverslips treated in duplicate (n=4). aP< 0.05 effect of glucose and oP< 0.05 
effect of DON. 
113
DAPI             ChREBP Overlay  
DAPI             ChREBP Overlay  
Figure 4.12  Effects of xylitol, PFK-WT and S4048 on gene expression
Hepatocyte monolayers were untreated or treated with vectors for expression of 
PFK/WT and pre-cultured overnight in MEM containing 10 nM dexamethasone, 5 
mM glucose and +/- DON.  They were then incubated for 4 h in MEM containing 5 
mM and 25 mM glucose and 5 mM xylitol, with 40 µM DON and indicated for 
determination of gene expression of G6Pc (A) and PTG (B). Mean ± SEM 4-6 
experiments, duplicate treatments (n=8-12), aP< 0.05 effect of glucose, oP< 0.05 
effect of DON yP< 0.05 effect of xylitol wP< 0.05 effect of PFK-WT and qP< 0.05 
effect of S4048. 
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Figure 4.13  Effects of kinase-deficient PFK2/FBP2 (PFK-KD) on G6P, NAG-
metabolites, gene expressions and fructose 2,6-bisphosphate
Hepatocyte monolayers were pre-cultured untreated or pre-treated with adenoviral 
vectors for PFK-KD and overnight in MEM containing 10 nM dexamethasone, 5 
mM glucose.  They were then incubated for 4 h in MEM containing 5 mM and 25 
mM glucose and indicated for determination of G6P (A), frucotose 2,6-bisphosphate 
(B), G6Pc mRNA gene expression (C) and NAG-metabolites (D) and Mean ± SEM 
4-6 experiments, duplicate treatments (n=8-12), aP< 0.05 effect of glucose and kP< 
0.05 effect of PFK-KD.
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Figure 4.14  Effects of 6-diazo-5-oxonorleucine (DON) on NAG-metabolites, gene 
expressions and fructose 2,6-bisphosphate
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 mM and 25 mM glucose, with 40 µM DON and indicated for 
determination of G6Pc mRNA gene expression (A) NAG-metabolites (B) and 
frucotose 2,6-bisphosphate (C) Mean ± SEM 4-6 experiments, duplicate treatments 
(n=8-12), aP< 0.05 effect of glucose and oP< 0.05 effect of DON.
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Figure 4.15  Effects of 6-diazo-5-oxonorleucine (DON) and glucosamine (GlcN) 
on gene expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and +/- DON.  They were then incubated for 4 h in 
MEM containing 5 mM and 25 mM glucose and 0.5 mM glucosamine (GlcN), with 40 
µM DON and indicated for determination of gene expression of (A)ChREBP and  (B) 
FOXO1. Mean ± SEM 4 experiments, duplicate treatments (n=8), aP<0.05 effect of 
glucose
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Glucose-induction of G6Pc and TXNIP by Mlx-independent 
mechanisms 
5.1 Aims and rationale 
The work in the previous chapter confirmed effects of glucose on G6Pc gene 
expression in both the absence and the presence of insulin, and it showed that 
inhibition of the HBP with DON inhibits glucose-induced G6Pc expression and 
also the induction of G6Pc mRNA caused by overexpression of ChREBP. 
Although ChREBP is thought to be the major transcription factor that is involved 
in the regulation of gene expression by high glucose concentration (Ma et al., 
2006) other transcription factors may also be involved. Transcription factors 
involved in regulation of G6Pc expression by insulin include FOXO1 and 
FOXO3A (Onuma et al., 2006). These transcription factors are targets for 
covalent modification by O-GlcNAc (Housley et al., 2008; Kuo et al., 2008). The 
FOXO transcription factors are also regulators of the TXNIP gene in other cell 
types (Al-Mubarak et al., 2009; de Candia et al., 2008). This gene like G6Pc is 
induced by glucose and repressed by insulin (Parikh et al., 2007). However, its 
regulation in liver has been less extensively studied than for G6Pc. In non-hepatic 
cells including muscle cells and islet beta cells TXNIP is induced by 2-
deoxyglucose (2-DOG) and by glucose (Peterson and Ayer, 2011). 
The aims of this study were: first to determine the role of Mlx-dependent 
mechanisms in the glucose induction of G6Pc and TXNIP; second to determine 
whether these two genes share similar regulatory mechanisms by glucose; third to 
determine the potential role of FOXO transcription factors in the regulation of 
these genes by glucose and by the HBP.  
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5.2 Results 
 
5.2.1 Role of Mlx-dependent mechanisms in the glucose induction of G6Pc and 
TXNIP 
 
To identify candidate transcription factors involved in the glucose induction of 
G6Pc and TXNIP we first tested the effects of a dominant-negative variant of 
Mlx. Mlx forms complexes with ChREBP and MondoA as well as other 
transcriptional regulators that are thought to function predominantly as repressors 
including Mad1, Mad4 and Mnt (Billin et al., 1999; 2000; Meroni et al., 2000).  
Previous studies using the same dominant-negative variant of Mlx showed that 
during glucose stimulation of gene expression in the presence of insulin, Mlx 
dependent mechanisms account for a high proportion of gene expression (Ma et 
al., 2006). The first experiments tested the Mlx-dependence of the glucose 
induction in both the absence and the presence of insulin. Stimulation of L-PK by 
glucose was greater in the presence of insulin, whereas stimulation of G6Pc  and 
TXNIP was greater in the absence of insulin (Fig. 5.1, A-C). Overexpression of 
Mlx-dominant negative (Mlx-DN) abolished the glucose induction of L-PK and 
also TXNIP and it also abolished the glucose induction of G6Pc in both the 
absence and presence of insulin. These results together suggest a major role for 
Mlx-dependent mechanisms in the glucose induction of L-PK, G6Pc and TXNIP 
in both the absence and the presence of insulin. 
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5.2.2 Mlx is required for the induction of TXNIP by glucose but not by 2-DOG 
 
Previous studies have shown that TXNIP is induced in various cell types 
including islet beta cells and other non-hepatic cell lines by 2-DOG (Kaadige et 
al., 2009; Stoltzman et al., 2011; Minn et al., 2006).  However, whether glucose 
and 2-DOG act through a similar mechanism as is generally assumed remains 
unclear (Peterson et al., 2011). We therefore tested the effects of overexpression 
of Mlx-DN on the induction of G6Pc and TXNIP by glucose and 2-DOG (Fig 5.2, 
A and B).  Treatment with Mlx-DN inhibited the glucose induction of TXNIP but 
significantly increased the induction of TXNIP by 2-DOG. Similar results were 
obtained when the effects of Mlx-DN were tested over a range of titres (Fig 5.2, C 
and D). Thus the converse effects of Mlx-DN on the glucose and 2-DOG 
induction show that these substrates act through different mechanisms. 
 
5.2.3 Expression of FOXO3A causes a greater enhancement of the glucose 
induction than the 2-DOG induction 
Both FOXO1 and FOXO3A are known to be involved in the induction of G6Pc 
(Guo et al., 1999; Hall et al., 2000) and TXNIP (Fa-Xing and Luo, 2009; Zhuo et 
al., 2010), and the effects of FOXO1 and FOXO3A on G6Pc are mediated through 
the same DNA elements (Onuma et al., 2006). We therefore tested the effects of 
overexpression of FOXO3A on the substrate induction of G6Pc and TXNIP (Fig 
5.3, A and B). Overexpression of FOXO3A had a small stimulatory effect on the 
expression of both G6Pc and TXNIP when measured at 5mM glucose. However, 
overexpression causes a much larger induction of both G6Pc and TXNIP at 25mM 
glucose. Interestingly, in incubations with 2-DOG, the effect of FOXO3A 
overexpression was similar to that in control conditions at 5 mM glucose. When  
Chapter 5                                                                                                   Results 3 
 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5                                                                                                   Results 3 
 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5                                                                                                   Results 3 
 133 
the effects of a titration of FOXO3A were tested the enhancement at 25 mM 
glucose was mainly observed at low titres of FOXO3A overexpression (Fig 5.3, C 
and D). Indicating that unlike the effects of Mlx-DN, the effects of FOXO3A 
were confined to a narrow range of titres. Low titres (4µl/ml) were therefore used 
in later studies.  
 
5.2.4 Induction by FOXO3A of the glucose stimulation occurs in both the 
absence and the presence of insulin 
 
The FOXO transcription factors are major mediators of the insulin repression of 
G6Pc (Onuma et al., 2006). Additional experiments were performed comparing 
FOXO3A overexpression in incubations both with and without insulin. In these 
experiments overexpression of FOXO3A markedly enhanced the stimulation by 
25 mM glucose of the induction of G6Pc and TXNIP also in the presence of 
insulin (Fig 5.4), but had little effect in the presence of 2-DOG. 
 
5.2.5 Mlx-DN inhibits the stimulation by FOXO3A 
 
We next tested whether the induction of G6Pc and TXNIP by FOXO3A is Mlx 
dependent, by combined overexpression of Mlx-DN and FOXO3A (Fig 5.5).  
Overexpression of Mlx-DN markedly attenuated the induction by FOXO3A at 
high glucose of both G6Pc and TXNIP, suggesting that the induction by high 
glucose is dependent on both FOXO3A and Mlx dependent mechanisms. 
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5.2.6 Insulin-dependence and glucose counter-regulation of the subcellular 
location of FOXO1 and FOXO3A 
 
The above studies suggest that the induction of both G6Pc and TXNIP by high 
glucose in the absence or presence of insulin are dependent on both Mlx and 
FOXO3A. Because insulin regulates FOXO-dependent mechanisms by Protein 
kinase B (PKB/AKT) mediated phosphorylation of FOXO proteins which results 
in the exclusion from the nucleus (Desvergne et al., 2006; Housley et al., 2008), 
we next tested whether glucose affects the subcellular location of both 
overexpressed FOXO3A and of endogenous FOXO1. Using commercially 
available antibodies to FOXO1 we were able to detect endogenous protein.  
However, with the antibodies to FOXO3A we could only detect the protein when 
overexpressed with the adenoviral vector. 
In cells not treated with insulin, FOXO1 was present in the nucleus of all 
hepatocytes irrespective of the glucose concentration.  Time course studies with 
insulin showed significant translocation from the nucleus within 15 min during 
incubation with 5 mM glucose. However translocation in response to insulin 
measured at 15, 30 and 60 min time points was markedly inhibited by 25 mM 
glucose (Fig 5.6). The subcellular location of FOXO3A in cells overepressing 
FOXO3A differed from that of endogenous FOXO1 in that translocation from the 
nucleus in response to insulin was more rapid for FOXO3A and the effects of 25 
mM glucose on increased nuclear staining of FOXO3A were seen in both the 
absence and the presence of insulin (Fig 5.7). This shows that glucose promotes 
the retention of both FOXO1 and FOXO3A in the nucleus. 
  
 
Chapter 5                                                                                                   Results 3 
 137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5                                                                                                   Results 3 
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5                                                                                                   Results 3 
 139 
5.2.7 DON inhibits the glucose regulation of FOXO1 and FOXO3A 
translocation 
To test for possible involvement of the hexosamine pathway in the effect of 
glucose on the subcellular location of FOXO1 and FOXO3A, the effects of DON 
were determined. Treatment with DON inhibited the effect of high glucose on 
translocation of both FOXO1 (Fig 5.8) and FOXO3A (Fig 5.9).   
 
5.2.8 DON counteracts O-GlcNAc modification of FOXO3A 
 
We next tested for covalent modification of FOXO3A glycosylation by pull down 
with wheat germ agglutinin-agarose beads followed by immunoblotting as 
described previously for ChREBP (Guinez et al., 2011). In Figure 5.10 
interestingly, recovery of FOXO3A in the WGA pull-down was greater in the 
presence of insulin. Pre-treatment with DON markedly counteracted the FOXO3A 
recovery in the WGA pull-down and combined treatment with GlcN partially 
reversed the effect of DON. Immunoblotting to FOXO3A protein showed that the 
effect of DON was on binding to WGA not on total proteins. In parallel 
experiments DON also inhibited the induction of TXNIP by high glucose in the 
absence of insulin but had a much smaller effect in the presence of insulin (Fig. 
5.11).   
 
5.2.9 OGT overexpression enhances FOXO3A induced G6Pc. 
 
To further test for a possible role for covalent modification of FOXO3A by O-
GlcNAc we tested the effects of combined overexpression of FOXO3A and OGT 
on glucose induced gene expression. Overexpression of OGT was confirmed by  
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immunoblotting. Overexpression of OGT alone had no significant effect on the 
glucose induction of G6Pc (Fig 5.12). However, combined overexpression of 
OGT and FOXO3A modestly enhanced the induction of G6Pc at high glucose, 
supporting a potential role of covalent modification of FOXO3A in the glucose 
induction. 
 
5.2.10 Induction of TXNIP by 2-DOG is inhibited by actinomycin-D and 
calcium antagonist 
 
The above studies indicate involvement of both FOXO transcription factors and 
Mlx-dependent mechanisms in the induction of G6Pc and TXNIP by high 
glucose. However, TXNIP but not G6Pc was induced by 2-DOG by an Mlx-
independent mechanism (Fig. 5.13). We next tested whether the increase in 
TXNIP mRNA expression by 2-DOG is due to transcriptional or post-
transcriptional mechanisms by incubation with the transcriptional inhibitor 
actinomycin D. Treatment with actinomycin D totally abolished the increase in 
mRNA by both 25 mM glucose and 10 mM 2-DOG suggesting that these effects 
are due to transcriptional rather than post-transcriptional control. Interestingly 
actinomycin D also markedly lowered TXNIP mRNA levels in basal conditions at 
5 mM glucose, suggesting that the mRNA has a short half-life and a high turnover 
at basal glucose concentration. Immunoblotting to TXNIP protein showed lower 
immunoactivity in the presence of insulin and also an increase in TXNIP protein 
with both 25 mM glucose and 2-DOG (Fig. 5.14). We next tested the effects of 
the calcium channel blocker, verapamil, which was shown in recent studies on 
islet beta cells and cardiomyocytes to decrease TXNIP mRNA expression in cells 
treated with 25 mM glucose (Chen et al., 2009; Xu et al., 2012; Cha-Molstad et  
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al., 2012). Verapamil at a concentration of 150 µM lowered TXNIP mRNA levels 
by about 70% in basal conditions and also during stimulation with 25 mM glucose 
or 10 mM 2-DOG. However, unlike actinomycin D which totally abolished the 
increase in TXNIP mRNA by glucose and 2-DOG, verapamil did not fully block 
the 4-fold increase by 25 mM glucose or 10 mM 2-DOG (Fig. 5.15). These results 
suggest that the induction of TXNIP by 2-DOG like that by 25 mM glucose is 
largely through transcriptional mechanisms. They also suggest that the inhibition 
of TXNIP expression which had previously been shown only in incubations at 
high glucose is glucose independent because it does not block the induction by 
glucose. 
 
5.2.11 Allose and 3-MOG but not 6-DOG, 5TG and glucosamine mimic 2-DOG 
induction of TXNIP 
 
 
In various non-hepatic cell lines and also in islet beta cells the induction of 
TXNIP by 2-DOG is mimicked by 3-O-methylglucose (3-MOG) and allose 
(Pedersen et al., 2011). We compared the effects of 2-DOG with other glucose 
analogues and found that similar to non-hepatic cells, TXNIP was induced in 
hepatocytes by 3-MOG and allose but not by 6-deoxyglucose (6-DOG), which is 
not a substrate for hexokinase. TXNIP was also not induced by 5-thioglucose 
(Fig. 5.16). This sugar has been reported to be phosphorylated by hexokinases 
(Carabaza et al., 1992), but it is also a very potent inhibitor of glucokinase (Agius  
and Stubbs, 2000). GlcN had no effect on TXNIP mRNA. However, a recent 
study (Stoltzman et al., 2001) reported that 10 mM glucosamine has a small 
stimulatory effect on TXNIP expression. 
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Two other substrates that were found to cause induction of TXNIP mRNA by 3.4-
fold and 2.9-fold were fructose (10 mM) which is rapidly metabolised by 
fructokinase to fructose 1-P and glycerol (2 mM) which is rapidly phosphorylated 
to glycerol 3-phosphate (Fig. 5.17).  Both fructose and glycerol cause acute 
lowering of ATP.  However, none of the glucose analogues caused ATP depletion 
(results not shown), suggesting that the induction of TXNIP mRNA by the 
glucose analogues is not due to ATP depletion. 
 
5.2.12 5TG but not bromopyruvate inhibits the induction by the glucose analogs 
 
The induction of TXNIP by glucose analogues in non-hepatic cells has been 
suggested to be secondary to the phosphorylation of these sugars, based on the 
inhibition of the glucose effect by 3-bromopyruvate (Stoltzman 2008; Stoltzman 
et al., 2011) and also the demonstration of phosphate esters of 3-O-methylglucose 
and allose by mass spectrometry (Stoltzman et al., 2011). Surprisingly, in the 
present study 3-bromopyruvate, used at the same concentration as in the previous 
studies (20 µM) had no effect on the induction of TXNIP mRNA by any of the 
glucose analogues (Fig. 5.18, C). However, 5TG which is a very effective 
hexokinase inhibitor in primary hepatocytes abolished the induction by 25 mM 
glucose and significantly inhibited the induction by allose and 3-MOG, but had no 
significant effect on the induction by 10 mM 2-DOG (Fig. 5.18, A). To 
investigate the latter further we tested the effects of 3 mM 5TG over a range of 
concentrations of 2-DOG (2, 5 and 10 mM). In these experiments 5TG 
significantly attenuated the stimulation by 2 mM 2-DOG but not by higher 
concentrations (Fig. 5.18B). This suggests that 5TG may be a weak inhibitor of 
hexokinase with 2-DOG as substrate. The inhibitory effect of 5TG on the  
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induction of TXNIP by the glucose analogues in hepatocytes suggests a 
mechanism dependent on the phosphorylation of the analogues, as proposed 
recently by Stoltzman and colleagues (Stoltzman et al., 2011).  Whether the lack 
of effect of 3-bromopyruvate is due to lack of uptake by hepatocytes or lack of 
effect on phosphorylation by glucokinase was not tested in this study.  
 
5.2.13 S4048 enhances the induction by glucose but not by 2-DOG 
 
We next tested the effects of the chlorogenic derivative S4048, a potent inhibitor 
of the glucose 6-P transporter (SLC37A4) that transfers cytoplasmic hexose 6-P 
into the ER (Härndahl et al., 2006). S4048 causes a large increase in cytoplasmic 
accumulation of glucose 6-P and also 2-deoxyglucose 6-phosphate (2-DOG 6-P) 
confirming that both glucose 6-P and 2-DOG 6-P are substrates for SLC37A4 
transporter (Arden et al., 2012).  SLC37A4 is one of three hexose 6-P transporters 
present on the ER membrane. A recent study comparing the properties of 
SLC37A1, SLC37A2 and SLC37A4 in microsomal membranes showed that all 
three transporters exchange glucose 6-P for Pi but only SLC37A4 is sensitive to 
chlorogenic inhibition and is coupled to glucose 6-P hydrolysis (Pan et al., 2011). 
Whether the other transporters are coupled to the hexose 6-phosphate 
dehydrogenase which has a broader substrate affinity than the cytoplasmic 
glucose 6-phosphate dehydrogenase is not known (Czegle et al., 2012). Because 
S4048 inhibits the entry of hexose phosphates into the ER via the SLC37A4 
transporter, this means that S4048 limits but does not prevent the entry of glucose 
6-P into the ER lumen and it elevates the cytoplasmic concentration of these 
phosphate esters. We therefore tested the effects of S4048 on the TXNIP 
induction by the sugars. S4048 significantly increased TXNIP induction by 25 
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mM glucose but not by 10 mM 2-DOG (Fig. 5.19, A) or by lower 2-DOG 
concentrations (Fig. 5.19, B). Because S4048 increases 2-DOG 6-P accumulation 
(Arden et al., 2012), possible explanations for the lack of effect of S4048 on the 2-
DOG induction of TXNIP are that it is not mediated by cytoplasmic 2-DOG but 
by entry of substrate into the ER. 
 
5.2.14 Action of 2-DOG may be mediated by ER stress 
 
Various substrates can be transported into the endoplasmic reticulum (ER), and 
can induce ER stress at high concentrations, such as glucosamine, tunicamycin 
and glycosylation inhibitors. Tunicamycin and 2-DOG are inhibitors of N-
glycosylation but 2-DOG is less efficient than tunicamycin (Yoshida, 2007; 
Werstuck et. al., 2006; Kim et. al., 2004). Chaperone proteins such as BiP, GRP78 
and GRP94 are induced during endoplasmic reticulum (ER) stress (Sundar Rajan 
et al., 2007; Robertson et. al., 2006). We therefore tested whether the sugar 
analogs such as 2-DOG, allose, 3-MOG and 6-DOG induce the ER stress markers 
GRP78 and GRP94 mRNA expression. In these experiments, we found elevation 
in both GRP78 and GRP94 by 2-DOG (10 mM) but not by allose (Fig 5.20), 
which caused a larger increase in TXNIP (Fig. 5.16 and 5.18).  Because GRP78 
was also induced by 6-DOG which does not induced TXNIP mRNA,  these results 
on GRP78 and GRP94 mRNA do not support a role for ER stress in the induction 
of TXNIP.  
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5.2.15 Effects of inhibition of stress kinases and histone deacetylase on TXNIP 
expression 
 
A recent study suggested that the induction of TXNIP may be mediated by 
activation of p38 MAPK based on the inhibition of induction by the p38MAPK 
inhibitor with 4-(4-Fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole 
(PD1693160) (Li et al., 2009). We tested whether the induction of TXNIP mRNA 
by glucose or 2-DOG is inhibited by the MAPK inhibitor.  Interestingly the 
induction by glucose but not by 2-DOG was inhibited by PD169316 (Fig. 5.21, 
A), suggesting that the glucose stimulation but the not that by 2-DOG may 
involve activation of MAP-kinase. Inhibitors of histone deacetylation (trichostatin 
A (TSA)) were shown to enhance the induction of TXNIP by glucose in islet beta 
cells (Cha-Molstad, 2009). We tested whether the effects of 2-DOG are affected 
by the histone deacetylase inhibitor. The stimulation by glucose was enhanced by 
TSA, similar to previous findings in beta cells (Fig. 5.21, B). However, the 
stimulation by 2-DOG was not affected. This further supports a different 
mechanism for glucose and the glucose analogs.   
 
5.2.16 Glucose and 2-deoxylguocse (2-DOG) Recruitment of Acetyl-Histone 4, 
NF-Y and FOXO1 to the TXNIP promoter 
 
Previous studies have shown that NF-Y and FOXO binding sites near the glucose 
response elements in the TXNIP promoter (Yu and Luo, 2009). However, 
recruitment of NF-Y, Acetyl-Histone 4 (Acetyl-H4), FOXO1 and FOXO3A 
transcription factors to the TXNIP gene in hepatocytes has not been studied. To 
test for effects of glucose and 2-DOG on recruitment of transcription factors to the  
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TXNIP promoter we performed ChIP assays using antibodies to NF-Y, Acetyl-
H4, FOXO1 and FOXO3A using primers spanning the two ChoRE sequences. 
The results showed that binding of acetyl-H4 to the TXNIP promoter was greater 
with 2-DOG and also binding of FOXO1 was greater with 2-DOG but there was 
not statistically significant. Binding of NF-Y was less with both 25 mM glucose 
and 2-DOG but also not statistically significant. There was very little or no 
binding of FOXO3A with 25 mM glucose (Fig. 5.22).    
 
5.2.17 2-DOG mimics the effect of glucose on FOXO1 and FOXO3A 
translocation 
 
Comparison of the effect of glucose and 2-DOG on the subcellular location of 
FOXO1 and FOXO3A (Fig. 5.23) showed that 2-DOG like 25 mM glucose causes 
increased nuclear staining of both FOXO1 and FOXO3A.   
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5.3 Discussion  
The aims of this study were to test whether glucose induces G6Pc and TXNIP by 
both Mlx-dependent and Mlx-independent mechanisms and to test the potential 
role of FOXO transcription factors in regulating the glucose induction of these 
genes. 
Previous studies have shown that TXNIP is induced by glucose in several cell 
types and repressed by insulin in adipocytes (Parikh et al., 2007). The glucose 
induction has been shown previously to be mediated by ChREBP-Mlx in islet beta 
cells (Cha-Molstad et al., 2009) and by MondoA-Mlx in other cell types 
(Stoltzman et al., 2011). Studies on the TXNIP promoter have identified 2 
ChOREs and a FOXO binding site (Yu and Luo, 2009) suggesting that FOXO 
may have a role in the regulation of this gene. A role for FOXO transcription 
factors in mediating the activation of TXNIP by cell stress was shown in 
HepG2/C3A human liver cells and senesant fibroblasts (de Candia et al., 2008; 
Zhuo et al., 2010). FOXO1 and FOXO3A transcription factors have a major role 
in the regulation of G6Pc gene expression by insulin (Onuma et al., 2006). 
However, the role of these regulators in gene regulation by glucose has been less 
extensively studied.   
 
5.3.1 The role of Mlx-dependent and Mlx-independent mechanisms in glucose 
regulation 
 
This study shows that the glucose induction of both G6Pc and TXNIP is at least in 
part Mlx-dependent in both the absence and in the presence of insulin. The 
induction of G6Pc by glucose is much greater in the absence of insulin than in the 
presence of insulin and based on titration experiments with different adenoviral 
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titres of the Mlx-DN it can be concluded that in the absence of insulin there may 
also be Mlx-independent mechanism. However, in the presence of insulin there 
was no clear evidence for an Mlx-independent stimulation of G6Pc. Because 
insulin causes a large inhibition of G6Pc expression and glucose causes a large 
stimulation in the absence of insulin; the simplest explanation is that Mlx-
independent stimulation of G6Pc by glucose is inhibited by insulin and the Mlx-
dependent stimulation is not inhibited by insulin.  
The regulation of TXNIP by glucose and insulin differs from G6Pc regulation in 
two ways: (i) The stimulation by glucose (in the absence of insulin) is smaller for 
TXNIP. (ii) The inhibition by insulin is also smaller for TXNIP than for G6Pc.  
Also the experiments with the glucose analogues show clearly that this 
mechanism is unique to TXNIP but does not apply to G6Pc and also that this 
glucose analogue stimulation is  by an Mlx-independent mechanism.  However, as 
discussed below, the glucose analogues may be acting by a different mechanism 
from glucose. This study provides evidence that glucose induces both G6Pc and 
TXNIP more strongly in the absence of insulin than in the presence of insulin. 
Because the FOXO transcription factors are major negative regulators of insulin 
action, they are strong candidates for the stimulation by glucose of these genes. 
 
5.3.2 The role of FOXO transcription factors in glucose regulation  
 
Endogenous expression of FOXO1 was clearly detectable by immunostaining in 
hepatocytes and it was present in the nucleus in hepatocytes not incubated with 
insulin and it translocated to the cytoplasm within 15 to 60 min of addition of 
insulin to the hepatocytes. Endogenous expression of FOXO3A was not 
detectable in hepatocytes suggesting that FOXO3A may be expressed at lower 
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levels than FOXO1. When FOXO3A was overexpressed with low adenoviral 
titres it was clearly present in the nucleus at much higher concentrations than in 
the cytoplasm, although it was also present in the cytoplasm. Interestingly, 
FOXO3A translocated from the nucleus in response to insulin much more rapidly 
than FOXO1. The effects of overexpression of FOXO3A on G6Pc and TXNIP 
gene expression were tested over a range of concentrations in the titration 
experiments, and both genes were induced by FOXO3A overexpression. 
However, the effect was bisphasic and was greatest at the low titres of FOXO3A. 
Overexpression of FOXO3A stimulated both G6Pc and TXNIP at 5 mM glucose 
but caused a much greater stimulation of both these genes at 25 mM glucose. For 
both genes this stimulation was greatest at the lowest titres of FOXO3A 
expression. The immunostaining experiments showed that glucose caused the 
accumulation of FOXO1 and FOXO3A in the nucleus in the absence of insulin as 
expected from studies on other cell types (Wilk et al., 2011; Chong et al., 2011; 
Meur et al., 2011; Cifarelli et al., 2012) and also in the presence of insulin. The 
effect of glucose on nuclear accumulation of FOXO3A was much smaller in the 
presence of insulin, because of the very rapid and stronger effect of insulin on 
nuclear exclusion of FOXO3A compared with FOXO1. Together these results 
suggest that the FOXO transcription factors are very strong candidates for the 
glucose stimulation of both G6Pc and TXNIP especially in the absence of insulin.    
Experiments testing combined expression of FOXO3A and Mlx-DN suggested 
that the induction of both genes by FOXO3A may also be at least in part Mlx-
dependent. This suggests that there may be an interaction between Mlx-
mechanisms and FOXO-dependent stimulation. There may also be other 
transcription factors involved in the Mlx-independent stimulation of G6Pc and 
TXNIP by high glucose. 
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5.3.3 Regulation of FOXO transcription factors by glucose and the HBP 
 
This study shows that the GFAT inhibitor DON strongly inhibits the glucose-
induced expression of both G6pc and TXNIP in the absence of insulin but has a 
smaller effect in the presence of insulin. The FOXO transcription factors are 
covalently modified on various serine / threonine residues by PKB/Akt which is 
activated by insulin (Gross et al., 2009) and they are also covalently modified by 
O-GlcNAc (Housley et al., 2009). Insulin and 25 mM glucose had opposite effects 
on the subcellular location of both FOXO1 and FOXO3A. Insulin caused the 
movement of FOXO1 and FOXO3A from the nucleus to the cytoplasm and 25 
mM glucose opposed the effect of insulin by causing the accumulation of both 
FOXO1 and FOXO3A in the nucleus in the presence of insulin.  This “counter-
regulatory” effect of high glucose on the insulin translocation out of the nucleus 
could be due to either inhibition of insulin signalling or to an effect of glucose that 
is independent of insulin signalling. Other studies from our lab showed that high 
glucose does not affect the stimulation by insulin of Akt phosphorylation (Arden 
et al., 2011) suggesting that high glucose may be acting by other mechanisms. In 
this study the GFAT inhibitor DON, opposed the effect of high glucose on the 
sub-cellular location of both FOXO1 and FOXO3A. The effects of DON were 
greater on FOXO3A than on FOXO1. This inhibitory effect of DON on the 
glucose induced retention of the FOXO transcription factors in the nucleus 
suggests involvement of the HBP and O-GlcNAc modification of FOXO 
transcription factors by high glucose resulting in their retention in the nucleus and 
also involvement of these FOXO regulators in the glucose induction of G6Pc and 
TXNIP. Pull-down experiments of O-GlcNAc modified proteins with wheat-germ 
agglutinin in hepatocytes overexpressing FOXO3A confirmed that incubation 
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with high glucose increases the covalent modification of FOXO3A by O-GlcNAc 
and that this effect is reversed by DON and also by insulin. The stimulation of 
G6Pc expression by combined expression of OGT and FOXO3A also supports a 
role for modification of FOXO3A by O-GlcNAc in the glucose induction of 
G6Pc. Together these results support a model that the glucose induction of both 
G6pc and TXNIP involves the covalent modification of FOXO transcription 
factors by O-GlcNAc causing their retention in the nucleus, and that the inhibition 
by the GFAT inhibitor involves decreased covalent modification of FOXO 
transcription factors and decreased retention in the nucleus.   
 
5.3.4 Effects of glucose analogues on TXNIP expression 
 
A major difference between G6Pc and TXNIP regulation is that TXNIP but not 
G6Pc was induced by glucose analogues. Studies on adipocytes, muscle cells and 
other non-liver cell types have shown inhibition of TXNIP expression by insulin 
and induction by glucose (Parikh et al., 2007), 2-DOG and other glucose 
analogues including 3-MOG (Stoltzman et al., 2011). However, whether glucose 
and 2-DOG act by the same or different mechanisms was not demonstrated 
(Stoltzman et al., 2011).   
Several experiments suggested that the induction of TXNIP by 2-DOG involves a 
different mechanism from the regulation by glucose: (i) induction by 2-DOG was 
Mlx-independent; (ii) unlike induction by glucose it was not enhanced by the 
histone deactylase inhibitor, trichostatin A; (iii) unlike the induction by glucose it 
was not inhibited by the MAP-kinase inhibitor. The effect of 2-DOG is most 
likely due to control of gene transcription because it was inhibited by the 
transcription inhibitor, actinomycin D. A previous study by Petersen and Ayer 
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suggested that 2-DOG needs to be phosphorylated to induce TXNIP expression 
(Petersen and Ayer, 2011). Our results are consistent with a phosphorylation 
mechanism because 6-DOG which cannot be phosphorylated and 5TG which is 
only weakly phosphorylated did not induce TXNIP expression.  Also, 5TG, which 
is a hexokinase inhibitor, inhibited the induction by allose and partially inhibited 
the induction by 3-MOG and low concentrations of 2-DOG, consistent with a 
mechanism that involves phosphorylation of the analogues. After phosphorylation 
of 2-DOG to 2-DOG 6-P it is not further metabolised by glycolysis.  However, it 
is metabolised by glucose 6-P because the chlorogenic derivative which inhibits 
transport hexose 6-phosphates into the ER causes accumulation of both glucose 6-
P and 2-DOG 6-P (Arden et al., 2012). The action of the glucose analogues on 
TXNIP expression could occur by a mechanism in either the cytoplasm or the ER.  
Unlike the induction of TXNIP by glucose, the induction by 2-DOG was not 
enhanced by the chlorogenic derivative (S4048) which inhibits the glucose 6-P 
transporter on the ER membrane that is coupled to glucose 6-P (Pan et al., 2011).   
A possible explanation for the lack of effect of S4048 on the 2-DOG stimulation 
of TXNIP is that the glucose analogues may be phosphorylated in the cytoplasm 
and transported into the ER on other transporters that are insensitive to S4048 
(Pan et al., 2011) and metabolism of the analogues in the ER lumen by the hexose 
6-phosphate dehydrogenase may be involved in TXNIP regulation.   Further work 
using inhibitors of the hexose 6-phosphate dehydrogenase would be required to 
test this possibility (Zielinska et al., 2010). The induction of the ER stress markers 
GRP78 and GRP94 is consistent with a possible role of metabolism in the ER in 
the induction of TXNIP. Two sets of evidence support possible involvement of 
FOXO transcription factors in the regulation of TXNIP by the glucose analogues.  
First, overexpression of FOXO3A at low concentrations enhanced the induction 
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of TXNIP by 2-DOG.  Second, 2-DOG and 3-MOG increased the nuclear 
accumulation of both FOXO1 and FOXO3A. Similar results were not observed 
for allose which is a strong inducer of TXNIP. However in some experiments the 
combination of FOXO3A overexpression and treatment with allose resulted in cell 
death (results not shown). Measurement of mRNA changes can only be performed 
on the whole cell population, whereas nuclear accumulation of FOXO 
transcription factors is measured in individual cells. We cannot exclude the 
possibility that the glucose analogs may induce TXNIP in a small proportion of 
the cells and the formation of TXNIP protein may lead to apoptosis as has been 
reported for islet beta cells (Minn et al., 2005). 
 
5.3.5 Role of histone acetylation in TXNIP expression 
 
Previous studies (Butler et al., 2002) testing the effects of inhibition of Histone 
deacetylases (HDAC) with SAHA followed by gene microarrays identified 
TXNIP as the main gene that was induced 2-fold by inhibition of HDAC. In this 
study they identified through promoter deletion constructs that the region of the 
TXNIP promoter contains an NF-Y binding site and they confirmed using a 
dominant negative NF-Y construct that the induction of TXNIP expression by the 
HDAC inhibitor is dependent on NF-Y binding. These results suggest that TXNIP 
expression is regulated by HDAC binding to NF-Y (Butler et al., 2002) and that 
deacetylation by HDAC inhibits TXNIP expression. Later work confirmed the 
induction of TXNIP by HDAC inhibitors and showed that combined inhibition of 
HDAC with TSA and methylation with 5-aza caused a greater induction of 
TXNIP (Lee et al., 2010).  A recent study on islet beta cells showed that the 
HDAC inhibitor stimulated TXNIP expression at both 5mM and 25mM glucose 
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and it caused increased binding of Acetyl-H3 and Acetyl-H4 at the TXNIP 
promoter. They also showed an increase in recruitment of Acetyl-H4 in response 
to glucose (Cha-Molstad et al., 2009). 
Two key findings from the present study are: (i) TSA increased TXNIP 
expression with 25mM glucose but not with 2-DOG; (ii) Binding of Acetyl-H4 to 
the TXNIP promoter was significantly increased by 2-DOG but not by 25mM 
glucose.   The simplest explanation for these two observations is that in the 
presence of 2-DOG there is little or no binding of HDAC to the TXNIP promoter.  
This would explain both the lack of effect of TSA and the very high Acetyl-H4.   
Interestingly, Butler et al., (2002) concluded that HDAC binds to the TXNIP 
promoter through the NF-Y site.  In the ChIP experiments in this study there was 
little or no binding of NF-Y with 25mM glucose and 2-DOG.  A possible 
explanation is that there are other binding sites for HDAC apart from NF-Y that 
are activated by glucose but not by 2-DOG.  One possibility would be an Mlx-
dependent mechanism, because this was activated by glucose but not by 2-DOG.  
In addition the induction of TXNIP by 2-DOG was increased by the Mlx-
dominant negative, which also supports this explanation. Therefore the activation 
of TXNIP by 2-DOG and other analogues is most likely explained by dissociation 
of HDAC and increased histone acetylation.  
 
5.4 Summary 
This study has shown that: 
• Mlx-dependent mechanisms are involved in the glucose induction of both 
G6Pc and TXNIP mRNA expression but not in the induction of TXNIP by 
2-DOG.  
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• A major role for FOXO transcription factors in the converse effects of 
glucose and insulin on the expression of both G6Pc and TXNIP is 
supported by: (i) the enhanced expression of these genes at high glucose 
by FOXO3A overexpression; (ii) the opposite effects of glucose and 
insulin on the subcellular location of FOXO1 and FOXO3A. 
 
• A role for the HBP in the glucose regulation of G6Pc and TXNIP by 
FOXO transcription factors is supported by the following sets of evidence:  
(i) inhibition by DON on glucose induced FOXO translocation;  (ii) 
greater inhibition by DON of glucose induction of these genes in the 
absence of insulin;  (iii) inhibition of covalent modification of FOXO3A 
by O-GlcNAc as determined in the wheat germ agglutin assays; (iv) 
additive induction of G6pc in incubations with overexpression of OGT and 
FOXO3A at high glucose.  
 
• Induction of TXNIP by glucose analogues is mediated by a different 
mechanism from the glucose induction as supported by: (i) lack of Mlx-
dependence; (ii) lack of effect of stress kinase inhibitors and histone 
deacetylase inhibitors; (iii) increased binding of histone Acetyl-H4 
indicating increased histone acetylation.  
 
Figure 5.1  Effects of Mlx-DN on G6Pc, TXNIP and L-PK mRNA  expression
Hepatocytes were untreated or treated with adenoviral vectors for dominant 
negative (DN) variant of Mlx Mlx-DN in serum free MEM were added to cells at 2 
to 4 h after plating and cultured for 4 h after cultured overnight in MEM containing 
10 nM dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5 mM and 25 mM glucose, with or without 10nM insulin and indicated 
for determination of gene expression (A) G6Pc, (B) TXNIP and (C) L-PK. Mean ±
SEM 8 experiments, duplicate treatments (n=16) , aP< 0.05 effect of glucose, bP< 
0.05 effect of Mlx-DN, cP< 0.05 effect of  insulin. 
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Figure 5.2  Effects of Mlx-DN on G6Pc and TXNIP mRNA expression
Hepatocytes were untreated or treated with adenoviral vectors for Mlx-DN in 
serum free MEM were added to cells at 2 to 4 h after plating and cultured for 4 h 
after cultured overnight in MEM containing 10 nM dexamethasone, 5 mM
glucose.  They were then incubated for 4 h in MEM containing 5 mM and 25 mM
glucose and 10 mM 2-deoxyglucose (2-DOG) and indicated for determination of 
gene expression, 6 experiments, duplicate treatments (n=12) (A) G6Pc, (B) TXNIP 
and overexpression of Mlx-DN, 2 experiments, duplicate treatments (n=4) (C) 
G6Pc and (D) TXNIP. Mean ± SEM, aP< 0.05 effect of glucose, bP< 0.05 effect of 
Mlx-DN. 
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Figure 5.3  Effects of FOXO3A on G6Pc, TXNIP mRNA expression
Hepatocytes were untreated or treated with adenoviral vectors for FOXO3A in
serum free MEM were added to cells at 2 to 4 h after plating and cultured for 4 h 
after cultured overnight in MEM containing 10 nM dexamethasone, 5 mM
glucose.  They were then incubated for 4 h in MEM containing 5 mM and 25 mM
glucose and 10 mM 2-deoxyglucose (2-DOG) and indicated for determination of 
gene expression, 6 experiments, duplicate treatments (n=12) (A) G6Pc, (B) TXNIP 
and overexpression of FOXO3A, 2 experiments, duplicate treatments (n=4) (C) 
G6Pc and (D) TXNIP. Mean ± SEM, aP< 0.05 effect of glucose, dP< 0.05 effect of 
FOXO3A. 
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Figure 5.4  Effects of FOXO3A without or with insulin on G6Pc and TXNIP mRNA 
expression
Hepatocytes were untreated or treated with adenoviral vectors for FOXO3A in serum 
free MEM were added to cells at 2 to 4 h after plating and cultured for 4 h after cultured 
overnight in MEM containing 10 nM dexamethasone, 5 mM glucose.  They were then 
incubated for 4 h in MEM containing 5 mM and 25 mM glucose and 10 mM 2-
deoxyglucose (2-DOG), without or with insulin and indicated for determination of gene 
expression, G6Pc and TXNIP. Means ± SEM for 4 experiments, duplicate treatments 
(n=8), aP< 0.05 effect of glucose, cP< 0.05 effect of  insulin and dP< 0.05 effect of 
FOXO3A. 
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Figure 5.5  Effects of FOXO3A and Mlx-DN on G6Pc and TXNIP mRNA 
expression
Hepatocytes were untreated or treated with adenoviral vectors for wild type
FOXO3A and dominant negative (DN) variant ofMlx in serum free MEM were 
added to cells at 2 to 4 h after plating and cultured for 4 h after cultured overnight in 
MEM containing 10 nM dexamethasone, 5 mM glucose.  They were then incubated 
for 4 h in MEM containing 5 mM and 25 mM glucose, with or without 10 nM
insulin and indicated for determination of gene expression (A) G6Pc and (B) 
TXNIP. Mean ± SEM 4 experiments, duplicate treatments (n=8), aP< 0.05 effect of 
glucose, bP< 0.05 effect of Mlx-DN, cP< 0.05 effect of  insulin and dP< 0.05 effect 
of FOXO3A. 
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Figure 5.6  Effects of insulin on translocation of FOXO1 
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 1 h in MEM containing 5 
mM and 25 mM glucose and 10 mM 2-deoxyglucose (2-DOG), with time course of 10 
nM insulin. Cells were scored as having greater levels of FOXO1 in the cytoplasm or 
nucleus as described in methods. Images representative of 2 experiments, coverslips
treated in duplicate (n=4). aP< 0.05 effect of glucose and cP< 0.05 effect of insulin. 
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Figure 5.7  Effects of insulin on translocation of FOXO3A
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 1 h in MEM containing 5 
mM and 25 mM glucose and 10 mM 2-deoxyglucose (2-DOG), with time course of 10 nM
insulin. Cells were scored as having greater levels of FOXO3A in the cytoplasm or 
nucleus as described in methods. Images representative of 2 experiments, coverslips
treated in duplicate (n=4). aP< 0.05 effect of glucose and cP< 0.05 effect of insulin. 
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Figure 5.8  Effects of DON on translocation of FOXO1 
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and -/+ DON.  They were then incubated for 1 h in 
MEM containing 5 mM and 25 mM glucose, with or without 10 nM insulin for 15 min. 
Cells were scored as having greater levels of FOXO1 in the cytoplasm or nucleus as 
described in methods. Images representative of 2 experiments, coverslips treated in 
duplicate (n=4). aP< 0.05 effect of glucose and oP< 0.05 effect of DON. 
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Figure 5.9  Effects of DON on translocation of FOXO3A 
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose and -/+ DON.  They were then incubated for 1 h in 
MEM containing 5 mM and 25 mM glucose, with or without 10 nM insulin for 15 
min. Cells were scored as having greater levels of FOXO3A in the cytoplasm or 
nucleus as described in methods. Images representative of 2 experiments, coverslips
treated in duplicate (n=4). aP< 0.05 effect of glucose and oP< 0.05 effect of DON. 
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Figure 5.10  Effects of DON on O-GlcNAc modification of FOXO3A 
Hepatocytes were untreated or treated with adenoviral vectors for FOXO3A in
serum free MEM were added to cells at 2 to 4h after plating and cultured for 4h after 
cultured overnight in MEM containing 10 nM dexamethasone, 5 mM glucose and 
+/- DON.  They were then incubated for 4 h in MEM containing 5 mM and 25 mM
glucose and 40 µM DON, without or with 10 nM insulin and indicated for 
determination of protein by immunoblotting assay for FOXO3A . 
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Figure 5.11  Effects of FOXO3A without or with DON on G6Pc and TXNIP mRNA 
expression
Hepatocytes were untreated or treated with adenoviral vectors for FOXO3A in serum 
free MEM were added to cells at 2 to 4 h after plating and cultured for 4 h after cultured 
overnight in MEM containing 10 nM dexamethasone, 5 mM glucose and +/- DON.  
They were then incubated for 4 h in MEM containing 5 mM and 25 mM glucose and 40 
µM DON, without or with 10 nM insulin and indicated for determination of gene 
expression, (A) G6Pc, (B) TXNIP. Mean ± SEM, 3 experiments, duplicate treatments 
(n=6) aP< 0.05 effect of glucose, cP< 0.05 effect of  insulin and dP< 0.05 effect of 
FOXO3A oP< 0.05 effect of DON. 
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Figure 5.12  Effects of FOXO3A and OGT on G6Pc mRNA expression
Hepatocytes were untreated or treated with adenoviral vectors for FOXO3A and 
OGT in serum free MEM were added to cells at 2 to 4 h after plating and cultured 
for 4 h after cultured overnight in MEM containing 10 nM dexamethasone, 5 mM
glucose.  They were then incubated for 4 h in MEM containing 5 mM and 25 mM
glucose and indicated for determination of G6Pc mRNA levels, 1 experiments, 
triplicate treatments (n=3). Mean ± SEM, aP< 0.05 effect of glucose, dP< 0.05 
effect of FOXO3A tP< 0.05 effect of OGT. 
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Figure 5.13  Actinomycin D lowers basal TXNIP mRNA and the stimulation by 
glucose and 2-DOG  
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5mM and 25 mM glucose and10 mM 2-deoxyglucose (2-DOG), without or with 5 µg/ml 
actinomycin D  and indicated for determination of TXNIP mRNA levels, 1 experiments, 
triplicate treatments (n=3). Mean ± SEM, aP< 0.05 effect of glucose, rP< 0.05 effect of 
actinomycin D. 
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Figure 5.14  Effects of glucose and 2-DOG withou or with insulin on TXNIP 
protein expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5 mM glucose,  25 mM glucose and 10 mM 2-deoxy-glucose (2-DOG), with or without 
insulin and determination of protein by immunoblotting assay for TXNIP and GAPDH 
. 
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Figure 5.15  Effects of verapamil on TXNIP mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5mM and 25 mM glucose and 10 mM 2-deoxyglucose (2-DOG), without 
or with 150 µM verapamil and indicated for determination of TXNIP mRNA levels, 
1 experiments, triplicate treatments (n=3). Mean ± SEM, aP< 0.05 effect of glucose, 
vP< 0.05 effect of verapamil. 
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Figure 5.16  Effects of sugars on TXNIP and PTG mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5 mM and 25 mM glucose, 5 mM allose, 10 mM 2-deoxyglucose (2-DOG), 10 mM 3-
O-Methyl-glucose (3-MOG), 20 mM 6-deoxyglucose (6-DOG), 0.5 and 1 mM
glucosamine (GlcN) and 3 mM 5-thioglucose (5TG) and indicated for determination of 
TXNIP mRNA levels, 2-8 experiments, duplicate treatments (n=4-16). Mean ± SEM, 
aP< 0.05 effect of glucose. 
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Figure 5.17  Effects of fructose and glycerol on TXNIP mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing  
5 and 25 mM glucose, 10 mM fructose and 2 mM glycerol and indicated for 
determination of TXNIP mRNA levels, 4 experiments, duplicate treatments (n=8) . 
Mean ± SEM, aP< 0.05 effect of glucose.
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Figure 5.18  Effects of 5-thioglucose (5TG) on TXNIP mRNA  expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 5 
mM and 25 mM glucose, 5 mM allose, 10 mM 2-deoxyglucose (2-DOG), 10 mM 3-O-
Methyl-glucose (3-MOG), 20 mM 6-deoxyglucose (6-DOG), without or with 3 mM 5-
thioglucose (5TG) (A), 2, 5 and 10 mM 2-deoxyglucose (2-DOG) without or with 3 mM
5-thioglucose (B), 5 mM and 25 mM glucose, 5 mM allose, 10 mM 2-deoxyglucose (2-
DOG), 10 mM 3-O-Methyl-glucose (3-MOG), 20 mM 6-deoxyglucose (6-DOG), without 
or with 3 mM 5-thioglucose (5TG) and 20 µM bromopyruvate (C) and indicated for 
determination of TXNIP mRNA levels, 2-8 experiments, duplicate treatments (n=4-16). 
Mean ± SEM, aP< 0.05 effect of glucose and zP< 0.05 effect of 5TG. 
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Figure 5.19  Effects of S4048 on TXNIP mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing 
5 and 25 mM glucose and  2, 5 and 10 mM 2-deoxyglucose (2-DOG) without or with 
S4048 and indicated for determination of TXNIP mRNA levels, 6 experiments, 
duplicate treatments (n=12). Mean ± SEM. aP< 0.05 of glucose, qP< 0.05 effect of 
S4048
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Figure 5.20  Effects of sugars on GRP78 and GRP94 mRNA expression 
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing 5 mM and 25 mM glucose, 5 mM allose, 10 mM 2-deoxyglucose (2-
DOG), 10 mM 3-O-Methyl-glucose (3-MOG) and 20 mM 6-deoxyglucose (6-DOG) 
and indicated for determination of GRP78 (A) and GRP94 (B) mRNA levels, 2-8 
experiments, duplicate treatments (n=4-16).  Mean ± SEM, aP< 0.05 effect of 
glucose. 
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Figure 5.21  Effects of PD and TSA on TXNIP mRNA expression
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM 
containing  5 and 25 mM glucose and 10 mM 2-deoxyglucose (2-DOG) without or 
with 100 nM PD169316 (A) and 60 nM TSA (B) and indicated for determination of 
TXNIP mRNA levels, 3 experiments, duplicate treatments (n=6). Mean ± SEM aP< 
0.05 effect of glucose, eP< 0.05 effect of DOG fP< 0.05 effect of PD, gP< 0.05 effect 
of TSA
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Figure 5.22  Effect of glucose and 2-deoxyglucose (2-DOG) on recruitment of 
Acetyl-H4, NF-Y, FOXO1 and FOXO3A to the TXNIP promoter
Hepatocyte monolayers were pre-cultured overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 4 h in MEM containing  
(5) and (25) mM glucose and 10mM 2-deoxyglucose (2-DOG) and 30mins in final 
incubation with 10nM insulin. ChIP assays were performed as described in the 
Methods section using control IgG or antibody to Acetyl-H4, NF-Y, FOXO1 or 
FOXO3A for determination of binding of these proteins to established ChRE
elements in the TXNIP promoters.Results are expressed relative to control IgG, 5mM 
glucose. Mean ± SEM, 3 experiments, aP< 0.05 effect of glucose
a
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Figure 5.23  Effects of 2-DOG on translocation of FOXO1 and FOXO3A 
Hepatocyte were plating and cultured for overnight in MEM containing 10 nM
dexamethasone, 5 mM glucose.  They were then incubated for 30 min in MEM 
containing 5 mM and 25 mM glucose and 10 mM 2-deoxyglucose (2-DOG), with 1h 
incubation of  10 nM insulin for FOXO1 and 15 min incubation of 10 nM insulin for 
FOXO3A. Cells were scored as having greater levels of FOXO1 and FOXO3A in the 
cytoplasm or nucleus as described in methods. Images representative of 5 
experiments, coverslips treated in duplicate (n=10). aP< 0.05 effect of glucose. 
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General Conclusions 
 
Chronic hyperglycaemia in type 2 diabetes causes various secondary 
complications including insulin resistance by mechanisms that are often described 
as glucotoxicity. The HBP and modification of proteins by O-GlcNAc have both 
been suggested to be involved in development of insulin resistance by glucose 
toxicity in diabetes (Whelan et al., 2008; Yang et al., 2008; Vosseller et al., 2002; 
Arias, 2004). Since 1980, more research studies have been published on the role 
of hexosamine pathway through modification of proteins by O-GlcNAc in 
diabetes and to understand the mechanism by which O-GlcNAc modification of 
proteins affects their function (Copeland et al., 2008; Teo et al., 2010). In 
addition, O-GlcNAc plays an important role in other chronic diseases such as 
cardiovascular and cancer (Hart et al., 2011). Marshall first reported the 
correlation between the HBP and insulin resistance in adipocytes (Marshall et al., 
1991), and proposed that increased flux through the HBP causes hyperlipidaemia 
and insulin resistance.  This raised important questions on the role of the HBP in 
the liver (Veerababu et al., 2000). The HBP leading to formation of UDP-GlcNAc 
and covalent modification of proteins by addition of O-GlcNAc is thought to be a 
mechanism for switching off insulin signalling by prolonged hyperglycaemia 
(Hart et al., 2011). Various mechanisms by which O-GlcNAc modification of 
proteins can regulate insulin signalling have been reported including: protein 
tyrosine phosphatases (PTPases) which reverse the effect of tyrosine kinases; 
phosphoinositide phosphatase which reverse the effect of PI-3-kinase (Akt/PKB) 
and serine/threonine phosphorylation of IRS proteins which counteracts the 
tyrosine phosphorylation of these substrates (Yang et al., 2008). Akt/PKB 
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activated phosphorlyation of FOXO which causes exclusion from the nucleus and 
decreased transcription of gluconeogenic genes.  
In the liver several genes are regulated at the transcriptional level by both insulin 
and glucose. Enzymes of glycolysis (e.g. pyruvate kinase) and lipogenesis (ACC 
and FAS) are induced by both insulin and glucose, by activation of SREBP-1c and 
ChREBP-Mlx, respectively. The increased expression of lipogenic enzymes in 
Type 2 diabetes is thought to be due to increased activation of both SREBP-1c 
and ChREBP-Mlx because knock down of both SREBP-1c and ChREBP 
improves the lipogenic defect. Type 2 diabetes is also associated with increased 
hepatic glucose production and increased expression of G6Pc, which catalyses the 
final step in hepatic glucose production. This enzyme is repressed by insulin and 
induced by glucagon and it is induced by glucose. FOXO transcription factors are 
major regulators of the repression of G6Pc by insulin (Onuma et al., 2006) and 
various studies have proposed that the glucose induction of G6Pc is mediated by 
covalent modification by O-GlcNAc of either FOXO transcription factors (Kuo et 
al., 2008; Housley et al., 2009) which are regulated by insulin or transcription 
factors that are regulated by glucagon such as CRTC2, the binding protein of 
CREB (Dentin et al., 2008); or co-regulators of transcription such as PGC-1α 
(Housley et al., 2009). Evidence for covalent modification of transcription factors 
involved in G6Pc regulation by O-GlcNAc has been obtained from studies with 
GlcN (generally at concentrations of 5 to 10 mM) and from use of inhibitors of 
GFAT (DON) and OGA (PUGNAc) (Dentin et al., 2008; Kuo et al., 2008; 
Housley et al., 2009).  UDP-NAG the substrate for covalent modification of 
proteins by OGT is generated by the HBP.    
Recent work in our laboratory had shown that the transcription factor ChREBP-
Mlx which is widely implicated in the regulation of enzymes of glycolysis and 
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lipogenesis is also a target gene for ChREBP (Arden et al., 2012). This suggests 
that there are various mechanisms by which glucose can induce G6Pc: (i) through 
ChREBP activation by a similar mechanism as enzymes of glycolysis and 
lipogenesis; (ii) through covalent modification by O-GlcNAc of other 
transcription factors that are regulated by insulin and glucagon; (iii) through 
inhibition of insulin signalling by O-GlcNAc. The aim of this study was to 
determine the role of the HBP and O-GlcNAc modification mechanisms in 
glucose regulated gene expression of G6Pc.  The focus of this study was G6Pc 
and not other ChREBP targets because of the major role of this enzyme in hepatic 
glucose metabolism and also because G6Pc unlike most other ChREBP targets is 
regulated oppositely by insulin and glucose. Another gene that is regulated 
oppositely by glucose and insulin in extrahepatic tissues is TXNIP. Studies on 
subjects with type 2 diabetes identified elevated expression of this gene in muscle 
of diabetics and showed that increased TXNIP expression inhibits glucose uptake 
by adipocytes (Mootha et al., 2007). TXNIP was therefore also studied in parallel 
with G6Pc to test whether the HBP is involved in glucose regulation of this gene.   
 
6.1 The study of the HBP in hepatocytes 
 
In order to study the relative roles of ChREBP-Mlx and O-GlcNAc modification 
in regulation of gene expression it was first necessary to establish valid tools that 
are specific for the HBP and / or O-GlcNAc modification that do not interfere 
with other mechanisms of glucose signalling.  The most commonly used method 
for increasing HBP flux and covalent modification with O-GlcNAc is incubation 
with 5-10 mM GlcN or incubation with the OGA inhibitor, PUGNAc and 
overexpression of OGT to increase covalent modification of proteins without 
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changing HBP flux. Inhibitors of GFAT (AZN and DON) or of OGT (BADGP) 
are also used to inhibit HBP flux and OGT activity. 
This study tested the effects of various GlcN concentrations and confirmed that 
GlcN is rapidly metabolised by the HBP from the measurement of NAG 
metabolites which accumulated within 4 h incubation to much higher levels than 
occur with 25 mM glucose. Unlike 25 mM glucose which increased the 
concentration of NAG-metabolites but not of GlcN 6-P, concentrations of GlcN at 
5mM or above caused a large accumulation of GlcN 6-P showing that at these 
concentrations of GlcN the activity of GlcN 6-P NATase becomes rate limiting 
and its substrate accumulates. This was associated with inhibition of glucose 
phosphorylation, and accumulation of glucose 6-P and also activation of 
phosphorylase independently of the lowering of glucose 6-P. Titration with a 
range of concentrations of GlcN showed that the minimum concentration that 
raises NAG metabolites (0.5 mM) also caused inhibition of glucose 
phosphorylation and lowering of both glucose 6-P and F2,6P2.  Therefore GlcN 
could not be used as a tool to increase HBP flux without interfering with other 
metabolic pathways. 
Experiments with GFAT inhibitors established that DON could be used at a 
concentration of 40 µM to inhibit GFAT. At this concentration, the inhibitor had 
negligible effects on glucose phosphorylation and protein synthesis and it did not 
affect F2,6P2 which is a regulator of ChREBP-Mlx and MondoA-Mlx. Therefore 
DON was established to be a valid tool to inhibit flux through the HBP with 
negligible effects on other metabolic pathways.   Experiments on protein labelling 
with 14C-glucose and without or with DON to inhibit HBP allowed the estimation 
of flux through the HBP resulting in the labelling of proteins. This gave an 
estimate for HBP flux of 3% of the rate of glucose phosphorylation. The 
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effectiveness of PUGNAc and BADGP as inhibitors of OGA and OGT was tested 
from protein labelling with GlcN. These experiments did not show increased 
labelled with PUGNAc but showed inhibition with BADGP. However this 
inhibitor unlike the GFAT inhibitor inhibited protein synthesis and was therefore 
considered to be non-specific. These studies therefore only provided support for 
use of the GFAT inhibitor. 
 
6.2 Control of G6Pc and TXNIP gene expression by glucose 
 
This study showed that expression of TXNIP in hepatocytes like expression of 
G6Pc was inhibited by insulin and induced by glucose. In the presence of insulin 
the induction by glucose of both genes was much smaller than in presence of 
insulin. This indicates that insulin inhibits the expression of these genes both 
independently of the high glucose stimulation and also possibly by inhibiting the 
glucose stimulation.  Experiments with a dominant-negative variant of Mlx (the 
partner of both ChREBP and MondoA) showed that the glucose induction of both 
G6Pc and TXNIP in the absence of insulin was largely Mlx-dependent.    
The Mlx-dependence of the glucose induction of G6Pc and TXNIP is consistent 
with the findings from the study by Ma (Ma et al., 2006) which was the first study 
to determine the role of Mlx in glucose regulation of gene expression.  
Experiments with ChREBP or FOXO3A overexpression confirmed that both these 
transcription factors cause induction of G6Pc and TXNIP and this induction of 
both genes was greater in the presence of glucose suggesting that both 
transcription factors mediate the effect of glucose.   
An interesting finding from this study was the converse effects of insulin and 
glucose on the subcellular location of both FOXO1 and FOXO3A. The available 
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antibody to FOXO1 detected the endogenous protein. However, overexpression of 
FOXO3A was necessary to measure immunoactivity and translocation. The 
available results are therefore for endogenous FOXO1 and overexpressed 
FOXO3A. Insulin caused rapid translocation of FOXO1 from the nucleus to the 
cytoplasm (> 60% within 30 min) and almost total exclusion of FOXO3A from 
the nucleus within 15 min. Whether the difference between FOXO1 and FOXO3A 
is a true isoform difference or the result of overexpression of FOXO3A could not 
be determined. However, interestingly, high glucose had clear and opposite 
effects from insulin on the subcellular location of both FOXO1 and FOXO3A.  
High glucose inhibited the effect of insulin on FOXO1 translocation and caused 
the retention of FOXO1 in the nucleus and it caused increased accumulation of 
FOXO3A in the nucleus in the absence of insulin. Athough the studies on FOXO1 
could not distinguish between effects of glucose on the insulin mechanism and 
effects of glucose that are independent of insulin, because in these conditions the 
protein was present exclusively in the nucleus, the studies on FOXO3A suggest 
that glucose causes translocation of the protein into the nucleus independently of 
insulin action.  
 
6.3 Role of the HBP in glucose-regulation of G6Pc and TXNIP gene 
expression 
 
The starting point for this project were the reports from various research groups 
that modification of transcription factors by O-GlcNAc is the major mechanism 
by which glucose induces G6Pc (Dentin et al., 2008; Housley et al., 2008; 
Housley et al., 2009; Kuo et al., 2008). In particular the study by Dentin on 
primary hepatocytes showed that GlcN causes a larger induction of G6Pc than 25 
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mM glucose.  The present study could not replicate an effect of GlcN on the 
induction of G6Pc. For these experiments GlcN was tested over a range of 
concentrations and in different hormone conditions. Interestingly an earlier paper 
by Masillon (2002) that used Northern blots for visualisation of G6Pc mRNA 
showed stimulation by both xylitol and glucose but inhibition of the glucose 
stimulation by 2 mM GlcN, in agreement with the present findings. In this study 
GlcN (0.5 mM) inhibited the stimulation by 25 mM glucose.  This effect is most 
likely explained by the inhibition of glucose phosphorylation by GlcN and the 
lowering of F2,6P2 which has been shown to be essential for glucose induced 
activation of ChREBP (Arden et al., 2012; Petrie et al., 2013). 
The experiments with the GFAT inhibitor DON, provided clear evidence for 
inhibition of the glucose-induction of both G6Pc and TXNIP.  This effect of DON 
is most likely explained by inhibition of GFAT because it was not observed in the 
presence of 0.5 mM glucosamine which increase flux through GFAT.  
 
 The inhibitory effect of DON on G6Pc gene expression was associated with 
decreased nuclear staining of ChREBP, which was also associated with lower 
ChREBP protein as shown by immunoblotting.   DON had no effect on the 
increase in F2,6P2 caused by glucose indicating that it does not interfere with the 
ChREBP translocation signalling metabolite  However whether in addition to a 
decrease in ChREBP protein there is also a defect in the translocation could not be 
determined from the present experiments because the immunostaining studies are 
based on a count of stained nuclei and not on the relative distribution of staining 
in the nuclei and cytoplasm, because the cytoplasmic fluorescence of hepatocytes 
is in part due to non-specific autofluorescence.      
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The studies testing the role of the HBP on the glucose stimulation of translocation 
of FOXO transcription factors showed a strong inhibitory effect of the GFAT 
inhibitor on translocation of FOXO3A without a lowering of FOXO3A protein 
immunoactivity. They also showed inhibition with GFAT inhibitor of covalent 
modification of FOXO3A by O-GlcNAc in the WGA-precipitation assays. Further 
evidence supporting a role for increased activation of G6Pc by FOXO3A by O-
GlcNAc modification was obtained by combined expression of FOXO3A and 
OGT which caused a greater increase in G6Pc expression.  Together the results 
from this thesis support a role for increased modification of FOXO3A by O-
GlcNAc in contributing to the raped glucose induction of G6Pc expression. 
 
6.4 Regulation of TXNIP by glucose analogues  
 
An interesting finding from this study was that glucose analogues which have 
been shown previously to induce TXNIP in other cell types (Pedersen and Ayer, 
2011) were also found to be inducers of TXNIP but not of G6Pc or PTG, showing 
clearly that regulation by TXNIP differs from that of both ChREBP targets 
(G6Pc) and also MondoA targets (PTG). Interestingly, the induction of TXNIP by 
2-DOG unlike the induction by glucose was not Mlx-dependent, further 
confirming that this mechanism does not involve with ChREBP-Mlx or MondoA-
Mlx. However, experiments with actinomycin D confirmed that the induction by 
2-DOG was due to a transcriptional mechanism. 3-MOG and allose but like 2-
DOG also induced TXNIP, and the effect of theses analogues was inhibited by the 
hexokinase inhibitor 5TG suggesting that it is most likely mediated by the 
phosphorylated form of these sugars as proposed in the recent study by Pedersen 
(Pedersen and Ayer, 2011). In this study 6-DOG and GlcN had no effect on 
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induction of TXNIP, because 6-DOG cannot be phosphorylate this further 
supports that the mechanism of TXNIP activation is most likely mediated by a 
phosphorylated intermediate. However, it is clearly mediated by a different 
mechanism from glucose because it is Mlx-independent.  
Other different binding the TXNIP induction by glucose compared with 2-DOG 
pointed to a role of histone acetylation. The induction of TXNIP by 2-DOG was 
not further inhibited by the HDAC inhibitor and it was associated with increased 
binding of Acetyl-H4 to the TXNIP promoter by 2-DOG indicated a role for 
acetylation with activation of TXNIP by glucose analogues.     
 
6.4 Summary 
 
1. In summary this study shows that the induction of G6Pc by glucose is 
inhibited by both lowering of F2,6P2 with a kinase-deficient variant of 6-
phosphfructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFK-KD) which 
had no effect on NAG-metabolites and by inhibition of the HBP with the 
GFAT inhibitor which had no effect on F2,6P2. This indicates that at least 
two independent metabolite signalling pathways are involved in the 
glucose induction of G6Pc: elevation in F2,6P2 which causes translocation 
of ChREBP and flux through the HBP which causes covalent modification 
of FOXO transcription factors and accumulation in the nucleus.   
 
2. Regulation of TXNIP by glucose that regulation of G6Pc was also 
dependent on flux through the HBP. However, glucose analogues also 
induced TXNIP by a mechanism involving histone acetylation. 
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Appendix I: TXNIP proximal promoter sequence and ChIP primers 
 
 
AGAAACAATAGCTGTGCAGGGAACAAGACACAGAACTGTCCACGGGGCTTTTCTTAATTA
AAAATTCAATTACTCCATAGACAACCCCAAATAAATATCAGCATTGCCTCCTCTGAGACAT
CCCAAGTCAACACCCTCTGACCCTTAGCGGCCTCCTCTCTTCCTTTCAGATCTCAAGATTTA
AAAACAATAGTAACTTTTTACATCTAAAGAGGTTATTTCGGGTGTCTCTGGAGTGAGTACT
GGGGGCACAGGGGAGGTCCGAACTGG 
TTCTTTTTCTACTGTGTGGGTTCTGCTATTGAACTCAGGTTGTCAGGCCTGGCACCATCTCT
GGTTCTCCTCAAATCTTATGTAGCTGGGGCTGAAGAGATGGCTTGGTGGTTAGTATCAGAG
GAACGAGTTTCAGTCCGAGAACCAAAATGGCAGCTTACAACTCTTGACTCCAGTTCTAAG
GCATCTGACACCCTCTTCTGGCCTCTACCTGCAGCAGGCACACGTGTGGCAAAAACGACA
ACGAAAAAAAAAACCCAACCCTATACATACAAAATTTTAAATCTTATGTTGCTACATACC
ACACTATTTAACAATATGAATATATGCACTTTCGGTAAATATTTTGATATTTCATACCATC
AAGCTAGGATTTTCTCAGATGCCTGCTACAGGCACTGAGAAACTAAAGTTAGTGAGAGTC
CTACCTCCCTTGTCCTTGATAAATACTGTTTATCATCGGAAAACACCTCGAGCCCAGTTAG
TTCACTTTCTGGAACAAACACGCACACCCTAGGCAAGGGATCAAGGTGTTCCTAGGCTTTG
GTGTTGTGTATGTTTTTCAACCATGTGATGCTGTTCGTCTCTGAGCTTGCTTAAGATTAAGG
TTGAGTTGTAACTTTGTTAGCCTTAGGGATTCAACTCAGTTAAGGCATGTGAGCAAGGGGA
GGGAGGGTTGTTTCCAAACAGCAGTGAACAGGATTCTAACTGCATGCAAAAGCTTTTTGC
TTCTCCATCTTTTTTTTTTTTTTTTTTTTTTGGGTCTTTTTTTCAGAGCTGGGGACTGAACCC
AGGGCCTTGCGCTTCCTAGGCAAGCGCTCTACCACTGAGCTAAATCCCCAACCCTTTGCTT
CTCCATCTTAATCTCGGGGCTACTGTCTTTATATTCCAGGGCAAGGAAAAAGGCGATAGAT
AAACGCCTAATAATTCTGCCCAAATATGGAAGGAGGCTAGGACTCAATGACAAGGCTCTG
GCGGGGTGGAGGTGGGAGGAGGTGGGTGAGGAATAGGGTAGGGGCCCTGGGGTGTCAGG
GAGTGGTGGGTAGTCCTTCAACATACAAGAGTTTCTTTGCACTCAAGTTATTTCTCTAGTC
AGCTCCTGAAGCATTTCTCAGCAAGGTTTGCCAAATAGCCAAGTGAAACCAATACAGCTT
CAGCCCTGGGGAGACTGAAACAGGCTGAGGGGTATGCATTTCATTTAGTGATTTTGATGA
GAGGACAAATGGGGAAAAAAAAAAAGAGTGACAGGAACTCGGGAACAAAGTAAGGAGT
GACAGATCGTTTTCTTCCTTTTTCTTCCCCCCTGTTTGTTTGTTTGTACCCACCCCTTGTTTC
CTGGAGGAGCAGGGACGAAGGGAGAGATCAGTGTAAAGGTACACACCTCACTAAAGCTA
CAGTGAGGTAAATAAGGGAACATATACAAAATGTTCCCCAACCTCACAGGTACACTGAAG
AGATGAGGGGATAAGCAACAGGATGTGGACACTCCCTTACTGCTTCCGTTCCAGAGAACA
GAACAGAATAGAACGTAATGGGCGAGGAACAATAGCAGCACATAGGGCATGGAACGAAG
GGGTACACACCAGACCATGTACCAATAAGGACTTTAAGCCAGACTTAAAATATCTGACAA
GTCCCCCGCCCCCGGGAGATGGAAGCGTTTTATTCAATAGAAGTGTAATGGGAGCACATC
GGGTAGGCTCTTTCTCACTAACACAACTGCACTCTCGCCCTCCGCTCCATCCTGAAGTATC
CTTGGGGATTGTTTTTCACAGACTTGCGAACTTGTGAGCCAGGAATAAATGGTCACGTCGA
AATGAATTGCGCTGGCTAAGACAGGCATGAAATCCTCTCCTAAGCACATTTTTCTTTTACC
TAAAAAAAGAAGGGGAAAAAAACCAACAAAGCACACACCCAAACAACCCAGCTCCCGAG
AGGAGTACCCTGGATGAGGTTCAGGGTCTCGGGGTCCCAGACTCCCGAGGGAGCCACCCG
CTGCCCCAGGCCCCGCCCCTCCTCCCTGGCAAGGCTGCGCACCCGAACAACAACCATTTT
CCCCGCTAAGAGCACACTGTGTCCACGCGCCTCTGCGGCCTCGCTGATTGGTTAGAGGC
CTGGTAAACAAGGACCAAGTAGCCAATGGGAGAACTGTGCACGAGGGATGCACGAGCC
TCCGGGCCAGCACTCGCGTGGAGCGTCAAGCCAGGCGGCTATATAATGCCGTTTCCGGC
TCCCGCTTGACACTCTCCTCTTCTGGTCTTTGGATATCCAGAGTTCCTCCAGTTGCGAGAA
AACAGCTGTTATTTTTCTCCTGAAAGCTTTTGGCACAACCAGCTGGTTGAAACTTTCAGGC
ACCTTTTAGAGAAGTTGTTAAGGTTTTGTTTGAGGCTTTCTTTGGGTTTTTAAGCCCTCTCT
GCCTCACGGAGAGACTTAAGTTCTTAGTTTGCTGAGAAGGATTCTGAAGAGTTTTTCCTCT
CCGGCTTCCGTTTTTCTTGAACCCACTCGGCTCAATCATG 
 
ChoRE-a - Ayer 
ChoRE-b - Luo 
FOXO binding site - Luo 
NF-Y binding site - Luo 
 
 
Luo & Hagen primers  
